Molecular and genetic approach to an investigation of Pyrimethamine resistance in malaria parasites by Culleton, Richard
A Molecular and Genetic Approach to an Investigation of 
Pyrimethamine Resistance In Malaria Parasites 
Richard Culleton B.Sc. 
Submitted to the University of Edinburgh for the degree of 
Doctor of Philosophy 
Institute of Immunology and Infection Research, 
University of Edinburgh 
2005 
I hereby declare that I alone have composed this thesis, and that, except where 





The following people contributed immensely to the work described in this thesis. They 
are mentioned here, in order of height*.  Thanks to my parents, Angela and Peter, for all 
their support over the past 4 years.Richard Carter started the research programme of 
which the work presented here is a small fraction. More importantly from a personal 
point of view, Richard tried his hardest (I believe) to persuade me not to start this PhD, 
but whether this was some kind of cunning reverse psychology, or an actual genuine 
request not to waste his time, remains vague. His perseverance and friendship made the 
whole process immensely enjoyable. David Walliker's help with things on a fundamental 
biological level was indispensable. Jaap de Roode spent many long, extremely silly, 
hours in the animal house with me during the experiments presented in Chapter 3. Paul 
Hunt contributed a lot of time, patience, blood, sweat and tears to the entire work, as did 
Axel Martinelli who pioneered the AFLP side of LGS. I am happy to be able to count 
them both as close friends. Pedro Cravo was the person who introduced me to the field of 
malariology by supervising my honours project - his enthusiasm and sense of fun were 
infectious. Richard Fawcett helped with the technical side of proportional sequencing. 
Jeff Bond's role was as my "outside" supervisor, who's input, both scientific and 
personal, was extremely appreciated. Mark Wilson went through many of the same things 
at mostly the same time, and although his friendship was probably more a hindrance to 
the completion of this work than a benefit, it is greatly valued. Sandie Cheesman helped 
me think through a lot of the concepts of molecular genetics that I find so difficult, and 
her technical assistance for the more molecular side of LGS was invaluable. Les Steven 
helped immensely with the mosquito and' mouse work. Last, and so by definition, least, I 
thank my wife, Rie, who suffered atthe hands of a husband who for most of the first year 
and half of marriage spent more time with mosquitoes, mice and parasites than with his 
wife. Her patience, understanding, and above all support, helped to keep-me focused on 
the reasons why I started this PhD in the first place, and also to put it all in perspective 
when it threatened to overwhelm me. I'm sorry, and I promise I won't do another one. 
* Heights are based purely on guesswork, and not on any actual measurements. They are dependent entirely 
on how large I picture the people involved to be in my mind's eye. This order may not accurately reflect the 
true standings, physical or otherwise, of the people involved. 
"While neither is particularly tall, they come first by virtue of combined height 
111 
STATEMENT OF CONTRIBUTIONS 
The following people contributed to the work presented in this thesis: 
Drug Selection Experiment B (Chapter III) was designed and performed in collaboration 
with Dr. Jaap de Roode 
The production of the genetic crosses described in Chapter V were performed with 
Professor Richard Carter 
The bioinformatics required to locate homologues of AFLP markers in the Plasmodium 
falciparum database was carried out in collaboration with Dr Paul Hunt, who also 
designed the proportional sequencing technique. 
Dr. Axel Martinelli produced the Plasmodium chabaudi genetic linkage map and 
contributed to the analysis of AFLP markers described in Chapter IV 
Some of the proportional sequencing of dhfr, dhfs, dhps and 6-pthps described in Chapter 
IV was performed by Mr Richard Fawcett 
The three progenies from genetic crosses described in at the beginning of Chapter IV 
were produced by Dr. Jane Carlton, Dr. Rose-Ann Padua and Dr. Virgilio Rosario at the 




Statement of Contributions  
Table of Contents iv 
List of Figures ix 
List of Tables xiii 
List of Abbreviations xiv 
Abstract 
1. Introduction 2 
1.1 Ancient History 3 
1.2 Recent History 5 
1.2.1 Discovery of the mosquito transmission ofparasites 8 
1.3 Malaria Today 10 
1.4 The parasite and its life-cycle 15 
1.5 Clinical manifestations of the disease 19 
1.6 Natural history of the malaria parasite 20 
1.7 The genetics of malaria parasites 23 
1.8 Control strategies 27 
1.9 DrugResistance 29 
1.9.1 Resistance to pyrimethamine 33 
1.9.2 Fitness cost of resistance 38 
1.10 Growth rates 43 
1.11 Plasmodium chabaudi 46 
1.12 Linkage Group Selection 48 
1.12.2 Amplified Fragment Length Polymorphism 51 
1.13 Aims of the project 54 
1.13.1 Summary of main aims 55 
2. Materials and Methods 	 56 
2.1Mice 	 56 
2.2 Mosquitoes 	 56 
2.3 Parasites 56 
2.3.1 Definition of terms 	 57 
2.4 Routine maintenance of parasites 	 58 
.2.5 Experiments with mixed infections of ASpyrl and AJ 
(Chapter III) 	 59 
2.5.1 Preparation of inocula for the production of mixed 
infections containing equal proportions of 3 parasite clones 
(AfandASpyrl) 	 59 
2.5.2 Preparation ofpyrimethamine 	 59 
2.5.3 Blood collection for Proportional Sequencing 	 60 
2.5.4 Extraction of Parasite DNA 	 60 
V 
2.5.5 Determination of the proportions of the strains in the 60 
mixed infections by Proportional Sequencing 
2.5.6 PCR reagents and reaction conditions 62 
2.5.7 Sequencing and pur/Ication of PCR products 63 
2.5.8 Analysis of sequencing results 63 
2.6 Production of cross progeny 64 
2.61 Overview ofprocedure 64 
2.62 Mosquito feeds 64 
2.63 Infection of mice from sporozoites 65 
2.7 Selection of cross progeny 65 
2.8 Amplified Fragment Length Polymorphism 
(AFLP) analysis 66 
2.8.1 Preparation ofparasite DNA from experimental groups 66 
2.8.2 AFLP analysis 67 
2.8.3 Measurement and comparison of the intensity ofAFLP 
markers 70 
2.8.4 Assignment ofAFLP markers to locations in a P. 
chabaudi genetic linkage map. 72 
2.8.5 Sequencing ofAFLP markers, and their location on the 
Plasmodiumfalciparum genome 73 
2.9 Proportional Sequencing of dhps, dhfs, 6-pthps and mdr-1 73 
Results 	 75 
3. Experiments with drug selection of mixed infections of 
pyrimethamine resistant and sensitive strains 76 
3.1 Introduction 76 
3.2 Drug selection experiment A 77 
3.2.1 Results 78 
3.2.2 Discussion 80 
3.2.2.1 Untreated control group 80 
3.2.2.2 High drug-dose group 81 
3.2.2.3 Low drug-dose group 81 
3.3 Drug selection experiment B 82 
3.3.1 Results 83 
3.3.1.1 Statistical analysis of parasitaemia differences 85 
3.3.1.2 Effect of parasite strain on host body weight 87 
3.3.1.3 Analysis of strain composition of mixed 
infections 89 
3.3.2 Discussion 91 
3.3.2.1 Host heterogeneity and the dynamics of co- 
infections with parasites of differing growth rates and 
susceptibilities to pyrimethamine 92 
3.3.2.2 Implications of these results for the design of an 
LGS investigation into pyrimethamine resistance 93 
vi 
4. Experiments to prove the principle of Linkage Group Selection 95 
using pyrirnethamine selection 
4.1 Introduction 95 
4.2 LGS experiment on previously generated crosses 96 
4.2.1 Results 98 
4.2.2 Discussion 100 
4.3 LGS analysis of a new cross between ASpyr1 and AJ 100 
4.3.1 Results 103 
4.3.1.1 analysis of individual linkage groups and data 
summaries 109 
4.3.1.2 Data Summary 127 
4.3.2 Further investigation of markers under selection on 
chromosome 7 133 
4.3.3 Proportional Sequencing of the dhfr locus 135 
4.3.4 Evidence of a selection valley on chromosome 13 138 
4.3.5 Estimate of the size of a centiMorgan in the dhfr 139 
selection valley 
4.4 Discussion 142 
4.4.1 Evidence for PYR selectin ofASpyrl markers on P. 145 
chabaudi Chromosome 13 
4.4.2 Selection for an Aflocus on Chromosome 11 148 
4.4.3 Growth rate advantage ofAJ alleles 152 
5. Experiments investigating the fitness cost of pyrimethamine 
resistance 153 
5.1 Introduction 153 
5.2 Further analysis of the progeny of a cross between ASpyrl 
and AJ described in Chapter IV (Section 4.3) 154 
5.2.1 Results 156 
5.2.2 Estimate of the relative fitness ofparasites carrying the 
ASpyrl allele of dhfr 160 
5.3 Analysis of a cross between Aspyrl and CB (pyrimethamine 
sensitive) 161 
5.3.1 Results 163 
5.4 Analysis of a cross between AS(sens) and AJ (both 
pyrimethamine sensitive) 165 
5.4.1 Results 168 
5.5 Discussion 173 
5.5.1 Summary 174 
6. Discussion 176 
6.1 Summary 176 
6.2 Experiments described in Chapter III 176 
6.3 Linkage Group Selection (Chapter IV) 177 
6.4 Growth-rate cost associated with pyrimethamine resistance 178 
Appendix 1 Solutions and Buffers 181 
vii 
Appendix 2 The relative intensity indices and comparative 
intensities of all AFLP markers analysed in the LGS 
experiment described in Chapter IV 	 182 








Figure 1.1 One of Laveran's original drawings of the parasites he observed in the 
blood of a malaria patient. 7 
Figure 1.2. Global status of Malaria (2003) 11 
Figure 1.3. Global prevalence of undernourishment (1998) 11 
Figure 1.4 Life cycle of human Plasmodia. 16 
Figure 1.5 The ultra-structure of the Pfalciparum merozoite 17 
Figure 1.6 The erythrocytic cycle of P. falciparum 18 
Figure 1.7 Phylogeny of malaria parasites using mitochondrial cytochrome b 22 
gene. 
Figure 1.8 Crossing and chromosomal events in Plasmodium. 25 
Figure 1.9 The emergence and distribution of chloroquine resistant malaria 32 
parasites 
Figure 1.10 The folate biosynthesis pathway of P. falciparum, 34 
Figure 1.11 The chemical structures of the natural substrate of DHFR 	. 35 
(dihydrofolic acid) and of pyrimethamine. 
Figure 1.12 Inhibition by pyrimethamine, Ki (nM), oenzymes encoded by the 36 
various mutant alleles of dhfr that arise to confer drug resistance. 
Figure 1.13 Proposed sequence of sequential evolution of dhfr mutants 37 
Figure 1.14 kcat/Km values of the enzyme isoforms associated with the various 41 
mutations in the dhfr gene 
Figure 1.15 Competition between T gondii parasites transformed to include 43 
mutations homologous to the SI 08N + C59R pyrimethamine resistant mutation in 
P. falciparum 
Figure 1.16 Parasitaemia through time of three different strains of P. chabaudi. 44 
Figure 1.17 The origins of the rodent malaria parasites 46 
Figure 1.18 Plasmodium chabaudi parasites (early trophozoite stage) in mouse 48 
blood. 
Figure 1.19 	A schematic representation of the genetic principles of Linkage 50 
Group Selection 
lx 
Figure 1.20 An outline of the AFLP process 	 52 
Figure 1.21 Example of a section of an AFLP gel showing polymorphic markers 	53 
in two strains of P. chabaudi parasites (AS and AJ) 
Figure 2.1 The single point mutation on the pcdhfr gene that confers 	 61 
pyrimethamine resistance to ASpyrl parasites. 
Figure 2.2 A section of an AFLP polyacrylimide gel showing an AJ marker under 
71 
PYR slection 
Figure 3.1 The experimental groups used in drug selection experiment A 	 77 
Figure 3.2 The mean parasitaemias of the three treatment groups through time. 	78 
Figure 3.3 The percentage of ASpyrl parasites in the three treatment groups 	79 
through time. 
Figure 3.4 The experimental groups used in drug selection experiment B. 	£3 
Figure 3.5 The mean parasitaemias of all treatment groups (n5) up to day 21 P1. 	84 
Figure 3.6 The mean weights of mice in all treatment groups (n5) up to day 21 	88 
PT. 
Figure 3.7 The proportion of ASpyri in mixed infections of ASpyrl+AJ for the 	90 
drug treated 
Figure 4.1 Schematic representation of LOS experiment utilising previously 97 
generated crosses between AJ and ASpyrl 
Figure 4.2 Parasitaemia curves for the Untreated and Pyrimethamine Treated 	98 
uncloned cross progeny of 3 independent crosses of AJ and ASpyrl. 
Figure 4.3 Example of an AFLP gel showing markers generated from the 	99 
experiment described above 
Figure 4.4 A schematic representation of the procedure for the experiment to test 	102 
LOS with a newly generated cross 
Figure 4.5 Parasitaemia curves for the Untreated and Pyrimethamine Treated 	103 
uncloned cross progeny of a new AJ and ASpyrl cross 
Figure 4.6 AFLP gel showing bands generated from the experiment described 	105 
above. 
Figure 4.7 Comparative Intensities of AJ (sensitive parent) markers in the PYR 	106 
treated group compared to the untreated group 
x 
Figure 4.8 Comparative Intensities of ASpyrl (resistant parent) markers in the 107 
PYR treated group compared to the untreated group 
Figure 4.9 The Comparative Intensities of AJ markers (red line), and ASpyrl 108 
markers (blue line) in the PYR treated group compared to the 'untreated group 
Figures 4.10— 4.24AJ Markers on Chromosomes 1 -13, an Linkage Groups A- 110- 
F; the Relative Intensities of markers positioned along the chromosome according 
124 
to the genetic linkage map are compared between all three treatment groups 
Figure 4.25 AJ Markers in All chromosomes / linkage groups. A; the average 
Relative Intensities of markers in the three treatment groups 
125 
Figure 4.26 Mean Relative Intensity values of AJ markers for all chromosomes / 
linkage groups. Error bars represent the standard error of the means. 
126 
Figure 4.27 The distribution of numbers of AJ markers to chromosomes and 
linkage groups on the genetic linkage map between ASpyrl and AJ 
128 
Figure 4.28 The relative intensity indices of repeated intensity measurements of 
selected specific markers. 130 
Figure 4.29The comparative intensities of repeated intensity measurements of 
selected specific markers between the PYR and unselected groups. 132 
Figure 4.30 The Comparative Intensities of AJ AFLP markers after selection of 
the cross progeny, and their positions on P. chabaudi chromosome 7 135 
Figure 4.31 The proportions of AJ alleles of 4 genes associated with the 
Plasmodium folate biosynthesis pathway, as determined by Proportional 
Sequencing. 137 
Figure 4.32 The comparative intensities of AJ AFLP markers after selection of the 
cross progeny, and their positions on P. c. chabaudi chromosome 13. 139 
Figure 4.33 The Comparative Intensities of AJ AFLP markers in the PYR versus 
the Unselected treatment groups. 141 
Figure 4.34 Positions of homologues of AJ markers within the chromosome 13 
selection valley. 146 
Figure 4.35 The deoxypyrimidine nucleotide/side metabolism pathway of P 
falciparum showing the actions of cytidine and deoxycytidylate deaminase and 
DHFR / thymidylate synthase 147 
xi 
Figure 4.36 The comparative intensities of AJ (blue line) and ASpyrl (red line) 
AFLP markers after selection of the cross progeny, and their positions on P. c. 
chabaudi chromosome 11. 149 
Figure 4.37 The formyl THF biosynthesis pathway of P. falciparum showing the 
actions of methylenetetrahydrofolate dehydrogenase I methylenetetrahydrofolate 
cyclohydrolase and DHFR / thymidylate synthase 150 
Figure 4.38 The folic acid biosynthesis pathway of P.falciparum showing the 
actions of methylenetetrahydrofolate dehydrogenase I methylenetetrahydrofolate 
cyclohydrolase and DHFR I thymidylate synthase 151 
Figure 5.1 A schematic representation of the procedure for the generation of a 
cross between ASpyrl and AJ 
156 
Figure 5.2 Comparative Intensities ofASpyrl (resistant parent) markers in the 
Second Passage group compared to the First Passage group, for markers assigned 
to P. chabaudi chromosomes 157 
Figure 5.3 Comparative Intensities of AJ (sensitive parent) (red line) and ASpyrl 
(resistant parent) (blue line) markers in the Second Passage group compared to the 
First Passage group, for markers assigned to P. chabaudi chromosomes. 158 
Figure 5.4 Proportions ofASpyrl alleles of dhfr, dhps, dhfs and 6-pthp in the First 
Passage and Second Passage progeny of the cross between ASpyrl and AJ, 
measured by Proportional Sequencing. 159 
Figure 5.5 A schematic representation of the procedure for the generation of a 
cross between ASpyrl and CB. 162 
Figure 5.6 Proportions ofASpyrl alleles of dhfr, dhps, and 6-pthp in the First 
Passage and Second Passage progeny of the cross between ASpyrl and CB, 
measured by Proportional Sequencing. 164 
Figure 5.7 A schematic representation of the procedure for the generation of a 
cross between AS(sens) and AJ, and the subsequent passage of the uncloned 
recombinant progeny through a series of groups of mice. 
167 
Figure 5.8 The parasitaemias of individual mice inoculated with sporozoites from 
a cross between AS(sens) and AJ. 	 168 
xli 
Figure 5.9 The proportions of AS(sens) and AJ alleles of dhfr and mdr-1 in two 
individual mice (from group 2432AS/AJ) inoculated with sporozoites from a cross 
between the two parasites, as determined by Proportional Sequencing. 	 170 
Figure 5.10 Mean parasitaemias (n5) of infections of uncloned AS(sens) x AJ 
cross progeny in 4 serial passage infections in mice. 	
172 
Figure 5,11 The proportions of AS(sens) alleles of dhfr and mdr-1 in infections of 
uncloned progeny of a cross between AS(sens) and AJ in serial passage through 4 
groups of5mice 	 172 
Tables 
Table 1.1 The main groups of anti-malarial drugs in use today 	 29 
Table 1.2 Comparisons of the features of P. chabaudi and P. falciparum parasites 47 
Table 3.1 The results oft-tests between individual treatment groups 86 
Table 4.1 Information relating to the history of the three crosses used in this 96 
experiment 
Table 4.2 Numbers of oocysts present in mosquitoes 8 days post-infection. 	101 
Table 4.3 Comparative Intensities of AJ AFLP markers under selection in the 	104 
PYR treated group, compared to the untreated group, and their chromosomal 
locations according to the AS/AJ Image map. 
Table 4.4. The Comparative Intensities of markers under pyrimethamine selection, 134 
and their positions on the P. chabaudi linkage map. 
Table 5.2 Numbers of oocysts present in mosquitoes 8 days post-infection. 	163 
XIII 
ABBREVIATIONS 
6-PTHPS 6-pyruvoyl tetrahydropterin synthase 
AFLP Amplified Fragment Length Polymorphism 
AMA-i Apical Membrane Antigen -1 
ATP Adenosine Tn-Phosphate 
BCE Before Common Era 
CE Common era 
cM centiMorgan 
CQ Chioroquine 
CSP Circumpsorozoite protein 
DDT Dichloro-diphenyl-trichloroethane 
DHFR Dihydrofolate Reductase 
DHFS Dihydrofolate synthase 
DHPS Dihydropteroate synthase 
DNA Deoxyribonucleic acid 
dTMP Thymidylate 
EDTA Ethyleninediamine tetraacetic acid 
GDP Gross Domestic Product 
HIV Human Immunodeficiency Virus 
Kb Kilobase 
LGS Linkage Group Selection 
LGS Linkage Group Selection 
Mg/kg Milligrams (of drug) / Kilogram (of body weight) 
MSP-1 Merozoite Surface Protein-i 
PABA Paraminobenzoic Acid 
PCR Polymerase Chain Reaction 
PYR Pyrimethamine 
TAE Tris-acetate/EDTA buffer 
TBE Tris-borate/EDTA buffer 
TE Tris/EDTA buffer 
xiv 
TRAP Thrombospondin related adhesive protein 
v/v volume for volume 
w/v weight for volume 










The identification of parasite genes controlling phenotypes such as drug resistance, 
virulence, immunogenicity, and transmission is vital to malaria research. Classical 
genetic methods have achieved these goals only rarely and with difficulty. The work 
presented in this thesis describes the development of, and an investigation into a novel 
genetic method, Linkage Group Selection (LGS), which achieves rapid de novo location 
of genes encoding selectable phenotypes of malaria parasites. A phenotype-specific 
selection pressure is applied to the uncloned progeny of a genetic cross between two 
malaria parasites that differ in the phenotype under investigation. Selected and unselected 
progeny are analyzed using genome-wide quantitative genetic markers. Markers of the 
"sensitive" parent, which are reduced after selection, are sequenced and located in 
genomic databases. They are expected to be closely linked to gene(s) determining the 
phenotype under selection. The validation of LGS presented in this work was carried out 
with the rodent malaria parasite Plasmodium chabaudi chabaudi using a phenotype, 
pyrimethamine resistance, whose controlling gene, that encoding dihydrofolate reductase 
(dhfr), is known. The results show that molecular markers closely linked to dhfr, and only 
those linked to this gene, were reduced or removed by pyrimethamine treatment in 
accordance with the expectations of LGS. 
In addition, experiments investigating the "fitness cost" of pyrimethamine resistance are 
described. The recombinant progeny of a cross between drug-sensitive and drug-resistant 
parasites were grown in infections in mice, and the proportions of the sensitive and 
resistant alleles of dhfr were measured throughout the infection. It was found that 
parasites carrying the pyrimethamine resistance mutation at dhfr grew more slowly than 
those carrying the sensitive allele, indicating this specific mutation for drug resistance 
carries a fitness cost to the parasite. This result may have important implications for the 




The aim of the work presented in this thesis is to explore and validate a novel method 
(Linkage Group Selection (LGS)) for the identification of genes controlling important 
phenotypes in malaria parasites. The results presented herein relate to the 
accomplishment of these aims through investigating LGS using pyrimethamine resistance 
in the rodent malaria parasite, Plasmodium chabaudi. The genetic basis underlying the 
ability of resistant parasites to proliferate under drug pressure is analysed, along with the 
related subjects of fitness costs associated with drug resistance, competition between 
sensitive and resistant parasites in mixed infections, and the genetic basis of differing 
growth rates. 
In this introduction, the historical aspects of malaria are discussed (including an overview 
of the current status of the disease and its socio-economic causes and consequences), 
followed by the current understanding of the parasite's life cycle and essential genetics. 
There follows a discussion on the emergence and genetics of drug resistance, focussing 
specifically on pyrimethamine. The subject of fitness costs associated with mutations 
conferring drug resistance is then addressed, succeeded by a brief discussion of virulence 
and growth rate differences between strains of parasites. Finally, there is an introduction 
to the principles behind linkage group selection including the rationale behind the work 
presented in this thesis. 
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1.1 Ancient history 
Every nasty bug has schemed to plague me with disease, 
The twin Gods of illness bore holes inmy chest and diaphragm 
("He 's old - why not kill him off?"), 
Send vermin of darkness to release their poisonous venom. 
The suffocating heat of my body has steamed my vitality away, 
I quake as though struck by thunder; 
Heaven and earth have become a gigantic iwo-part steamer 
And all the gravy pours out of me. 
But suddenly comes a chill to chase away the heat, 
And Ishiver as though drowning under ice, 
Pile up more blankets of coverlets and quilts, 
No end to the number I can take. 
Why, in such a brief span of time, 
Do Yin and Yang alternate so violently? 
I cough and sneeze, 
Tears running mixed with phlegm, 
Toss and turn but can 'tfind peace 
No matter how I rearrange pillow and mattress; 
Ihave trouble whether I'm up or down, 
For the slightest movement someone must support me, 
So dizzy I confuse square and round, 
Fall over all the time go black and pass out. 
All my life I've eaten a vegetarian diet, 
And it's always suited my taste just fine: 
So the five whole mullet they've set before me now 
Taste about as appetizing as frozen quinine bark. 
In the short while I've been confined to this hammock, 
My scrawny body has turned to Jerky; 
People passing by look in 
Wondering ifFm not dead andjust pretending to be alive. 
All day groans issue from my mouth - 
Whatever comes brings anger or terror. 
Returning to consciousness, I compose myseif 
A visitor from far across the seas, 
No one knows my mind 
Or has pity for a strange accent 
-Chugan Engetsu (1300-1375 CE) 
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Writing in China in the 14 th Century, the Japanese monk Chugan Engetsu describes the 
symptoms of a disease we can now identify as malaria. The disease had been known in 
China since at least 2700 BCE when it was described in the Nei Ching - the Canon of 
Medicine (edited by the Emperor Huang Ti). In the second century BCE, the first 
mention is made in Chinese medicine of a "cure" for the disease - the Quinhao plant 
(Sweet Wormwood - Artemisia annua), which is described in the medical treatise 52 
remedies. It is from this ancient herbal remedy that the current antimalarial drug 
artemisinin and its derivatives have recently been developed, which offer one of the most 
promising new treatments for the disease. It is possible to speculate that Engetsu himself 
may have been treated with Quinhao, as it is known that he made a full recovery from his 
illness before returning to Japan. His intriguing reference to another ancient herbal cure 
for malaria - "quinine bark", is, unfortunately, an elaboration by the poem's translator 
who was attempting to introduce some revisionist continuity on the theme of malaria 
(David Pollackpers. comm.). 
The disease has also been described outside of China since ancient times. Fevers 
associated with splenomegaly (two of the most characteristic symptoms of the disease) 
were described in the Egyptian Ebers papyrus - reputedly found between the legs of a 
mummy in the Assassif district of the Theben necropolis and dating from about 1550 
BCE. It is also from ancient Egypt that the first mention is made of "bed-nets" in human 
history, with Herodotus (c. 490 - 431 BCE) describing how Egyptian fishermen would 
arrange their nets around them as they slept to protect themselves from mosquitoes 
(Schmidt and Roberts, 2004). 
) 
	
Hippocrates (c. 460-377 BCE) was the first person to differentiate between different 
types of malarial fever when he categorised the disease into "quotidian" (daily), "tertian" 
(alternate days) and "quartan" (three days apart) depending upon the fever periodicity. He 
also noted that the disease was common among those who lived near swamps (but 
attributed this to the drinking of stagnant water). Indeed, this association of the disease 
with swampy habitats has given us the name "malaria", a contraction of the Italian "mala 
4 
aria" which means "bad or evil air", in reference to the foul vapours associated with 
swamps. 
1.2 Recent History 
Although the symptoms of malaria were known since ancient times, the discovery of the 
cause of the disease had to wait until the end of the nineteenth century. A French military 
doctor - Alphonse Laveran - was the first person to recognise a parasite as the causative 
agent of malaria. Medicine in Europe had been revolutionised by Robert Koch and Louis 
Pasteur's work in the 1860s and '70s that showed that most infectious diseases are caused 
by microbial agents (the "germ theory" of disease). With the wide-spread acceptance of 
this idea, researchers (the first modern malariologists) were soon looking for the 
microbial agent that caused malaria, and many studies were conducted on various algae, 
protozoa, fungi and bacteria that were associated with malarious areas. 
It appeared that the problem was solved when, in 1879, Corrado Tommasi-Crudeli and 
Edwin Klebs (already famous for his isolation of the diphtheria bacillus) identified a 
bacterium in the soil of the swamps of the Roman Campagna, which, they claimed, could 
induce a malaria-like disease when injected into rabbits. It was duly named "Bacillus 
malariae", and despite some unsuccessful attempts to reproduce the rabbit-infection 
experiment, such was Klebs' reputation at the time that this bacterium was widely 
accepted as the causative agent of malaria. 
In fact, this theory actually ignored evidence to the contrary that had been known for over 
150 years before the discovery of Bacillus malariae. It had long been observed that the 
spleen and brain of malaria victims contained a dark pigmented material which had first 
been described by Giovanni Maria Lancisi in 1717 (Lancisi was a remarkable character 
in the history of malaria research who not only appears to be the first person to have 
described evidence of malaria parasites, but, who also suggested a link between the 
disease and the mosquitoes associated with malarious areas). Laveran's breakthrough was 
5 
to realise that this dark pigmented material was associated with the cause, and not the 
result, of malaria. 
In 1878 he began working with malarious French soldiers in Constantine, Algeria, and 
his autopsies of the victims of the disease constantly revealed the same pigmented bodies 
in the spleen and brain that had first been described by Lancisi. He was unable, however, 
to collate any evidence from tissue samples that these pigmented bodies were anything 
other than a pathological symptom of the disease, and he switched his investigations to 
the study of fresh blood from malaria patients. This was to prove to be the decisive step 
in the discovery of the malaria parasite, when on November 6th  1880, Lavern observed 
the vigorous movement of one of the pigmented bodies in fresh blood. He instantly 
realised that the pigmented malarious bodies that he and other researchers had long 
observed in the tissue and blood of malaria patients were living parasites, and were the 
causal agents of the disease (see Figure 1.1). Laveran communicated his discovery to the 
Academy of Medicine in Paris, and named the parasite "Oscillaria malariae" (Lehrer, 
1979; National Center for Infectious Diseases, 2004; Schmidt and Roberts, 2004). 
ó'oe 
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Figure 1.1 One of Laveran's original drawings of the parasites he observed in the blood of a malaria 
patient. Source: National Center for Infectious Diseases 
There followed a period of some years in which the scientific community were slow to 
accept Laveran's discovery, such was the enthusiasm for Bacillus malariae, but by the 
early I 890s, it was generally accepted that Laveran's parasites were, indeed, responsible 
for malaria. This acceptance was bolstered by the new blood staining techniques 
developed by Romanovsky in Russia that allowed the parasites to be visualised in great 
detail in blood smears. In 1884, Ettore Marchiafava (a long time advocate of Bacillus 
malariae) and Angello Celli verified Laveran's claims, and named the parasite they'd 
observed "Plasmodiurn malariae". Camillo Golgi was the first to realise that there were 
different species of the parasite, each with a characteristic morphology and pathology, 
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and by 1897 three distinct human parasite species had been described; 	Plasmodium 
vivax, Plasmodium malariae and Plasmodium falciparum. A fourth, Plasmodium ovale, 
was described in 1922. 
1.2.1 Discovery of the mosquito transmission of parasites 
It was now known that malaria was caused by a parasite rather than by vapours, bacteria, 
or other such airborne agents. The question arising from this discovery, then, was how 
does the parasite get from one person to the next? Again, Giovanni Maria Lancisi had a 
theory. "Mosquitoes", he proposed, "always inject their salivary juices into the small 
wounds on the surface of the body." And ". . .no controversy can arise concerning the 
harmful effects which [they], by mixing their injurious juices with the saliva.., inflict 
upon us" (quoted in Lehrer, 1979). His idea, presented in 1717, was not significantly 
elaborated upon until the wonderfully named Albert Freeman Africanus King proposed a 
similar theory in a lecture to the Philosophical Society of Washington in 1882 (Cook and 
Webb, 2000). King went further than Lancisi, stating that the mosquito was the source of 
malaria, and that eradication of the disease could be achieved by preventing mosquitoes 
from biting people. He elaborated on this idea by suggesting that Washington city could 
be covered by a giant mosquito net as tall as the Washington Monument in order to rid 
the city of the disease. This last comment proved too much for his scientific audience, 
and somewhat undermined his fundamental ideas, which were, with the benefit of 
hindsight, extremely prescient. 
It was a Scotsman, Patrick Manson, who became the most vigorous exponent of the 
mosquito vector theory of malaria transmission, when in the 1880s, inspired by Laveran's 
publication of the parasitic nature of the disease, he began to wonder if it could be 
transmitted by a mosquito in the same way that he had recently shown for the filarial 
nematodes (Wuchereria bancrofti) that cause elephantiasis. He was further inspired by 
the work of Smith and Kilbourne, who in 1893, proved that Texas Cattle Fever (bovine 
babesiosis) was transmitted by the tick Boophilus bovis, and of David Bruce who proved 
the following year that th tsetse fly, Glossina morsitans, was the vector of nàgana 
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(Gubler, 2001). In the light of these findings Manson postulated that the flagellated forms 
of malaria parasites were taken up by mosquitoes during feeding, and these would then 
migrate into the tissues where they would become forms that were infectious to another 
human. He went on to theorise, however, that as mosquitoes were, at the time, thought to 
die straight after laying their eggs, the parasites escaped from the dead body of the flies 
into the marshy waters and infected people who drank them, thus returning to the ideas of 
Hippocrates. 
Manson clearly saw the urgency of experimental work to prove this theory, and initially 
applied for funding to travel to malarious areas to undertake such endeavours himself. He 
was refused, however, but managed to convince Surgeon-Major Ronald Ross to 
investigate his theories while serving in the Indian Medical Service. Ross quickly applied 
his considerable enthusiasm and dedication to the attempt to find evidence of malaria 
parasites in mosquitoes. After much laborious dissection of countless mosquitoes of 
various different genera, Ross eventually found what he was looking for - on August 201h 
1897 he saw the pigmented parasites first described by Laveran in the mid-gut of an 
Anopheles mosquito known to have fed on a malarious patient. He immediately reported 
this discovery to Manson, and published a description of his work in the British Medical 
Journal. He had planned to prove that infected mosquitoes were able to transmit the 
parasites to an uninfected host, but his was interrupted when he was posted to a non-
malarious area of India. Manson, however, arranged for him to continue his work the 
following year When he embarked upon a study of the avian malaria parasite Plasmodium 
relictum, with which he demonstrated the presence of sporozoites (which he named 
"germinal rods") in the salivary glands of a mosquito that had fed on an infected lark. 
Manson presented the results of Ross' work at the Edinburgh meeting of the British 
Medical Association on the 28 th of July 1898; the transmission of malaria by mosquitoes 
had been proven (Cook, 1997). It remained to be shown, however, that human malaria 
could be induced in man by the bite of an infected mosquito. This was finally proven by 
Amigo Bignami and Giovanni Grassi, who successfully infected Abele Sola (a volunteer 
with no history of malaria) with malaria from an infected mosquito in October 1898 
(Ascenzi A, 1999). 
1.3 Malaria Today 
Today, over 100 years after the work of the pioneering malariologists who uncovered the 
causes of the disease, malaria is responsible for 300-500 million cases worldwide every 
year, of which 0.5 - 2.5 million are fatal (White et al., 1999b). The majority of these 
deaths are of children under five years old, and it is estimated that every 30 seconds a 
child dies of malaria (WHO, 2004). Most of these deaths occur in sub-Saharan Africa 
where the most virulent species of human malaria, Plasmodiumfalciparum, is endemic. 
The disease is also widespread in South Asia, Central and South America, and the 
Western Pacific. The mortality from malaria is less in these areas than inAfrica, but 
morbidity is high leading to considerable social and economic costs (Trigg and 
Kondrachine, 1998). These enormous socio-economic costs are made even more 
significant by the fact that the areas affected are amongst the poorest in the world (Figure 
1.3). In 1995 alone, the direct and indirect cost attributed to the malaria problem world-
wide was estimated at us$1800 million (The Wellcome Ttüst, 1998), despite concerted 
efforts by organisations such as the World Health Organisation (WHO) to control the 
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Figure 1.3 Global prevalence of undernourishment (1998) The prevalence of chronic under-nutrition is a 
relevant and valid measure of endemic poverty and is a better indicator than estimates of per capita income 
(Food and Agriculture Organisation of the United Nations, 2004). Source: (UN, 2004) 
Comparing Figures 1.2 and 1.3, which show the distribution of malaria and the 
prevalence of global undernourishment respectively, it is easy to observe the correlation 
between the disease and poverty. In 1995 the gross domestic product (GDP) of malarious 
countries was more than 5 times less than that of non-malarious areas (Gallup and Sachs, 
2001). This correlation between malaria and poverty can be interpreted in a number of 
ways. It is possible that the link between poverty and malaria is purely co-incidental, with 
tropical countries being impoverished for reasons of geography, climate, political history 
and other tropical diseases, independent of malaria. Gallup and Sachs (2001) analysed the 
income per capita of malarious countries and included these other factors in their analysis. 
They concluded that the "association of malaria with poverty seems to be more than just 
a mask for other plausible causes of low income". 
Is, then, malaria a cause or an effect of poverty? It is true that the richer countries of the 
world have been able to eradicate malaria in the last 50 years. In 1946, for example, large 
areas of the USA, Southern Europe and northern Australia were afflicted with the disease, 
but managed to eradicate it by the mid 1960s (Sachs and Malaney, 2002). Certainly this 
was due, in part, to the economic power of the nations involved, which were able to 
organise efficient and effective strategies of mosquito control. The control attempts were 
probably aided by the affluence of the people living in these countries, particularly in 
relation to good quality housing and reliable access to medical services - both features of 
Western affluence that are sadly lacking in poorer nations. It is easy, then, to postulate 
that rich countries can afford to be malaria-free, while poorer nations are burdened with 
the disease due to the poor infrastructure associated with poverty. This explanation is 
overly simplistic, however, for though there is undoubtedly some truth in it, it ignores the 
very real biological differences in malaria, parasite transmission between the rich and 
poor countries. It is often overlooked that it is far easier to eliminate malaria in regions 
where transmission is low, (an effect of human population density, mosquito population 
density and, crucially, climate), than where transmission is high and endemic. Countries 
that have successfully eradicated malaria are predominantly found in temperate climate 
zones, which are associated with less efficient vectors, lower night-time temperatures and 
marked seasonality in parasite transmissior (Gallup and Sachs, 2001). Control of malaria 
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in tropical zones, then, is far more difficult. This argument against a purely economic 
cause of malaria is supported by rich countries in tropical locations that have not been 
able to eradicate the disease. Oman and Saudi Arabia, for example, whilst both enjoying 
high GDPs due to oil revenues, still suffer from the presence of malaria. 
The incidence of malaria, then, cannot be directly attributed to the poverty of the country 
in which it is found. What is attributable to poverty, to a certain degree, is death from the 
disease. The startling statistic mentioned above, that "a child dies of malaria every 30 
seconds" is often quoted in the introduction to scientific papers concerned with 
malariology, so much so that its impact is somewhat reduced on those working in the 
field. The fact is that this is a sickening statement to make in the 21st  Century. Malaria is 
completely curable today thanks to highly effective anti-malarial drugs. Yes, there are 
huge problems of drug resistance in large areas of the world, but the effectiveness of 
combination therapy with artemisinin has yet to be undermined by this problem. The 
simple fact is that any child that contracts malaria need not die if treated with effective 
drugs such as Coartem® (artemisinin-derivative in combination with lumefantrine), and 
yet 2000 children are dying every day, because, fundamentally, their parents simply 
cannot get access to a medicine that costs us$2 for an effective dose. 
There can be no doubt that increases in the economic development of malarious countries 
will decrease the terrible death rates presently associated with the disease. A case study 
conducted by Médecins Sans Frontières involving 5 African countries suffering huge 
malaria burdens (Burundi, Kenya, Rwanda, Tanzania and Uganda) estimated that for the 
25.3 million cases of malaria within these 5 countries to be treated with artemisinin 
combination therapy would cost an extra us$19.1 million per year (Kindermans et al., 
2002). Extrapolating this estimate to include the whole of Africa (in which there are 
approximately 200-450 million cases of the disease annually), the figure rises to 
approximately us$300 million extra a year. To put this figure into context, the combined 
yearly military expenditure of the 5 African countries listed above totals us$414.4 
million (SIPRI, 2004). 
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If the prevalence of malaria is a not direct result of poverty, then the problem is certainly 
exacerbated by it, but what of the effects of the disease on the prevalence of poverty? 
There can be little doubt that countries in which malaria is endemic bear a great 
economic burden which can be directly attributed to the disease. Gallup and Sachs (2001) 
showed that countries that suffered severe malaria in 1965 had "dramatically lower 
economic growth in the next 25 years" than malaria-free countries (even after controlling 
for other factors such as geographic location, initial poverty, political economic policies, 
etc.). This reduction in the economic viability of malarious countries can be attributed to 
a number of factors. There is the direct personal economic cost borne by the people living 
in malarious areas who are forced to pay for preventative and curative measures against 
the disease. There is also the proportion of government spending on programmes 
designed to control the disease. Then there is the loss of revenue from foreign tourism 
and investment, which suffers due to reluctance on the part of would-be tourists and 
investors to travel to countries with a serious malaria problem. When malaria was 
eradicated from Portugal, Spain, and Greece in the mid 1950s,   for example, there was 
huge economic development in these countries, which can be directly attributed to large 
increases in tourism and foreign investment (Sachs and Malaney, 2002). 
Less quantifiable, but certainly as important, is the reduction in economic growth 
associated with having a large proportion of the population unable to work due to 
sickness. High morbidity reduces the effective productivity of thepopulation directly, in 
terms of the numbers of people unable to work, and indirectly, with the loss of earnings 
of the many people who have to look after affected family members (Nur, 1993). The fact 
that malaria is mostly prevalent among children has huge implications for education in 
the poorest regions of the world, sick children being unable to attend school. A study by 
Brooker et al. (2000), attributed 13-50% of medically related school absences in Kenya 
to malaria (Brooker et al., 2000). Malaria has been shown to have an adverse effect on 
the school performance of infected children in Sri Lanka (Fernando et al., 2003). There is 
also evidence to suggest that people who suffer from the disease in infancy experience 
impairment of cognitive development and learning capabilities (Holding and Snow, 
2001). Related to this is the fact that mothers are particularly prone to malaria during 
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pregnancy. Malaria during pregnancy is directly associated with low birth-weights, which 
is also a risk factor for diminished cognitive development (Mccormick et al., 1992). 
Another malaria-related factor that affects economic development is that the disease 
limits the movement of people within malarious areas. When people move away from a 
malarious area for prolonged periods, there is an associated loss of immunity against the 
disease. This prevents those people who have gone to non-malarious areas to work or 
study returning to the areas they left, and so contributes to the lack of skills and education 
in endemic areas. Similarly, as immunity to malaria is known to be strain-specific ( so 
that immunity induced against a local population of parasites is not effective against a 
genetically different population of parasites), there is a risk involved in workers 
migrating from one endemic area to another, thus preventing the movement of labour to 
regions where it is most productive (Sachs and Malaney, 2002). All these factors 
combine to present the depressing picture of a disease strongly associated with poverty, 
both as a cause and as an effect. There can be little doubt that improving the economic 
development of the poorest countries will greatly aid the fight against malaria, while, at 
the same time, effectively reducing the disease burden will increase the economic 
development of the countries affected. 
1.4 The parasite and its life-cycle 
Malaria is caused by parasitic protozoa of the genus Plasmodium, with four species 
(Plasmodium falciparum, Plasmodium ovale, Plasmodium vivax and Plasmodium 
malariae) infectious to man. The life cycle of these parasites is complex (see Figure 1.4) 
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Figure 1.4 Life-cycle of human Plasmodia. (Adapted from www.dpd.cdc.gov ) 
Mammalian malaria parasites are parasites of erythrocytes that require a vector host for 
transmission and sexual reproduction. The life cycle in the vertebrate begins with the bite 
of a mosquito. During a blood meal, a malaria-infected female Anopheles mosquito 
inoculates sporozoites into the human host. Despite the fact that the salivary glands of an 
infected mosquito are likely to contain many thousands of sporozoites (11,000 in 
Plasmodi urn berghei infections of Anopheles stephensi, for example (Sinden, 1997)), less 
than 100 of these are believed to be transmitted in any one bite (Rosenberg et al., 1990). 
These sporozoites (typically around 11 jim in length, and I j.tm in diameter for P. 
falciparum) then enter the bloodstream and within 30-45 minutes migrate to the liver 
where they invade hepatocytes. This is achieved by the binding of the thrombospondin 
domains of the circumsporozoite and thrombospond in-related adhesive proteins (CSP and 
TRAP, respectively), to heparin sulphate proteoglycans on hepatocytes (Frevert et al., 
1993). Here they undergo asexual reproduction (schizogony), lasting for 5-15 days, the 
Er1 
end product of which is around 10,000 - 30,000 merozoites. In P. vivax and P. ovale a 
dormant stage [hypnozoites] can persist in the liver and cause relapses by invading 
erythrocytes weeks, or even years later (Mangoni et al.. 2003). Merozoites are released 
into the bloodstream following rupture of the hepatocyte, where they invade red blood 
cells. Merozoites are approximately 1.5 tm in length, and lj.tm in width, and contain 3 
membrane bound organelles at the apical end (dense granules, rhopteries and 
micronemes), characteristic of all Apicomplexan parasites (see Figure 1.5). 
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Figure 1.5 The uhra-structure of the Pfa/ciparum merozoite (Bannister et al., 2000) 
Invasion of erythrocytes by merozoites involves an initial low affinity interaction 
between proteins on the surface coat of the merozoite (possibly merozoite surface 
protein-i (MSP-l)) and the surface of the erythrocyte. The merozoite then orientates 
itself so that the apical prominence is in contact with the surface of the red blood cell, and 
there follows the release of the contents of the rhoptries, dense granules and micronemes. 
These assist with the penetration of the merozoite into the host cell (Chitnis and 
Blackman, 2000). Inside the erythrocytes the merozoites commence feeding, becoming 
trophozoites. These in turn become schizonts after undergoing another asexual 
reproductive stage (erythrocytic schizogony), and release more merozoites into the 
bloodstream, causing lysis of the host cell (see Figure 1.6 for a detailed explanation of the 
erythrocytic cycle). 
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(a) Invasion by MZ. (b) Rg stage 
The MZ attaches to the RBC surface, then re-orientates to bring The parasite flattens into a biconcave disc and begins to teed on 
its ap4cal prominence in contact with the host cell. The MZ secretes the RBC through a cytoslome. The ring grows and exports various 
material from Its apex to cause the formation of the membrane-lined molecules to the RBC surface, causing adhesion to non-infected 
PV into which the MZ propels itself. Once enclosed in the RBC, the RBCs (rosethng) and to endothelial cells of the viscera and the 
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Figure 1.6 The erythrocytic cycle of P.falciparum (Bannister and Mitchell, 2003) 
As well as releasing merozoites (that are able to invade more red blood cells), some 
parasites undergo gametocytogenesis within the erythrocyte, producing micro- and 
macrogametocytes, male and female respectively, that remain in the blood circulation 
18 
where they are available for ingestion by a feeding mosquito. Inside the insect mid-gut 
the gametocytes undergo gametogenesis, in which the female macrogametocyte escapes 
from the erythrocyte membrane, and the male microgametocyte undergoes the process of 
exflagellation which produces 8 motile microgametes. The micro- and macro-gametes 
fuse to form a zygote that in turn becomes an ookinete (the only diploid stages of the 
parasite) that crosses the gut wall and encysts. This oocyst then undergoes several rounds 
of division, producing thousands of haploid sporozoites that are subsequently released 
into the haemocoel of the mosquito where they migrate to the salivary glands (Barnwell 
and Galinski, 1998; Beier and Vanderberg, 1998; Frevert and Crisanti A., 1998; Sinden, 
1998). 
1.5 Clinical manifestations of the disease 
The physical symptoms of infection with malaria parasites vary with a number of factors, 
the two most important being the species of parasite and the immune status of the host. 
As the parasites proliferate during the erythrocytic cycle, and the percentage of infected 
erythrocytes increases, patients typically experience headaches, chills, joint pains and, 
characteristically, fever. The chills and fever (known as a paroxysm) are typically 
periodic, recurring at intervals characteristic of the species of parasite. A paroxysm lasts 
for 4-12 hours, after which time there is typically a cessation of symptoms for a period, 
before another wave of paroxysm. These paroxysms are extremely stressful for patients, 
which begin with an intense feeling of cold, and which can last for up to an hour. After 
this, the body temperature begins to rise and can reach to between 39 and 4 1°C. 
Associated with this fever are feelings of nausea and sometimes convulsions. The 
'paroxysms are associated with the rupture of infected erythrocytes and the release of 
merozoites into the blood stream, and the length of the inter-paroxysm period is defined 
by the parasite species, with P. vivax, P. falciparum and P. ovale cycling every 48 hours, 
and P. malariae every 60 hours. 
The most severe manifestations of the disease, such as cerebral malaria, severe anaemia, 
splenomegaly, hepatomegaly and nephritic syndromes are usually associated only with P. 
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falciparum. Cerebral malaria is, at least in part, caused by sequestration of the parasites in 
the capillary vasculature in the brain. This is thought to occur due to parasitized 
erythrocytes binding to each other (rosetting) (Pongponratn et al., 1991), and to the 
endothelium of the capillaries themselves (Macpherson et al., 1985) resulting in hypoxia. 
Another factor contributing to the severity of cerebral malaria is the release by the host of 
large amounts of toxic cytokines (Clark and Schofield, 2000). This combination of 
hypoxia and elevated cytokine levels has been shown to increase levels of nitric oxide 
synthase which in turn generates large amounts of pathogenic nitric oxide (Melillo et al., 
1995). Severe anaemia is caused by the destruction of erythrocytes infected by the 
parasite, but there is also evidence that the presence of the parasite reduces the host's 
capacity to produce more erythrocyes by suppressing the response of bone marrow to 
erythropoietin (Kurtzhals et al., 1997). 
1.6 Natural history of the malaria parasites 
The four human malaria parasites are members of a genus that includes some 180 species 
(Ash and Orihel, 1990). The genus Plasmodium is thought to have evolved from a 
coccidian ancestor that was parasitic on an insect host (Garnham, 1966). The Plasmodium 
genus is a member of the phylum Apicomplexa, the extant members of which are 
obligate intra-cellular animal parasites. The Apicomplexa are themselves members of the 
Alveolata superphylum which includes ciliates, dinoflagellates, perkinsida and marine 
alveolates. The phylum consists of 5000 described species, but there may be as many as 
60,000 still to be described (Escalante and Ayala, 1995). All members of the 
Apicomplexa contain a vestigial plastid called an apicoplast - a discrete organelle bound 
by three or four membranes (Kohler et al., 1997) (see Figure 1.5). The origin of this 
organelle is likely to have been in a "secondary endosymbiotic event" in which the 
ancestor of all Apicomplexans engulfed a photosynthetic unicellular alga and retained the 
algal plastid (which was itself the product of a previous endosymbiotic event) (Kohler et 
al., 1997; Palmer and Deiwiche, 1996; Wilson et al., 1996). Supporting this theory is the 
evidence that present day Apicomplexa such as Plasmodium and Toxoplasma have highly 
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organized cytoplasmic compartments which are associated with organisms of a 
phagotrophic nature (Robibaro et al., 2001). 
The Apicomplexa phylum is thought to be very ancient, and may have originated earlier 
than the multicellular kingdoms of plants, fungi and animals. The Plasmodium lineage 
may have diverged several hundred million years ago (before the appearance of 
vertebrates), with the radiation that gave rise to human parasites beginning around 130 
million years ago (Escalante and Ayala, 1995). Digenetic parasitism (requiring an 
alternation of hosts), a feature of Plasmodium and other Apicomplexa, may have evolved 
independently several times within the phylum (Barta, 1989; Escalante and Ayala, 1995). 
The phylogenetic relationship of the extant human parasites is somewhat contentious, 
with debate ongoing about the origin and age of P. falciparum in particular (see Tanabe 
et al. (2004) for the most recent addition to the literature). An extensive phylogeny of 
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Figure 1.7 Phylogeny of malaria parasites using mitochondrial cytochrome b gene. Vertebrate class 
exploited as the parasite's host is indicated with bars. This phylogeny is rooted with Theileria annulata (a 
related Apicomplexan parasite). Branch lengths are proportionate to number of nucleotide changes (Perkins 








1.7 The genetics of malaria parasites 
Malaria parasites are, like all members of the Apicomplexa, haploid for almost their 
entire life cycle. An exception is the zygote stage, which is diploid prior to the meiotic 
division that results in the production of sporozoites. The parasite possesses three 
individual genomes; an extra-chromosomal mitochondrial genome, known as the 6kb 
element, a 35kb circular genome associated with the apicoplast, and a large nuclear 
genome. The mitochondrial genome encodes two truncated ribosomal RNAs and three 
components of respiration (Cytochrome c oxidase subunits I and II, and cytochrome b 
(Funes et al., 2004). The apicoplast genome encodes 30 proteins which are primarily 
involved in gene expression (Funes et al., 2004; Gardner et al., 2002). It has been shown, 
however, that about 10% of the genes encoded by the nuclear genome are targeted to the 
apicoplast, supplementing its proteome via post-translational targeting into the organelle 
(Gardneret al., 2002; Roos et al., 1999b; Zuegge et al., 2001). The exact role of the 
apicoplast remains unclear, but it is known to be involved in the anabolic synthesis of 
fatty acids, isoprenoids and haem. (Gardner etal., 2002). 
The nuclear genome of P. falciparum consists of 14 chromosomes and encodes about 
5,300 genes with a total genome size of 22.8 megabases. It.is extremely (A+T)-rich, with 
an overall (A+T) content of 80.6%, rising to 90% in intronic and intergenic regions 
(Gardner et al., 2002). There is considerable chromosomal size polymorphism between 
strains of parasites (Corcoran and Kemp, 1986), which could be due to unequal crossing-
over of homologous chromosomes during meiosis, or non-meiotic chromosome breaking 
and healing events (Babiker et al., 1994; Gardner et al., 2002; HernandezRivas et al., 
1996; Scherfet al., 1992). 
Malaria parasites exhibit extensive genetic polymorphism between species and between 
strains within species. Some of these genetic polymorphisms manifest themselves as 
phenotypic differences between strains for quantifiable traits such as virulence and 
susceptibility to drugs. This genetic diversity is subject to natural selection, which is 
most intuitively apparent in the way that 'drug-resistance appears and spreads under 
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strong drug pressure. This diversity arises both by spontaneous genetic mutations, and by 
novel genotypes arising through recombination. The meiotic division and recombination 
which the parasites undergo in the mosquito can result in independent assortment of 
genes on different chromosomes, crossing-over events between linked genes on 
homologous chromosomes (both producing novel genotypes), and intragenic 
recombination (resulting in novel alleles of genes) (Walliker et al., 1998). 
Meiosis occurs after the fusing of the micro- and macrogametocytes to form a zygote. If 
gametocytes from two genetically distinct parasites are taken up by the mosquito, then 
crossing resulting in heterozygous zygotes can occur. Each heterozygote will, through the 
process of meiosis, produce 4 genetically distinct haploid daughter cells (recombinant 
progeny). If there are equal numbers of male and female gametes present from each 
parental strain in the mosquito, then selfing will occur 50% of the time, resulting in 25% 
of the zygotes being genetically identical to one parental strain, and 25% identical to the 
other. The remaining 50% will be hybrid between the two parentals (see Figure 1.8). 
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Figure 1.8 Crossing and chromosomal events in Plasmodium. A and D show the results of selfing, while B 
and C show the products of recombination (Walliker, 2000). 
Recombination between malaria parasites was first formally proven with genetic crossing 
experiments conducted with the rodent parasites Plasmodium yoelii (Walliker et al., 
1971), and Plasmodium chabaudi (Walliker et al., 1975a). In the P. chabaudi 
experiments, two cloned parasites which differed in their response to the anti-malarial 
drug pyrimethamine and in the electrophoretic patterns of two enzymes (6-
phosphogluconate dehydrogenase (6-PGD) and lactate dehydrogenase (LDH)) were 
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mixed in mosquitoes and the resulting progeny were cloned and characterised for their 
enzyme type and their phenotypic response to pyrimethamine. It was found that not only 
had the two enzyme isoforms recombined, but that pyrimethamine susceptibility 
segregated independently (Walliker et al., 1 975a). This showed that crossing between 
gametes, and recombination between the parental characters had occurred. 
The production of heterozygotes (in the oocyst or zygote stage in the mosquito) between 
two heterologous malaria parasites has been shown to occur experimentally with P. 
falciparum (Ranford-Cartwright et al., 1993). This study involved the typing of alleles of 
msp-1 and msp-2 from individual oocysts dissected from mosquitoes that had fed on a 
mixed blood infection of clones 3137 and 1-1133. It was found that some oocysts contained 
alleles exclusively from HB3, some contained alleles only from 3137, and the remainder 
of the oocysts contained alleles from both parents, and were therefore hybrids - the 
products of fertilisation between the two different parental strains. The proportion of the 
homozygous and heterozygous forms was consistent with random fertilisation between 
parents (Ranford-Cartwright etal., 1993). 
Evidence for intragenic recombination resulting in novel alleles of genes was 
demonstrated by the production of a novel msp-1 gene resulting from a crossing over 
event in a conserved region of the gene (Kerr et al., 1994). The possibility of intragenic 
recombination during mitosis has also been proposed, based on studies of the gene 
encoding circumsporozoite protein (csp) (Rich et al., 1997). 
The inheritance of the 6 kb element appears to follow the same pattern as other 
mitochondrial genomes in eukaryotes - it is inherited from the female parent only (1994; 
Creasey et al., 1993) 
The complete genome of Plasmodium falciparum (clone 3137) was published in 2002, 
and heralded the "post-genomic" age of malariology (Gardner et al., 2002). The genome 
presents researchers with a powerful new resource with which to work toward new drug 
and vaccine development. 
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1.8 Control strategies 
Current methods used for the control of malaria invariably rely on prevention through 
minimizing exposure to mosquitoes, and drug treatment of clinical disease. The fact that 
the parasite has to rely on an insect vector for its transmission immediately highlights a 
weakness that may be currently under-exploited. Malaria can be stopped by attacking the 
vector host effectively, as was proven by the WHO's (ultimately abandoned) eradication 
campaign in the early 1950s. By residual spraying of effective insecticides such as DDT, 
it is possible to reduce mosquito numbers to levels which do not permit the transmission 
of the parasite. 
Large scale public anti-mosquito measures such as the introduction of larvicides to 
breeding sites, non-selective residual insecticide spraying and effective drainage of 
potential breeding sites have all achieved the successful reduction of malaria in the past. 
Before the wide-scale use of DDT in India, for example, there were 75 million malaria 
cases and 0.8 million deaths from the disease yearly. This fell to 100,000 cases per year 
during the 1960s when around 18,000 tonnes of DDT were used annually. By the year 
2000, when DDT use had been considerably reduced due to the development of 
resistance in mosquitoes and environmental concerns, there were over 3 million 
incidences of the disease (Sharma GK, 1987). 
Personal anti-mosquito measures such as insecticide treated bed-nets have also been 
shown to greatly reduce the prevalence of disease in areas where they are used correctly. 
Admittedly, anti-mosquito control strategies work best in areas of low transmission, as 
shown by the effective elimination of the disease from many temperate countries in the 
latter half of the 20 th century. There are powerful arguments, however, for the 
introduction of free insecticide treated bed-nets to areas of Africa where the disease is 
endemic in order to attempt to reduce the terrible burden inflicted by the disease on 
children. 
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There are, however, many problems associated with effective anti-mosquito measures. 
The indiscriminate use of large amounts of insecticides may have environmental 
repercussions, and outcry by powerful environmental lobbyists, had, rightly or wrongly, 
greatly reduced the (very effective) use of residual DDT spraying until the United 
Nations Environmental Program sanctioned its use for malaria control (but not for 
agriculture) in 2000 (Taverne J, 2001). Mosquitoes have evolved resistance to widely 
used insecticides, both biologically and behaviorally. For example, the rationale behind 
spraying the inner walls of houses with insecticide was that mosquitoes settle there after 
taking a blood-meal. Extensive implementation of this technique was shown to select for 
those mosquitoes that flew straight out of the window after feeding. Other problems 
include the need to educate local populations effectively about the correct way to 
implement personal control methods, especially the need to maintain effective bed-nets. 
1.8.1 Anti-malarial drugs 
In areas of high transmission, where large numbers of malaria cases are presently 
inevitable, there is a reliance on anti-malarial drugs to treat the disease. The drugs used 
vary depending on the local conditions (prevalence and specificity of drug resistance, 
economic status, etc). Table 1.1 lists the main groups of anti-malarial drugs used today. 
* For a balanced review of the arguments for and against the use of DDT see Curtis and Lines (2000) 
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artemisinin derivatives e.g. artemether 
antibiotics 	 tetracycline, chioramphenicol 
drug éombinations 	 pyrimethamine + suiphadoxine ('Fansidar') 
pyrimethamine + sulphadoxine + 
mefloquine ('Fansimef) 
atovaquone + proguanil ('Malarone') 
Table 1.1 The main groups of anti-malarial drugs in use today (adapted from 
http://www.ncbi.nlm.nih.gov/proiects/Malarialantimalarialdrug.html)  
The following section discusses the problem of anti-malarial drug resistance, and focuses 
on our current understanding of the genetics behind pyrimethamine resistance. 
1.9 Drug Resistance 
The emergence and spread of parasite resistance to anti-malarial drugs has presented one 
of the largest obstacles hindering the effective treatment and control of malaria. The 
WHO's official definition of malaria parasite resistance dates from 1973; "the ability of 
a parasite strain to survive and/or multiply despite the administration and absorption of a 
drug in doses equal to or higher than those usually recommended but within the limits of 
tolerance of the subject" (World Health Organisation, 1973). Since then several authors, 
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including Basco & Ringwald (2000), have attempted to update this definition in the light 
of more advanced techniques available in the fields of genetics, pharmacology, and 
molecular biology that are able to elucidate factors such as the presence of genetic 
mutations that are linked to drug resistance in vitro, high 1050 values and varying plasma 
concentrations of drugs. The WHO (1 973)'s definition of the level of parasite drug 
resistance remains in use; 
Sensitive (5): The asexual parasite count reduces to 25% of the pre-treatment 
level in 48 hours after starting the treatment, and complete clearance after 7 days, 
without subsequent recrudescence - Complete Recovery. 
RI Delayed Recrudescence: The asexual parasitaemia reduces to <25% of pre-
treatment level in 48 hours, but reappears between 2-4 weeks. 
RI Early Recrudescence: The asexual parasitaemia reduces to < 25% of pre-
treatment level in 48 hours, but reappears within 2 weeks. 
RI! Resistance: Marked reduction in asexual parasitaemia (decrease >25% but 
<75%) in 48 hours, without complete clearance in 7 days. 
RI!! Resistance: Minimal reduction in asexual parasitaemia, (decrease <25%) or 
an increase in parasitaemia after 48 hours. 
A number of factors influence the likelihood of resistance occurring and the speed with 
which it spreads. The mechanism by which the drug works against the parasite is 
important; simple modes of action such as enzyme inhibition are likely to lead to rapid 
evolution of resistance, as the number of genetic mutations required to alter enzyme 
structure is low. This is the case with pyrimethamine resistance, which evolved very 
quickly after the, introduction of the drug, in contrast to the pattern seen with the 
emergence of chloroquine resistance, which took much longer to evolve. 
The pharmacokinetic dynamics of drugs are also important in determining the selection 
pressure for drug resistance. Watkins and Mosobo (1993), for example, showed that the 
long half-life of sulfadoxine-pyrimethamine was a considerable factor in the selection 
pressure for resistant mutants, as the drug was present in patients at sub-therapeutic levels 
for long periods of time. Drugs with high efficiencies of parasite killing, rapid 
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achievement of levels above the minimal inhibitory concentrations and short half-lives, 
will be the most effective at minimizing the selection pressure for resistant mutants 
(Winstanley et al., 2002). 
Resistance has been recorded to every anti-malarial drug currently in use, with the 
exception (to date) of artemisinin and its derivatives. Quinine, the first drug used 
specifically to treat malaria was "discovered" in the 17 th century by Jesuit priests in Peru, 
who identified the anti-fever properties of the bark of the Cinchona plant. The active 
alkaloid, quinine, was purified in Paris in 1820 by Pelletier and Caventou, and was used 
extensively as a treatment for malaria thereafter throughout the world. The first reports of 
resistance to the drug occurred at the beginning of the 20 th century, when Couto (1908) 
and Nocht and Werner (1910) reported the treatment of patients who did not respond to 
quinine treatment (cited in Peters, (1987). Despite the early appearance of quinine 
resistance, the drug remains remarkably useful today, especially asa first line drug for 
treating complicated cerebral malaria. In fact, quinine resistance is surprisingly 
uncommon, and in the few instances it has emerged, it is often associated with parasites 
that are already resistant to other drugs such as chloroquine and mefloquine 
(Looareesuwan et al., 1990; Peters, 1987; Pukrittayakamee et al., 1994). Quite why 
quinine remains so effective to the present day is not clearly understood (Meshnick, 
1997). Its use hascertainly declined since the introduction of less unpleasant (in terms of 
their side-effects) anti-malarials, but even so, resistance to the drug. seems very reluctant 
to emerge. 
Chioroquine, itself based on the structure of quinine, was developed in Germany in the 
early 1940s, and was first used extensively shortly after the Second World War. 
Resistance to chloroquine was far more forthcoming than with quinine, and the first 
reports of parasites failing to respond to the drug emerged independently from South 
America and South East Asia in the late 1950s (Harinasuta Ct al., 1965; Moore and Lanier, 
1961; Young and Moore, 1961). The spread of resistance from these pioneer areas was 
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relatively rapid (see Figure 1.9), and chioroquine resistance is now a major problem 










Figure 1.9 The emergence and distribution of chioroquine resistant malaria parasites. 
Source: http://www.rnw.nl/health/htrnl/drug_resistance.htmI  
One of the proposed mechanisms for the emergence of drug resistance is through the 
presence of a drug at sub-therapeutic levels within a population (see below). There can be 
no doubt that the emergence of chloroquine resistance in South America was facilitated 
by the policy of distributing chioroquinated salt to the area as part of a well-intentioned 
control problem. This resulted in a large proportion of the population being exposed to 
the drug at sub-curative doses, thus considerably enhancing the chances of selection of 
chloroquine resistant parasites (Payne, 1988). At a recent British Society of Parasitology 
meeting, a researcher was describing the difficulties of selecting artemisinin resistant 
parasites in rodents. One member of the audience suggested a method he was sure would 
work; "add the drug to the rodent's salt" he advised. 
The proliferation of chloroquine resistance prompted the US Army to search for a more 
effective alternative drug. A drug research programme was established specifically for 
this goal in the early 1960s, and resulted in the development of mefloquine, a drug that 
was effective against chioroquine resistant parasites. Initial indications that mefloquine 
resistance was likely to emerge came, however, in 1977, when resistance was 
experimentally induced in a rodent malaria parasite (Peters et al., 1977). Efforts to reduce 
the possibility of the emergence of resistant parasites in the field by using mefloquine in 
n 
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- 	combination with other drugs (especially pyrimethamine) met with failure, however,and - 
reports of mefloquine resistant parasites emerged throughout the 1980s   (reviewed in 
Peters (1998)). Introduced as a first line treatment to Thailand in 1984, substantial 
resistance had developed within 6 years (Price et al., 2004). Mefloquine resistance is now 
widespread in South East Asia, and there is a particularly high incidence in the 
ThailandlCambodialMayanmar borders (Wernsdorfer, 1994). 
1.9.1 Resistance to pyrimethamine 
Pyrimethamine was one of two highly effective antifolate malarial drugs first introduced 
in 1952 (the other being proguanil). Hopes were, high for this new weapon against 
malaria, as it was cheap to produce, and had been shown to be highly effective against 
Plasmodium spp. in relatively low concentrations. There was little toxicity to humans 
using the drug, and side-effects were negligible. Soon after its introduction, however, 
reports of pyrimethamine resistant P. falciparum emerged, when in 1952 treatment at 
established drug-concentrations failed to cure a baby in the Gambia (McGregor and 
Smith, 1952), reviewed in Peters (1987)). Soon after this case, several more reports of 
drug-tolerant malaria appeared from different areas around the world. Resistance to 
pyrimethamine is, at present, widespread in all malaria endemic areas (Talisuna et al., 
2004). One interesting aspect of the emergence of pyrimethamine resistance is the fact 
that it appears to have arisen independently in several locations around the world very 
shortly after its introduction. 
Pyrimethamine belongs to a group of drugs known as the "antifolates" as they target the 
folate biosynthesis pathway of the parasite (see Figure 1.10). Other drugs in this category 
include proguanil (and its active form, cycloguanil, which is metabolised from proguanil 
in vivo), the sulfonamides including sulfadoxine and sulfalene, and the sulfone, dapsone. 
Pyrimethamine and proguanil resistance arose in response to the extensive use of the 
drugs on their own. In order to minimize the development of drug resistance, and also to 
exploit the synergistic properties of antifolate and sulfonamide drugs (Chulay et al., 
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- - 1984), _pyrimethmine - is now commonly -used - in combination with sulfadoxine - 
(Fansidar®). 
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Figure 1.10 The folate biosynthesis pathway of P. falciparum, showing the stages at which inhibition by 
pyrimethamine, cycloguanil and the sulfonamides occurs (adapted from 
http://sites.huj  i.ac.iI/malarialmaps/folatebiopath.html). 
Malaria parasites are able to scavenge purines, but not pyrimidines from their hosts (Le 
Bras and Durand, 2003). They must, therefore, synthesise the latter themselves, a process 
that involves the folate biosynthesis pathway. Pyrimethamine works by competitively 
inhibiting the dihydrofolate-reductase enzyme (DHFR) which is used by the parasite to 
synthesise thymidylate (dTMP) from dihydrofolate (Ferone, 1977). Specifically, DHFR 
catalyses the NADPH-dependent reduction of 7,8-dihydrofolate to 5,6,7,8- 
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tetrahydrofolate (Sirawaraporn et al., 1997a). Pyrimethamine .works by binding to the 
active enzyme site of DHFR, preventing the binding of the natural substrate of DHFR 
(dihydrofolic acid). The chemical structure of pyrimethamine and dihydrofolic acid are 






Figure 1.11 The chemical structures of the natural substrate of DHFR (dihydrofolic acid) and of 
pyrimethamine. From Yuthavong (2002). 
The inhibition of DHFR gives rise to thymidylate depletion with ensuing disruption of 
DNA synthesis and resultant parasite death. DHFR is required for folate metabolism in 
both the host and the parasite, but pyrimethamine has a much higher affinity for binding 
to the parasites DHFR (several hundred times), and so disrupts the parasite without 
adversely affecting the host (011iaro and Yuthavong, 1999). 
The rapid way in which pyrimethamine resistance arose in the field suggested that a 
single point mutation might be responsible. This was proven correct by many different 
researchers working on a variety of malaria parasites including in vitro culture of P. 
falciparum, and murine models P. chabaudi, P.berghei and P. yoelii (Bzik et al., 1987; 
Cowman et al., 1988; Diggens et al., 1970; Foote et al., 1990; Morgan, 1972; Peterson et 
al., 1990; Rosario et al., 1976). Conclusive proof that a mutant allele of the DHFR gene 
confered pyrimethamine resistance to P. falciparum was obtained through transfection 
studies in 1996 (Wu et al.). 
Resistance to the drug has been to shown to be conferred by cumulative single nucleotide 
mutations in the dhfr gene (Cowman et al., 1988; Foote et al., 1990; Peterson et al., 1990; 
Sirawaraporn et al., 1997a). Changes in the amino acid sequence of this gene reduce the 





mutations causing amino acid replacements associated with pyrimethamine resistance in 
the wild; a change from serine to asparagine at amino acid position 108 (S108N), from 
asparagine to isoleucine at position 51 (N511), from cysteine to arginine at position 59 
(C59R), and from isoleucine to leucine at position 164 (1164L). It is thought that these 
mutations arise sequentially, starting with S108N. as this mutation confers a 10-fold 
increase in the K, value for pyrimethamine (the dissociation constant of the enzyme-
inhibitor complex) while maintaining similar kinetic parameters to the wild type enzyme 
(Sirawaraporn et at., 1997a). This is the only single mutation seen in the field. Each 
sequential mutation adds further increases in K values, with the quadruple mutant 
exhibiting the highest value (Figure 1. 12) 
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Figure 1.12 Inhibition by pyrimethamine, Ki (nM), of enzymes encoded by the various mutant alleles of 
dhfr that arise to confer drug resistance. Orange bars show mutants which do not appear in the field. Data 
for this figure was obtained from Sirawarapom (1997a). 
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- - - At is -likely that the evolution of-increased resistance-to pyrimethamine involves the initial 
SIO8N mutation arising in a single event, followed by subsequent mutations at the other 
positions in sequential fashion (Figure 1.13). Each further mutation in the gene acts 
synergistically with the preceding mutations to increase the overall resistance of the 
parasite. Indeed, it has been shown that each mutation in a double, triple or quadruple 
- 
	
	mutant allele contributes more to the overall resistance of the enzyme to pyrimethamine 






Figure 1.13 Proposed sequence of sequential evolution of dhfr mutants, beginning with the wild type (WT) 
and progressing to the quadruple mutant. Broken arrows shows single amino acid polymorphisms that do 
not occur in the wild. Adapted from Sirawaraporn et a! (1 997a). - 
There is evidence to suggest that there are other mechanisms, apart from the mutations 
described above, which may contribute to pyrimethamine resistance. Chromosomal 
rearrangement and gene amplification were found to have occurred in in vitro cultures 
which were subjected to increased levels of pyrimethamine over long periods (Thaithong 
et al., 2001). More recently it has been shown that pyrimethamine sensitive P. falciparum 
parasites are able to up-regulate DHFR enzyme translation upon challenge with 
pyrimethamine (Nirmalan et al., 2004). 
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- 	As previously mentioned, the speed with which parasites developed resistance to 
pyrimethamine in the field led to the policy of combining the drug with sulfadoxine 
(Fansidar®). This drug also targets the folate biosynthesis pathway, competitively 
inhibiting dihydropteroate synthase (DHPS) (see Figure 1.10). Thus, the pyrimethamine-
sulfadoxine combination acts synergistically, and any loss of efficiency in either 
component results in the reduction of the effectiveness of the combination as whole. For 
this reason, it has been suggested that pyrimethamine-sulfadoxine should not be 
considered a real "combination" therapy in the sense that the two components do not act 
independently with different mechanisms of action (Sibley et al., 2001). 
1.9.2 Fitness cost of resistance 
The development of resistance to drugs such as pyrimethamine involves the mutation of 
genes in a "wild type" parasite into alleles that encode modified protein products. It is 
possible that such mutations may render the parasite less fit than the wild type parasite in 
the absence of drug selection (Walliker et al., 2005). The emergence and survival of drug 
resistant mutants depends on a number of factors including; recombination between 
resistant loci (if resistance is controlled by more than one locus), the geographical 
transmission dynamics of the parasites, the strength of the selection pressure imposed by 
the drug and the effect of natural selection on the mutant (assumed to be unfavourable, 
indicating a fitness cost) (Mackinnon, 1997). Various theoretical models of the spread of 
drug resistance have identified natural selection against resistant mutants as an important 
factor determining the rate of emergence of drug resistance (Hastings, 1997; Hastings and 
D'Alessandro, 2000; Hastings and Mackinnon, 1998). In a study by Nair et al (2003), it 
was found that, contrary to expectations, pyrimethamine resistance had spread to a large 
geographical area of Southeast Asia from a single point of origin rather than by many 
independent mutations in different regions. This was unexpected, as the mutations that 
lead to pyrimethamine resistance are few, and so would be expected to arise frequently 
and independently within the parasite population. The explanation favoured by Nair et al, 
and supported by Hastings (2004), is that most of these mutations would have been 
eliminated by natural selection except for the extremely rare case in which such a 
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- mutation--was accompanied -by a "compensatory" mutation, which increases -the mutant's - - -- ' 	- 
intrinsic fitness to levels comparable with the wild type. 
Drug resistance mutations that carry a fitness cost might be expected to lead to the 
removal of drug resistant parasites through natural selection in the absence of drug 
pressure. It has been suggested that the cessation of a drug to which resistance has 
emerged would lead to the competitive exclusion of resistant parasites, returning the 
parasite population to sensitivity (Hayward et al., 2005). It has been proposed,, therefore, 
that a time-fixed cycle of different anti-malarial drugs could diminish the impact of drug-
resistant parasites on human health. Such a conclusion is not, however, supported by the 
findings of Clyde et al (1967) who reported the presence of pyrimethamine parasites 10 
years after the withdrawal of the drug in Tanzania. 
Fitness costs - associated with drug resistance have been documented for numerous 
organisms. Studies on Escherichia coil have shown that streptomycin resistant parasites 
bear a substantial fitness cost associated with the ribosomal mutations that confer 
resistance (Bilgin et al., 1992; Zengel et al., 1977). Rifampin resistance carries a 
physiological cost to Mycobacterium tuberculosis (Billington et al., 1999), the replication 
rate of the HIV virus with multiple drug resistance-associated mutations is retarded 
(Devereux et al., 2001), and mosquitoes (Cuiex pipiens) resistant to organophosphates 
have been shown to be less fit than their wild type contemporaries (Wang et al., 1998). 
The evidence for fitness costs associated with drug resistance is not confined to parasites 
and pathogens, however, as Baucom and Maurico (2004) show that weedy Morning 
Glory (Ipomoea purpurea) can develop resistance to the herbicide glyphosate, but that 
resistant plants produce fewer seeds than susceptible varieties. 
Evidence for fitness costs associated with drug resistance in malaria parasites is 
surprisingly sparse, given the large volume of research dedicated to the parasite and to 
drug resistance in particular. Circumstantial evidence from the field suggests there may 
be a cost levied by resistance to chloroquine among Pfalciparum parasites; studies from 
Hainan island in China (Liu et al., 1995) and Vietnam (Thanh et al., 2001) both show the 
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re-emergence of chioroquine sensitive parasites in areas with previously high rates of 
resistance (the former reporting a prevalence of 84% resistant parasites in 1981, dropping 
to 40% in 1991 after the cessation of chloroquine usage in 1979). The same pattern has 
been reported from Malawi which switched its first line drug treatment from chloroquine 
to sulfadoxine-pyrimethamine in 1993 due to an 80% failure rate of chloroquine 
treatment. It was shown that 7 years later the prevelance of the K76T pfcrt mutation (a 
marker for chloroquine resistance) was substantially lower (9%) than in other countries 
where chloroquine use had continued (4 1-80%) (Mita et al., 2003). A further survey from 
a different area of Malawi found a reduction in the proportion of parasites carrying the 
same allele from 85% in 1992 to 13% in 2000 (Kublin et al., 2003a). Two possible 
mechanisms for the re-emergence of sensitivity were proposed: Firstly, back mutation of 
resistant parasites, and secondly, the resistant parasites were out-competed by fitter 
chloroquine-sensitive parasites after the removal of the drug pressure. Extensive 
sequence analysis by Mita et al (2004) favoured the latter explanation, estimating the 
relative fitness of the resistant compared to the sensitive parasites to be 0.76 in the 
absence of chloroquine. 
Direct experimental evidence for a fitness cost associated with atovaquone resistance was 
presented by Peters et al (2002). Atovaquone resistance is conferred by mutations in the 
cytochrome b genes of Pfalciparum (Korsinczky et al., 2000), and in much the same way 
as for pyrimethamine resistance, there is a cumulative effect of single amino acid 
polymorphisms leading to increased levels of resistance. Peters et al. (2002) considered 2 
mutants; one in which there is a single mutation in the gene (a change from methionine 
to isoleucine at amino acid position 133 (M1331)), and a double mutant which includes 
the M1331 mutation and a further mutation at position 280 from glycine to aspartic acid 
(G280D). The single mutant had previously been shown to have a 25-fold increase in 
resistance to atovaquone, and the double mutant an 800-fold increase compared to the 
wild-type (Korsinczky et al., 2000). Direct competition through mixed infections in 
culture between wild-type parasites and the two resistant mutants revealed a 5-9% 
reduction in growth rate between the double mutant and the wild-type, but no difference 
in the growth rates of the single mutant and the wild-type. 
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It was suggested that the way in which the mutations altered the structure of the 
cytochrome b enzyme was responsible for the difference in fitness between the mutants. 
Both mutations confer drug resistance by reducing the binding affinity of cytochrome b 
to atovaquone. Mutation Ml 33!, however, achieves this reduction in atovaquone affinity 
without altering the enzyme's affinity for ubiquinone (its natural substrate), whereas 
mutation G28013, whilst conferring higher levels of drug resistance also lowered the 
ability of cytochrome b to bind to ubiquinone. 
There are few data available on the potential fitness cost associated with pyrimethamine 
resistance in malaria parasites. Sirawaraporn et al (1997a) conducted an extensive 
experiment in which kinetic analyses were performed on each of the DHFR isoforms 
encoded by the various dhfr mutants (described in Figure 1.11). They showed that for the 
majority of the naturally occurring resistant mutants, the kcat/Km values (the maximal 
catalytic rate of the enzyme when substrate is saturating) of the enzyme isoforms 
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Figure 1.14 ktatlKm values of the enzyme isoforms associated with the various mutations in the dhfr gene, 
calculated from K. values for dihydrofolate. Data for this figure was obtained from Sirawaraporn (1997a) 
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There is very little difference between the kcat/Km values for the wild type, the Si 08N and 
the N5 11 + Si 08N mutation carrying parasites, but the other naturally occurring mutants 
show large reductions in their catalytic rates. This reduction in the efficiency of resistant 
enzymes suggests that there may be fitness costs associated with these resistant mutations, 
although this cannot be proven without competing the mutants against the wild type 
parasites in a mixed infection. 
In a study on the rodent malaria parasite P. berghei, pyrimethamine resistant parasites 
displayed no growth rate reduction compared to sensitive parasites during the 
erythrocytic cycle in mice, but did proceed through the sporogonic development at a 
reduced rate compared to sensitive parasites (Shinondo et al., 1994). Earlier work with 
chioroquine and pyrimethamine resistant P. chabaudi parasites by Rosario et al (1978), in 
which sensitive parasites were competed with isogenic resistant clones in mixed 
infections in mice, showed that whereas pyrimethamine resistant parasites were out-
competed by sensitive clones in the absence of drug treatment, chloroquine resistant 
parasites appeared to posses a selection advantage over the sensitive parasites. 
In perhaps the most extensive investigation into fitness costs associated with 
pyrimethamine resistance to date, Fohl & Roos (2003) describe experiments with 
Toxoplasma gondii parasites in which pyrimethamine resistant mutants were grown in 
competition, both in vitro and in mice, with sensitive parasites. T gondii is an 
Apicomplexan parasite related to Plasmodium, which, although an important human and 
veterinary pathogen in its own right, has been used as a model for P. falciparum (Roos, 
1996; Roos et al., 1999a). Fohl & Roos (2003) engineered allelic replacements in T 
gondii parasites at the dhfr locus that were analogous to the pyrimethamine resistant 
mutations observed in P. falciparum, and competed the mutants (Si 08N + C59R) against 
wild type parasites both in vivo (in mice) and through in vitro culture. They found that 
the pyrimethamine resistant mutants had a significant growth rate disadvantage compared 
to the wild type parasites (Figure 1.15) 
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Figure 1.15 Competition between T. gondii parasites transformed to include mutations homologous to the 
S1O8N + C59R pyrimethamine resistant mutation in P. falciparum, and wild-type parasites, in vitro (A) and 
in vivo (B). The ratio of mutant/wild type parasites is plotted for several replicate experiments, indicated by 
the circle, square and triangle symbols. Each best-fit line represents the average of all data points on the 
graph up until fixation. Adapted from FohI & Roos (2003). 
From these results, the authors calculated that there was a fitness defect of 0.8% per 
generation for the 133 generations under observation (1 generation = 6.5h) in vitro and 
1.8% in vivo. These results correlate well with the large difference in '(cat/Km values 
observed by Sirawaraporn et al (1997), (Figure 1.14), between the S108 ± C59R mutant 
DHFR and the wild type. How well transfected T gondii parasites model natural 
populations of P. falciparum in the field is open to some debate. 
1.10 Growth Rates 
It has long been established that different strains of the same species of Plasmodia differ 
in the rate of their replication through the erythrocytic cycle. For example, several 
authors have shown that differences exist in the growth rates (or replication rates) of 
different strains of P. falciparum (Ariey et al., 2001; Hayward et al., 1999; Robert et al., 
1996). Field data show an over-representation of certain clones in severe malaria cases 
(Engelbrecht et al., 1995; Kun et al., 1998) suggesting that these clones are more virulent 
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than others (growth rate is an important factor in parasite virulence). Replication rate has 
been shown to be positively related to parasite virulence (Mackinnon and Read, 1999b), 
where the term virulence is defined as harm to the host following infection, where harm 
is disease severity (morbidity) and/or mortality". 
When P. falciparum malaria was used as a cure for neuro-syphilis in the first half of the 
last century, it was possible to collect data on the infection dynamics of malaria parasites 
in experimentally infected humans. Two such investigations by James et al. (1936), and 
Covell & Nicol (1951) demonstrated differences in virulence between two strains of P. 
falciparum. Evidence for genetic differences in growth rates between strains of the rodent 
malaria parasite P. chabaudi has also been reported (Mackinnon and Read, I 999b; Taylor 
et al., 1997; 1998; Timms et al., 2001). Figure 1.16 shows the average parasitaemias 
(percentage of erythrocytes infected by parasites) of mice infected with three different 
strains of P. chabaudi. It can be seen that the three strains differ greatly in the peak 
parasitaemia, and in the length of time it takes to reach this peak. 
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Figure 1.16 Parasitaemia through time of three different strains of P. chabaudi. Strains AS" and EF" are 
sub-species Plasmodium chabaudi chabaudi, and "DS" Plasmodiurn chahaudi adami. Each data point 
represents the mean of 5 mice (7 for strain 'EF"), and error bars represent 95% confidence intervals of the 
means. Data collected during this project. 
The mechanisms that enable one strain to grow faster than another are little understood. 
Possible phenotypic determinants of parasite growth rate include; erythrocyte selectivity 
(Simpson et al., 1999); antigenic variation (some parasites may elicit a stronger immune 
response in some hosts than others); intra-erythrocytic replication rate (simply the 
numbers of merozoites produced by each schizont, and the rate at which they are 
produced); the ability of the parasites to cause uninfected erythrocytes to bind to infected 
cells (rosette-formation) (Carlson 1990, and Rowe 1997), or to adhere to the walls of 
blood vessels (sequestration). These last two cytoadherence factors may be considered 
more determinants of the virulence of parasites rather than growth rate per Se, but some 
authors have suggested that the ability of parasites to form rosettes may increase the 
numbers of invadable erythrocytes in the vicinity of infected cells (Wahlgren et al., 1989). 
Sequestration could be advantageous to the parasite, and so increase growth rate, because 
it prevents their free circulation in the blood system, thus avoiding clearance by the 
spleen. 
Understanding the genetic mechanisms of parasite virulence is important for predicting 
parasite response to any malaria vaccine that may be introduced. It has been hypothesized 
that the wide-scale introduction of vaccines that are less than 100% efficient could lead to 
the evolution of more virulent parasite strains (Gandon et al., 2001). There are conflicting 
theories on this subject, however, with some evidence suggesting that the right sort of 
vaccine could lead to the proliferation of more avirulent strains (Ewald, 1996) (see also 
(Bergstrom et al., 1999; Bull, 1994; Ebert, 1998; Ewald, 1994). A clearer understanding 
of the genetic determinants of virulence would lead to a clearer picture of how parasites 
are likely to respond when faced with large-scale vaccination. 
The fact that there are so many factors involved in replication rates (see above) suggests 
that the genetic basis for differences in growth rates between parasite strains is likely to 
be complex, with many genes possibly involved. 
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1.11 Plasmodium chabaudi 
The experiments described within this PhD thesis were carried out using the rodent 
malaria parasite, Plasmodium chabaudi. P. cha baud! belongs to a group of four 
Plasmodium species that infect murine rodents from Central Africa the other species 
being Plasmodium vinckei, Plasmodium yoelii and Plasmodium berghei. A map of the 
locations from which the various rodent parasites were isolated is shown in Figure 1.17. 
The first of the rodent parasites to be discovered was P. berghei, which was found in the 
blood of a thicket rat, Grammomys surdaster, by Vincke and Lips in 1948. The discovery 
of P. vinckei followed in 1952, P. chabaudi in 1965, and P. yoelii was added to the 
taxonomy in 1974 (Killick-Kendrick and Peters, 1978). 
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Figure 1.17 The origins of the rodent malaria parasites (From Canton et at (2001)) 
There are many reasons for using rodent malaria parasites as models for human malaria. 
The most obvious of these is the ease with which the whole life cycle (including the 
sexual stages in mosquitoes) can be achieved in the laboratory. This is a crucial factor in 
studying malaria parasites, and one which is impossible to achieve with the human 
parasites with current methods and technology. Apart from the similarities in basic 
biology between the rodent and human malaria parasites, they share conserved genetics 
and genome organization, conserved housekeeping genes and biochemical processes, and 
there is considerable evidence for conservation of the molecular basis of drug-sensitivity 
and resistance (Janse and Waters, 2004). Table 1.2 shows some similarities and 
differences between P. chabaudi and the human malaria parasites. 
P. chabaudi P. falciparum 
Merozoites per schizont 6-8 8-24 
Reticulocyte preference No No 
Synchronous blood infection Yes Yes 
Optimum temperature range 24-26 >26 
mosquito transmission (sporogony) 
Oocyst size (pm) at optimum 50 50-60 
temperature 
Sporozoites in glands at optimum 11-13 10-12 
temp. (days after infection) 
Mean diameter of mature pre- 38-45 45-60 
erythrocytic schizonts (pm) 
Duration of pre-erythrocytic 50-58 hours 5.5 - 6 days 
development 
Duration of the asexual blood stage 24 48 
cycle (hours) 
Developmental time of gametocytes 36 hours 8-1 1 days 
Developmental time ookinete (hours) 18-24 12-24 
Sporozoite (size in pm) 10-15 10-14 
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Figure 1.18 Plasmodium chabaudi parasites (early trophozoite stage) in mouse blood. Picture from 
http://www.ncbi.nini.nih.gov/i)roiects/Malaria/Rodent/csmear  mid.html (NCBI 2004) 
1.12 Linkage Group Selection 
The identification of genes that control important parasite phenotypes such as drug 
resistance, growth rate (as a virulence factor) and strain-specific immunity, is of immense 
importance in the fight against malaria. Knowledge of the gene(s) controlling resistance 
to a specific anti-malarial drug, for example, enables the monitoring of the spread of 
resistance, as well as potentially increasing the effectiveness of decisions concerning drug 
policy. Knowing which genes are involved in resistance to a drug can also help us to 
understand the molecular basis of drug resistance and aid in the design of new versions of 
drugs which are unaffected by the mutations causing parasite drug resistance 
(Yuvaniyama et al. 2003). Similarly, the identification of genes involved in the parasite's 
immunogenicity is crucial to the development of vaccines. Other parasite traits for which 
the genetic basis is unknown include virulence (i.e. what causes some parasites to be 
more harmful to a host than others) and transmissibility through particular vectors. Both 
would be better understood if the genes underlying these traits were known. 
Existing methods in the genetic study of malaria parasites that attempt to locate genes 
controlling such traits, such as linkage analysis of individual cross progeny clones, are 
labour-intensive and expensive. Without the generation of an extremely large number of 
recombinant clones (>1,000),  they have poor resolution which makes the actual 
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identification of the underlying genes extremely difficult unless strong candidates are 
already suspected. There is an inverse relationship between the size of the locus within 
which possible target genes may be located and the number of recombinant clones that 
must be generated (Suet al., 1997; Wellems, 1991). 
Linkage Group Selection (LGS), whose principles are investigated in this project, was 
devised for application to malaria parasites in order to locate genes that control selectable 
phenotypes such as drug sensitivity, growth rate and strain-specific immunity without the 
disadvantages of classical linkage analysis. LGS (Figure 1.19) uses a genetic cross 
between two unrelated (genetically distinct) parasites of the same species, one of which is 
sensitive and the other resistant to the relevant selection pressure (e.g. drug treatment). 
Following cross-fertilisation between gametes of each parasite and zygote formation in 
the mosquito, there is recombination between the parental genomes during meiosis, 
producing haploid recombinant progeny. Each individual recombinant parasite will have 
inherited a random assortment of parental alleles; 50% of the parasites will have 
inherited the resistant" allele(s) of the gene(s) for the phenotype under investigation, and 
50% the "sensitive" allele(s). The uncloned population of haploid recombinant parasites 
is then exposed to the relevant selection pressure, as well as being passaged in the 
absence of the selection pressure. After such selection, alleles from both parents should 
still be equally represented except at those loci linked to the gene(s) that determine(s) the 
parasites' response to this selection. At these loci, alleles from the "sensitive" parent 
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Figure 1.19 A schematic representation of the genetic principles of LinkageGroup Selection 
Two cloned haploid parasites which differ in their sensitivity to a particular selection pressure are 
genetically crossed. In this example, resistance to the selection pressure is conferred by a gene at 
locus "A". The genome is represented by the coloured bars, while the flags represent dense, 
genome-wide markers between the two strains. 
The resulting recombinant progeny population will consist of thousands of parasites, each bearing a 
random assortment of parental alleles, and also a random assortment of parental markers. 
C) This uncloned population is then subjected to the selection pressure under investigation, and the 
resulting selected population will consist solely of parasites that possess the resistant allele of the 
gene that controls the phenotype of interest, and, therefore, any markers linked to this locus will be 
mainly from the resistant parent, their proportion increasing as the distance from the locus under 
selection decreases. We look for markers of the sensitive parent that are removed or reduced by the 
selection pressure; the greater the degree of reduction of a sensitive marker, the closer it is linked to 
the allele removed by the selection pressure. 
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By typing both the selected and the unselected recombinant populations with large 
numbers of quantitative, genome-wide, markers, it is possible to identify those markers 
from the sensitive parent that are removed or reduced by the selection pressure. These 
markers are likely to be linked to the loci involved in controlling the response of the 
parasite to the selection pressure. The closer markers are genetically linked to the target 
locus, the greater the reduction in their representation in the selected population. The 
markers can then be sequenced, and their positions located in the parasite genome (using 
the Plasmodium genome databases in conjunction with bioinformatics techniques) in 
order to identify the genes to which they are linked. 
1.12.2 Amplified Fragment Length Polymorphism (AFLP) 
LGS requires that the two parental clones are distinguished by a large enough number of 
genetic markers to ensure that some will be linked to the genes of interest. To obtain 
such markers, Amplified Fragment Length Polymorphism (AFLP) has been used, a PCR-
based method for amplifying DNA fragments from genetically distinct cloned lines of 
parasites. AFLP is a technique in which large numbers of markers are generated across a 
genome (Masiga et al., 2000) (Figure 1.20). The high density of these markers in the 
genome means that there is a high probability that some of them will be linked to the 
gene(s) of interest. 1t has been previously shown that AFLP meets the requirements of 
LGS both as regards numbers of markers generated in different strains of P. c. chabaudi 
(Grech et al., 2002b) and their quantitation in a mixture of the strains (Martinelli et al., 
2004). 
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Figure 1.20 An outline of the AFLP process. (a) Genomic DNA is digested with 2 restriction 
endonucleases (usually EcoRl (E) and Mse 1 (M)). (b) 3 types of restriction fragments are produced, with 
various combinations of the two primers at either ends. (c) Adapters which create binding sites for PCR 
primers are ligated to the ends of the fragments. (d) PCR amplification of the fragments is selective, using 
primers with 3' nucleotide extensions (boxed). These selective extensions define a subset of restriction 
fragments in order to reduce the numbers of fragments that are amplified to a manageable number. One of 
the primers is labelled with radioactive 33 P to allow visualisation on denaturing poly-acrylamide gels. From 
Masiga et al (2000). 
The AFLP technique allows the visualisation of restriction fragments of DNA. This 
enables the detection of the variation in DNA between two strains without prior 
knowledge of the nucleotide sequence. Depending upon the polymorphism between the 
two strains, large numbers of genetic markers can be produced in a relatively short time 
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(Vos et al., 1995). AFLP involves cutting genomic DNA into a large number of 
fragments with two different restriction enzymes (a "frequent'S and a "rare" cutter). The 
resulting DNA fragments are then amplified by PCR, using primers matching the 
adapters. The frequent cutter produces many small fragments, which are easily amplified 
and are the optimal size for separation on sequencing gels. The rare cutting enzyme 
produces fewer (but much longer) fragments. The AFLP procedure also results in the 
amplification of those restriction fragments which have a rare cutter sequence on one end 
and a frequent cutter sequence on the other end (Vos et al., 1995), thus generating 
optimal size fragments for visualisation on poly-acrylamide gels. Radio-labeling of one 
primer allows visualisation of the products. Genetic differences between strains occurring 
at a cutting site result in fragments of different sizes which can then be identified on a gel 
as being present in one strain and absent in the other (Figure 1.21). Polymorphic bands 
can be produced as a result of polymorphisms between strains at the enzyme recognition 
sites, polymorphisms between strains at the selective bases used in each PCR, or as a 







Figure 1.21 Example of a section of an AFLP gel showing polymorphic markers in two strains of P. 
chabaudi parasites (AS and AJ), and their representation in the uncloned recombinant progeny of a cross 
between the two strains (X). Two markers distinguishing the strains are shown, one unique to AJ (J), and 
one to AS (5). 4 non-polymorphic bands (NP), present in both strains, are also shown. 
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1.12 Aims of the project 
This project involves a "proof of principle" of the Linkage Group Selection approach to 
gene identification. Experiments were conducted using a selectable phenotype for which 
the controlling genetic factors were already understood. Two cloned P. chabaudi strains 
were available that differed in their sensitivity to pyrimethamine. These were ASpyri 
(resistant) and AJ (sensitive). The ASpyrl clone had been selected for pyrimethamine 
resistance by passage under drug pressure. In this parasite, pyrimethamine resistance is 
conferred by a single base mutation in codon 106 of pcdhfr (5106N), which is 
homologous to the Si 08N mutation in pfdhfr that confers pyrimethamine resistance to P 
falciparum (Cheng and Saul, 1994). The results , of LGS experiments using these parasites 
are presented in Chapter IV. 
Before proceeding with the full LGS investigation, it was necessary to investigate the 
interaction dynamics of the two parental strains (ASpyrl and AJ) under pyrimethamine 
pressure in mixed infections in mice. Experiments were designed in which mixtures of 
ASpyrl and-AJ were passaged through mice under different levels of drug pressure, and 
data were gathered on the growth of each individual strain in.the mixture throughout the 
infection. Results from these experiments are described in Chapter III. The purpose of 
these experiments was primarily to decide on a suitable drug regimen for the LGS 
experiments, and also to gain an understanding of how the two strains respond to drug 
pressure in the presence of the other strain. Experiments in this chapter also report on the 
effect of host genotype on competition between drug-sensitive and resistant strains. 
Fitness costs associated with pyrimethamine resistance in P. chabaudi are the subject of 
investigation in the experiments described in Chapter V. 
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1.12.1 Summary of main aims 
To investigate the interaction between pyrimethamine resistant and sensitive 
parasites in mixed infections, in the presence and absence of drug pressure, and 
within hosts with differing genotypes. 
To investigate the Linkage Group Selection technique as a method for identifying 
genes that control selectable phenotypes in malaria parasites using pyrimethamine 
selection in P. chabaudi. 
. To determine if there is a measurable fitness cost associated with the dhfr SI06N 
pyrimethamine resistance mutation in P. chabaudi. 
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CHAPTER II 
MATERIALS AND METHODS 
All work was carried out in accordance with the Animals (Scientific Procedures) Act 
1986 (UK) 
2.1 Mice 
Inbred female CBA/Ca and C57131/6J mice (Mus musculus) aged 4-6 weeks were used in 
the experiments described in this work. They were housed in polypropylene cages with 
sawdust bedding, and were provided with 41B rat and mouse maintenance diet (Harlan-
Tekld, England) and water supplemented with 0.05% paraminobenzoic acid (PABA), ad 
libitum. Cages were kept at a constant 25 ± 1°C, on a 12h light/dark cycle (light phase 
between 07.00 and 19.00, controlled by an automatic time-switch). Mice were supplied 
by the University of Edinburgh. 
2.2 Mosquitoes 
Anopheles stephensi mosquitoes were maintained in a temperature and humidity 
controlled room (25-27°C, 75-85 % humidity), kept on a 12-hour light/dark cycle. 
Larvae were maintained on LiquifryTM until first instar and thereafter on ground 
TetraminTM fish food, and adult flies on 10% glucose and 2% PABA-supplemented water 
solution. Stock adults also receive bi-weekly rat-blood feeds, which are essential for the 
production of eggs. 
2.3 Parasites 
All parasites used in these experiments were Plasmodium chabaudi chabaudi (refered to 
as P. chabaudi from here). 
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2.3.1 Definition of terms 
Isolate- refers to a population of parasites that have been collected from a single wild-
caught thicket rat, Thamnomys rutilans, on a single occasion. An "isolate" does not 
necessarily represent a homogeneous parasite population and may contain more than one 
representative of the same species or different species. 
Strain- refers to all parasites of a single subspecies present in a single isolate. For 
example, P. c. chabaudi strain AJ is composed of all the parasites belonging to the P. c. 
chabaudi sub-species in blood isolated from the T rutilans designated "AJ". 
Line- refers to a.population of parasites that have undergone one or more in vitro or in 
vivo laboratory passages. Usually, a "line" is produced when the parasites being passaged 
in the laboratory have been subjected to some kind of induced pressure, such as drug 
treatment. As above, parasites constituting a line may not be genetically identical. 
Clone- refers to parasites all of which have been derived from a single cell by asexual 
reproduction. Therefore, any particular clone should represent a population of genetically 
identical parasites, assuming that no spontaneous mutations had taken place during 
parasite growth. 
Stab/late - refers to a population of parasites that have been preserved in a viable 
condition in liquid nitrogen on a unique occasion. 
The clones used in these experiments were:- 
• P.chabaudiASpyrl - 
• P. chabaudi AJ 	- 
Pyrimethamine Resistant 
Pyrimethamine Sensitive 
• P. chabaudi CB 	- Pyrimethamine Sensitive 
• P. chabaudi AS(sens) - Pyrimethamine Sensitive 
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These strains were derived from parasites initially isolated from thicket rats, Thamnomys 
rutilans, in the Central African Republic(Landau, 1965; Landau and Chabaud, 1965). P. 
chabaudi AS(sens), CB and AJ were then cloned by limiting dilution of blood forms 
(Walliker et al., 1975a), and AS(sens) was subjected to selection for pyrimethmine 
resistance to produce clone ASpyrl. 
2.4 Routine Maintenance of Parasites 
All parasite clones were available as cryopreserved stabilates, deep-frozen in liquid 
nitrogen. To establish new infections, these stabilates were thawed by immersion of tubes 
in water and the contents inoculated intra-peritoneally into mice, in which a patent 
infection normally developed 5-10 days later. 
Parasites were maintained in laboratory mice by the collection of parasitised red blood 
cells from the tail vein of infected mice, and their inoculation into uninfected mice in 
suspension in citrate saline solution (Appendix 1). 
Thin blood smears were taken from the tail veins of infected mice daily. The smears were 
fixed with 70% ethanol solution and stained with Giemsa's solution for 30 minutes. They 
were then studied with a light stage microscope (1 OOx objective lens, oil immersion), and 
percentage parasitaemias were determined. This was done by counting the number of 
infected red blood cells (iRBCs) in ten microscope fields, and dividing by the total 
number of blood cells in the same ten fields and multiplying by 100; - 
Percentage IRBC = (No. of iRBCs in 10 fields / Total No RBCs in 10 fields) X 100 
Infected red blood cells were identified as those containing trophozoites or schizonts, 
which stain purple with Geimsa's solution. 
When necessary, infected blood was cryopreserved according to the following procedure: 
mice were anaesthetised by halothane and bled from the brachial artery. Blood was 
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collected into a tube containing citrate saline (2-3 times the volume of blood). The red 
cell suspension was centrifuged at 2000 r.p.m. for 5 minutes after which the red cell 
pellet was mixed with an equal volume of deep-freeze solution (Appendix 1). This 
mixture was then aliquoted into glass capillaries and deep-frozen in liquid nitrogen. 
2.5 Experiments with mixed infections of ASpyrl and AJ (Chapter III) 
2.5.1 Preparation of inocula for the production of mixed infections containing equal 
proportions of 2 parasite clones (AJ and ASpyrl) 
Infections of both ASpyrl and AJ clones were induced in mice as described above. 
Absolute numbers of parasites per volume of blood were worked out at peak parasiteamia 
for both infections by multiplying the parasitaemia recorded by thin blood smear against 
the numbers of red blood cells per volume of blood of each mouse (calculated by flow 
cytometry; Beckman Coulter). A volume of blood containing known parasite numbers 
was then taken from both ASpyrl and AJ infected mice by incision of the distal portion 
of the tail, and collected in glass capillaries. This blood was then mixed to produce a 
50150 mixture of the two clones, and diluted to a concentration of 1 x 106  parasites per 
0.1 ml with 50% ringers solution (Appendix 1), 45% heat-inactivated calf serum and 5% 
200 units/mI heparin solution. This solution was kept on ice, and administered intra-
peritoneally to each experimental mouse in 0.1 ml aliquots. 
2.5.2 Preparation of Pyrimethamine 
Pyrimethamine solution was prepared by dissolving pyrimethamine powder in 
dimethylsulfoxide (DMSO). This was administered to mice orally in 0.1 ml volumes 
using a lubricated catheter. Doses of drug varied between experiments, from 5mg/kg to 
20 mg/kg for four days. At the time of drugging, mice were individually weighed so that 
the amount of drug given could be adjusted accurately to each mouse. 
59 
2.5.3 Blood collection for Proportional Sequencing analyses 
5j.tl of blood was removed from each infected mouse daily using a glass capillary. This 
was immediately placed in an eppendorf tube containing 2 drops of citrate saline solution. 
The samples were then spun in a microcentrifuge at 10,000 rpm for 2 minutes, and the 
supernatent removed. The resulting pellet was frozen at -70°C. 
2.5.4 Extraction of parasite DNA 
Frozen blood pellets were thawed at room temperature, and the DNA extracted using the 
1nstaGene Matrix (Bio-Rad), following the manufacturers handbook protocol. The final 
volume of DNA was 49p.l. 
2.5.5 Determination of the proportions of the strains in the mixed infections by 
Proportional Sequencing 
The blood samples taken from each mouse were analysed using Proportional Sequencing. 
This technique allows the determination of the percentages of each parasite in a mixture 
on a given day of the infection. By applying this technique it was possible to determine 
the proportions of two parasites in mixed infections over the course of an infection. 
To directly quantify the proportions of the sensitive (ASpyrl) and resistant 
(AJ) parasites present in the selected and unselected mixed infections, DNA was 
amplified by nested PCR at the pcdhfr locus using primers common to non-polymorphic 
sequences from both parental alleles. The resulting PCR products were purified and 
sequenced. Sequencing results were analyzed using the SeqED v 1.0.3 software (Applied 
Biosystems, Inc., 1992), which allows the visualization of chromatograms of sequenced 
DNA and the quantitation of individual fluorescent peaks. The relative heights of peaks at 
the polymorphic sites in pcdhfr can be used as an index of the relative proportions of the 
AJ and ASpyrl parasites in each sample. With five replicate samples, and with reference 
to a calibrated series of mixtures between ASpyrl and AJ (Cheesman Ct al. 2003), it is 
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possible to estimate the percentage of parasites carrying the ASpyrl or AJ alleles of the 
pcdhfr gene with a standard error of <3% (P. Hunt, R. Fawcett, R. Carter, and D. 
Walliker, in prep.). 
A detailed description of the Proportional Sequencing technique is available elsewhere (P. 
Hunt, R. Fawcett, R. Carter, and D. Walliker, submitted). Briefly, the technique exploits 
the fact that during a PCR reaction, DNA is amplified in proportion to the initial template. 
If DNA containing a mixture of both ASpyrl and AJ type alleles is amplified in the same 
reaction, then the proportions of these clones will remain constant throughout the PCR. 
This means that the amplified PCR product will contain the same proportions of ASpyrl 
and AJ DNA as the template DNA that was amplified. When this DNA is sequenced, it is 
possible to determine the proportions of the clones in a population by measuring the 
proportions of a single base that differs between them. It is possible to distinguish AJ and 
ASpyrl parasites by 8 single nucleotide polymorphisms on the pcdhfr gene.One of these 
polymorphisms, which occurs at position 317 on the pcdhfr gene is responsible for 
conferring pyrimethamine resistance to ASpyrl (see Figure 2.1). 
AJ 	301 GTAATGGGAA AAGCAAGTTG GGAAAGCATC CCCTCAAAAT 
ASpyr 1301 GTAATGGGAA AAGCA?ATTG GGAAAGCATC CCCTCAAAAT 
Figure 2.1 The single point mutation on the pcdhfr gene that confers pyrimethamine resistance to ASpyrl 
parasites. At position 317, AJ has a G, and ASpyrl has an A. 
When both these parasites are present in an infection, both bases will be present at 
position 317 in the sequence. By measuring the proportions of each base (by comparing 
the size of the peaks on a sequence chromatograph) it is possible to determine the 
proportions of each parasite in the mixture. The use of a nested PCR may, however, 
introduce a bias towards the amplification of one of the alleles in a mixed infection, as 
the efficiency of amplification of the products may not be equal. 
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2.5.6 PCR reagents and reaction conditions 
Extracted parasite' DNA was subjected to a nested PCR, amplifying a portion of the 
pcdhfr gene that contains 8 single nucleotide polymorphisms between ASpyrl and AJ. 
The oligonucleotide primers used were as follows:- 
Outer PCR 
pcdhfr —09 : GAAGATATCTCTGAAATATTCG 
pcdhfr-14 : GGTGTGTGTGATGAAAAAAATA 
Inner PCR 
pcdhfr-16 : TTTTAAGGGACTTGGGAATG 
pcdhfr-07 : CCAGATATCAATGAAGATTTAT 
Individual PCR reactions were carried out in 50p1 volumes containing I OpM of both 
oligonucleotides, 1 X PCR buffer, 1 X dNTP solution, 1 unit Taq DNA polymerase 
(Boehringer Mannheim), and 20p1 of extracted DNA solution for the outer PCR ( from a 
total extracted DNA volume of 49 p1) and I p.1 of the resulting PCR product for the inner 
PCR. Negative controls were also prepared, which contained 1p.l of sterile distilled water 
in place of template DNA. Positive controls were prepared using a previously amplified 
DNA template. 
PCR reactions were carried out using a UNO-Thermoblock machine (Biometra), under 
the following standard conditions; 
Denaturing 	95°C for 1 minute 
Annealing 52°C for 1 minute X 30 cycles 
Extension 	65°C for 1 minute 
PCR conditions were the same for both rounds of the nested reaction. 
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PCR products were run and visualised on a 1.5% agarose gel in TBE solution. The 
resulting PCR products were then purified, using the QIAGEN QlAquick Tm PCR 
purification kit, following the manufacturer's instructions. 
2.5.7 Sequencing and purification of PCR products 
Sequencing PCR reactions were set up using the ABI PRISM®  Big DyeTm Terminator 
Cycle Sequencing Ready Reaction Kit, (PE Applied Biosystems). PCR reactions were 
prepared to a final volume of lOpi, containing the following reagents: 4jtl template DNA 
(100-250ng), 4p.l Terminator Ready Reaction Mix, Ipi primer (3.2pmol), ipi sterile 
distilled water 
Sequencing PCR conditions were as follows; 
Denaturing 95°C for 30 seconds 
Annealing 50°C for 20 seconds x 25 cycles 
Extension 60°C for 4 minutes 
Following the sequencing PCR, the products were purified by precipitation with sodium 
acetate and 95% ethanol, and washed in 70% ethanol 
For sequencing of purified PCR products, internal primers covering the etreme 5' and 3' 
ends of the fragments were used. All fragments were sequenced in opposite directions. 
2.5.8 Analyses of sequencing results 
Sequencing results were analysed using the SeqED V 1.0.3 software (Applied 
Biosystems Inc., 1992). The programme allows the visualisation of chromatograms of the 
sequenced DNA. The relative proportions of the two strains in each sample were 
63 
determined by measuring the two peaks associated with the single nucleotide 
polymorphism that confers pyrimethamine resistance. It was possible, therefore, to 
calculate the percentages of each allele of a gene in each sample. 
2.6 Production of cross progeny 
The experiments described in Chapters IV and V involve the analysis of uncloned 
recombinant progeny of crosses between parasite strains ASpyrl + AJ, ASpyrl + CB, 
and AS(sens) + AJ. All three crosses were carried out using the procedure outlined below. 
2.6.1 Overview of procedure 
To produce a genetic cross between two strains, the two parental clones are inoculated 
into mice to produce a mixed infection (as described in Section 2.5.1), and the resulting 
infections followed by microscopy for the presence of gametocytes. When gametocytes 
are present in the infection, mosquitoes are allowed to feed on the mice, and the 
sporozoites present in the salivary glands of infected mosquitoes 14 days later are 
inoculated intra-peritoneally into mice. 
During the early stages of this project, work was carried out to determine the optimum 
day post mouse inoculation to achieve infections in mosquitoes. The results of this work 
showed that feeding mosquitoes on mice at day 6 post-inoculation produced the greatest 
number of infected mosquitoes. All mosquito feeds in this experiment, therefore, were 
carried out at day 6 post mouse-infection. 
2.6.2 Mosquito feeds 
Six 30cm3 mosquito cages were set up containing & 200 female Anopheles stephensi 
mosquitoes, 5-7 days old. Mosquitoes were maintained on glucose and water solution, 
which was removed 24 hours prior to infective mouse feeds. Blood smears were taken 
from all infected mice on day 6 post infection, and the presence of gametocytes was 
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confirmed. Mice were then anaesthetized with rohypnol solution (Appendix 1), and 
attached to cork boards placed on top of the mosquito cages. Mosquitoes were allowed to 
feed for 30 minutes before the mice were removed. Mice were then killed before 
awakening from the anesthesia. Glucose and water solution was placed back into the 
cages, and egg bowls were provided 2 days post feed. 10 mosquitoes were dissected from 
each cage 7 days after the feeds, to check for the presence of oocysts. 
2.6.3 Infection of mice from sporozoites 
Fourteen days after the infective feed, mosquitoes from each cage were dissected, and the 
salivary glands examined for the presence of sporozoites. If the presence of sporozoites 
was confirmed, all mosquitoes from the cage were dissected, and the salivary glands 
removed. These were placed in a glass tube containing 50% Ringer's solution (Appendix 
1), 45% heat-inactivated calf serum and 5% 200 units/ml heparin solution. The glands 
were then gently crushed using a pestle and mortar in order to release the sporozoites. 
This solution was kept on ice, and injected intra-peritoneally into mice in 0.1 ml aliquots. 
Thin blood smears were taken from infected mice daily, and parasitaemias recorded. 
2.7 Selection of cross progeny 
When the sporozoite-induced infections reached peak parasitaemia (1 O%—1 5%), the 
parasites were harvested, pooled, and inoculated into a group mice (designated the "non-
passaged" group, and containing 3 -5 mice depending on the experiment). Each mouse in 
the group received I x 106  parasites. This initial experimental group was left untreated, 
and the parasites were harvested at peak parasitaemia for AFLP analysis to provide a 
reference point for markers analyzed in the subsequent treatment groups. For the ASpyrl 
+ AJ and the ASpyrl + CB crosses, parasites were pooled and sub-inoculated from the 
"non-passaged" group into two further groups of mice, one of which was treated with 
pyrimethamine ("PYR" group), and the other left untreated ("untreated" group). These 
two groups provided the material for the comparison of markers between drug-treated 
and untreated parasite populations. Pyrimethamine was administered orally at a dose of 
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10 mg/kg of mouse body weight daily at 24-h intervals for 4 days, starting 3h after 
parasite challenge. Both the pyrimethamine-treated and the untreated blood-stage cross 
progeny were allowed to grow to peak parasitaemia (30 0/o-40% for untreated, and I 5%-
20% for treated), at which point the blood was harvested. Two samples of parasite DNA 
were prepared for AFLP and other molecular analyses by pooling separately the blood 
from the treated and untreated mice. For the AS(sens) + AJ cross, blood from the 
sporozoite induced infections was pooled and inoculated into groups of 5 mice serially, 
for 4 passages. Blood was collected for analysis from each of these groups. 
2.8 Amplified Fragment Length Polymorphism (AFLP) analysis 
2.8.1 Preparation of Parasite DNA from experimental groups 
When infections reached peak parasitaemia, blood was extracted from all mice in each 
group by severance of the brachial artery, pooled, and prepared for DNA extraction: 
Blood was filtered in order to remove any mouse lymphocytes or other nucleated cells, 
by running through a 5 ml column of powdered cellulose (Sigma) washed with citrate 
saline. This was repeated twice. Blood was then filtered through PlasmodipurTM filters 
(Euro-Diagnostica) twice. The filtrate was centrifuged for 5 mins at 3000 rpm and the 
supernatant removed, leaving a pellet of packed cells. Twice the pellet-volume of 0.15% 
saponin in Phosphate Buffered Saline (PBS) was added to lyse cells. As soon as lysis of 
erythrocytes was judged to have occurred (associated with a change in colour of the 
solution from bright red to burgundy colour), PBS was added in excess to prevent 
parasite lysis. This solution was then centrifuged again at 4000 rpm for 5 minutes and 
washed twice in PBS. Supernatant was discarded and pellets stored at -70°C. Three thick 
blood smears were taken prior to filtration, after cellulose filtration and after 
PlasmodipurTM filtration in order to determine the efficiency of host cell removal at each 
stage. 
The frozen pellet was re-suspended in 0.4 ml buffer A (Appendix 1), and 10 p1 of 10% 
SDS and 50 tgProteinase K (Sigma) were added. The pellet was left at 37°C overnight. 
The following day, an equal volume of 1:1 phenol/chloroform mixture was added, mixed 
for 3 mm, and centrifuged at 5,000 g for 1-2 minutes. The upper aqueous layer was 
transferred to a fresh tube. The step was repeated 2-3 times. Then an equal volume of 
chloroform was added, and the tube was centrifuged as before for 1-2 minutes. The upper 
aqueous layer was removed to a fresh tube. This procedure was repeated once before an 
equal volume of ether was added, the solution centrifuged as before for 1-2 minutes and 
the upper layer removed. The remaining ether was left to dry in the air. Three volumes of 
absolute ethanol (0 °C) and 1/10th  volume of 3M sodium acetate (pH 5.2) were added to 
the dried pellet, and the tube was mixed and placed on ice for 15-45 minutes to 
precipitate the DNA. The tube was then centrifuged at 10,000 g in a Speed Vac (Savant) 
for 10 minutes and the ethanol mixture removed. The tube was again centrifuged at 
10,000 g for 5-10 minutes to remove final traces of ethanol and the pellet was 
resuspended in 100-200 tl of TE buffer (pH 8.0) (see Appendix 1) and left at 37°C for 10 
minutes before storage at -20 °C. Final DNA concentration was measured by 
spectophotometry (using a BioPhotometer spectrophotometer (Eppendorf)). 
2.8.2 AFLP analysis 
0.5pg of parasite genomic DNA were cut with two enzymes. Firstly, 10 U of EcoRI 
(MB! Fermentas, recognition sequence: GAATTC) were added and DNA incubated at 
37°C for 1 h, then 5 U of TruL/MseI (MBI Fermentas, recognition sequence: T.LTAA) 
were added and DNA incubated for further 3 h at 65°C. The digestion stage was 
performed in a 40 il solution containing 2X Y/ Tango buffer (Promega). The fragments 
were then ligated with adapters matching the cut ends produced by the enzymes. All 
primers used were provided by MWG-Biotech UK Ltd. Adapters disrupted the cutting 
site recognised by the enzymes in order to prevent cutting of the adapters from the DNA 
fragment. These adapters also provided a recognition site for primers. 
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-MseI adapters: MeI.al and MeI.a2 
-MeI.al: 5'-GACGATGAGTCCTGAG-3' 
-MeI.a2: 	3'-TACTCAGGACTCAT-5' 
-EcoRI adapters: EoI.al and EoI.a2 
-EoI.al: 5'-CTCGTAGACTGCGTACC-3' 
-EoI.a2: 	3'-CATCTGACGCATGGTTAA-5' 
Bold letters indicate base substitution to disrupt enzyme cutting site. 
Adapters were prepared by adding equimolar amounts of both strands and then 
performing the following procedure: 
Heat adapters at 94°C for 5 mins, then cool to 21°C for 5 mins 
Heat adapters at 72°C for 60 s., then cool to 21°C for 5 mins 
Heat adapters at 65°C for 60 s., then cool to 21°C for 5 mins. 
Adapters were then diluted to 50 pmol/jJ. 10 p.1 of ligation mixture (Appendix 1) were 
then added to 40 p.1 of digested DNA and this incubated at 37°C for 3h, then overnight at 
15°C. Ligated material was diluted 1:10 in TE buffer (pH 8.0) (Appendix 1) and stored at 
-20°C. 
A preliminary PCR amplification was performed involving the use of "non-selective" 
primers (i.e. primers with no extra nucleotides added at their 3' ends extending beyond 
the adapters sequence) matching the adapters: 
Non-selective EcoRI primer: 5' -GACTGCGTACCAATTC-3' 
Non-selective MseI primer: 5' -GATGAGTCCTGAGTAA-3' 
A 20p.l PCR solution containing 0.32 p.M of each of the non-selective primers, 1 p.1 
template DNA, 0.4 U Taq polymerase (Promega), 1X Mg-free PCR Buffer (Promega), 
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1.5 mM MgC12, and 0.2mM of all 4 dNTPs was set up. The following cycles were 
performed: 
- 94°C for 60 s., then 
- 94°C for 30 s. 
- 56°Cfor60s. 
- 65°C for 60 s. 
- repeat the three steps for 20 cycles 
The resulting PCR material was diluted 50-fold in TE buffer (pH 8.0) and stored at 
-20°C. 
Selective amplification was performed using radiolabelled primer (EcoRI-primer) and 
selective primers (i.e. primers with a selective extension at the 3'-end, in order to reduce 
the number of fragments amplified). For radiolabeling, 2.5X Kinase buffer (Promega), 
20U T4 polynucleotide Kinase (Promega), 100 pCi [y- 33P] ATP / [y-32P] ATP (ICN) and 
500 ng of oligonucleotide primer were incubated in a 20 p1 solution at 37°C for 60 mm. 
The reaction was stopped by adding I tl of 0.1 M EDTA pH 8.0 and heating at 70°C for 
10 mm. The mixture was then made up to a volume of 50 jil by adding sterile, distilled 
water. 
Primer purification was performed using TE Micro Select-D, G-25 microcentrifuge spin 
columns produced by Eppendorf-5 Prime Inc. 
Hot PCR with the radiolabelled primer was performed as follows: 0.32 jtM of the 
selective MseI primer, 0.05 gM of the labelled selective EcoRI primer, I .tl template 
DNA, 0.4 U Taq polymerase (Promega), IX Mg-free PCR Buffer (Promega), 2.5 mM 
MgC12, and 0.2mM of all 4 dNTP's were added to a 20p1 total volume PCR solution. 
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PCR conditions for this stage were: 
- 94°Cfor60s.,then 
- 94°Cfor30s. 
- 65°C for 60 s., annealing temperature is reduced at each cycle by 
0.7°C for the next 12 cycles, then remained at 56°C for the remaining 
23 cycles 
- 65°C for 60 s. 
- repeat the preceding three steps for 35 cycles 
The PCR products were mixed with 20 p1 of loading dye specific for poly-acrylamide 
sequencing gels (Anachem), then heated at 99°C for 3 min and immediately cooled on ice. 
5il of each sample was loaded onto a 5% denaturing polyacrylamide gel (5% acrylamide, 
0.25% methylene bisacryl, 7.5 M urea in 50mM Tris/50mM Boric acid/lmM EDTA). 
500 tl of a 10% Ammonium Persulfate solution (APS) and lOOp! of TEMED (Sigma) 
were added to 100 ml of gel solution and the gel cast using a SequiGen 38x50 cm gel 
apparatus (BioRad). Electrophoresis was performed at 110 W for 2 h in lx TBE buffer. 
Gels were then dried in a vacuum gel drier (model 583, Bio Rad) and exposed overnight 
in phosphorimager screens (Fuji) at -70°C. Results were visualised on an 
autoradiography film (Kodak XAR-5). They were developed in an automatic 
autoradiographer developer (Exograph). 
The entire AFLP procedure is summarised in Figure 1.18 
2.8.3 Measurement and comparison of the intensity of AFLP markers 
Markers between ASpyrl and AJ were identified as bands that were present in one clone, 
but not the other. Marker band intensities were measured with both Phosphorlmager 
(Molecular Dynamics) and IIVIAGEQUANT software (Molecular Dynamics), and the 
values were converted to relative intensity indices (Rils). The RII of an AFLP marker in 
a genetically mixed population of parasites is defined as the intensity of the AFLP marker 
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band in the mixture divided by the intensity of a designated non-polymorphic band in the 
same mixed parasite sample on the same AFLP gel (its intensity index), divided by the 
equivalent ratio (intensity index) of the same two bands (AFLP and non-polymorphic 
band) when measured in a sample of the pure parental strain (Martinelli et al., 2004). For 
the purpose of determining an intensity index, non-polymorphic reference bands were 
chosen close to the polymorphic AFLP bands to minimize error due to any variation in 
gel or image quality (Grech et al., 2002a). 
Comparative Intensity (Cl) is defined as the R11 of an AFLP marker in the cross progeny 
selected by pyrimethamine treatment of mice (Rllp), divided by the Rll of the marker of 
the cross progeny grown in a parallel non-pyrimethamine treated group of mice (RIInp), 
and expressed as a percentage, i.e., Cl = (Rllp/Rllnp) x 100. An example of the 
calculation of the Cl of a marker under selection is given below. 
AS AJ -PYR '+PYR 
Non-polymorphic band "Y"  
Marker "X" 	 NWP 
Ow- 
Figure 2.2 A section of an AFLP polyacrylimide gel showing a marker of the AJ parent which is reduced 
under pyrimethamine selection. 
In order to determine the Comparative Intensity of marker "X" (Figure 2.2, above), the 
following procedure was followed: 
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The intensity of marker "X" was measured in each treatment group, resulting in 
the following values; 
Treatment AS 
Group  
AJ -PYR +PYR 
Intensity 20 300 150 26 
These intensity readings were then corrected for lane bias by dividing the values 
by the intensities of a nearby non-polymorphic band (marked "Y" in Figure 2.2); 
Treatment AS 
Group  
AJ -PYR +PYR 
Intensity "X" 20 300 150 26 
Intensity "Y 400 400 400 400 
XIY 0.05 0.75 0.375 0.065 
"Relative Intensities" were then calculated by dividing the corrected intensities by 
the value for the AJ parent (0.75), giving; 
Treatment AS AJ -PYR +PYR 
Group  
Relative 0.06 1 0.50 0.08 
Intensity  
The degree by which the marker under PYR treatment was removed compared to 
the same marker in the non-treated group is given by the Comparitive Intensity - 
in which the Relative Intensity of the marker under PYR treatment is divided by 
the Relative Intensity of the same marker in the absence of drug treatment and the 




08 JX 100 = 16% 
2.8.4 Assignment of AFLP markers to locations in a P. chabaudi genetic linkage map. 
Markers were ordered on a genetic linkage map of P. c. chabaudi (Martinelli, 2003) 
obtained from previously generated crosses between AS-derived clones and AJ strains of 
P. c. chabaudi (Walliker et al. 1975; Rosario 1976; Carlton et al. 1998). A total of 674 
AFLP markers were typed for each of 28 cross-progeny clones, and were subsequently 
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assigned to linkage groups using the Map Manager QTX software (Manly et al. 2001). A 
total of 44 RFLP markers characterized in a previous study (Carlton et al. 1998) were 
used as genetic anchors to allow the assignment of the various linkage groups to 
chromosomes. In total, 11 chromosomes could be identified, while 12 linkage groups of 
as yet unknown assignment remain, which include the three remaining chromosomes 
(i.e. chromosomes 2, 4, and 14). A more detailed account of this process is available 
(Martinelli, A., Hunt, P., Fawcett, R., Cravo, P., Walliker, D. & Carter, R., in prep.). 
2.8.5 Sequencing of. AFLP markers, and their location on the Plasmodium 
falciparum genome 
AFLP bands that appeared to be under selection were excised from acrylamide gels using 
a sterile scalpel. The gel fragments were then soaked in an EppendOrf tube in 50 jtI of 
autoclaved distilled water (sdH20) overnight. Gel slices were centrifuged at 12000 g 
prior to removal of the liquid phase containing the DNA. DNA was precipitated using 
1/10 volume of 3M sodium acetate (1iH 5.2) and 3 volumes of ice-cold absolute ethanol. 
The solution was placed at -20°C for at least I h. Thereafter the tubes were spun for 30 
minutes at high speed. The liquid phase was removed and the DNA pellet washed twice 
in 70% ethanol, before air drying. The pellet was then dissolved in 50 .tl TE buffer (8.0 
pH). The extracted DNA fragment was amplified by PCR, using the same selective AFLP 
primers and PCR conditions that produced it. Sequencing reactions were carried out 
using the protocol described in Section 2.5.7. The sequences of markers were then 
physically mapped in the P. falciparum genome (sequence data for P. falciparum were 
obtained from the Sanger Centre website, which can be accessed at 
www.sanger.ac.uk_Proiects P_falciparum), using BLAST searches. 
2.9 Proportional sequencing of dhps, dhfs, 6-pthps and mdr-1 
The analysis of the cross progeny described in Chapters IV and V involved Proportional 
Sequencing (Section 2.5.5) of alleles of dhps, dhfs, 6-pthps and mdr-1. The same PCR 
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pcdhps —11: GTACGCAGAATATTTCAAATG 
pcdhps —12 : CTTTTTATTGGGTATTCAAGG 
Inner PCR 
pcdhps —07 : CTTTTGTTTCTCATAATCCAG 
pcdhps —07 : GGTTTAGGTTTTGCAAAGAA 
dhfs: 
Outer PCR 
pcdhfs —03 : ATTAGGAGGAAGATTGGATG 
pcdhfs—IO: GTTTTTTACTTGCCGTCAAT 
Inner PCR 
pcdhfs —04 : TTACATCAATTGGTTATGACC 
pcdhfs —09 : GGCAAGATATATACATTTG 
6-pthps: 
Outer PCR 
pcll.-cg25-02 : CAGAACTTTTAGTTGAATCA 
pci i-cg25-04 : GTGAACAAATCTGTGCAGCTA 
Inner PCR 
pc6pthps —05 : AATCACCAGCATTTACATTTC 
pc6pthps —06 : GGTATATATAAGAGAAATCAGG 
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RESULTS 
The results of the present work are divided into three chapters: 
Chapter III describes the results of experiments designed to determine the optimum 
drug regimen for the selection of pyrimethamine resistant parasites from a mixture 
containing both sensitive and resistant parasites. These experiments also involved the 
use of a quantitative technique (proportional sequencing) for following the fate of 
single clones in mixed infections. The second round of these experiments also 
investigated the results of competition between resistant and sensitive clones in two 
different strains of mice. 
Chapter IV is concerned with the results of an LGS experiment conducted with the 
uncloned recombinant progeny of a cross between a pyrimethamine resistant 
(ASpyrl) and a sensitive (AJ) cloned strain of P. c. chabaudi. This data forms the 
basis of the "proof of principle" for the validation of the theory of LGS. 
• Chapter V presents the results of an investigation into the fate of the resistant allele 
of dhfr in a population of parasites containing both the sensitive and resistant alleles 
in the absence of drug treatment. It also describes the results of experiments 
conducted on a cross between the pyrimethamine-sensitive precursor of ASpyrl and 
AJ parasites. These experiments were designed to investigate the "fitness cost" 
associated with the dhfr PYR resistance mutation. 
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CHAPTER III 
EXPERIMENTS WITH DRUG SELECTION OF MIXED INFECTIONS OF 
PYRIMETHAMINE RESISTANT AND SENSITIVE STRAINS. 
This chapter presents the results of experiments designed to investigate the drug response 
of mixtures of pyrimethamine resistant and sensitive parasites. The main aim of these 
experiments was to determine the optimum drug regimen for the selection of 
pyrimethamine resistant parasites grown in a mixture with a sensitive strain. 
3.1 Introduction 
The experiments described in this chapter are concerned with the dynamics of malaria 
infections in which both drug-resistant and drug-sensitive parasites are present. In order 
to carry out a complete LGS analysis on the progeny of a cross between ASpyrl and AJ 
(Chapter IV) it was essential to understand how mixtures of drug-sensitive and drug-
resistant parasites would respond to drug pressure. Although drug regimens had 
previously been optimised which effectively remove sensitive parasites but are tolerated 
by resistant clones, these had been tested only on pure clonal infections. It is possible that 
the presence of drug-sensitive parasites in an infection may alter the drug response of 
resistant parasites and vice versa (Burudi et al., 1994). The first experiment described 
here attempts to address this problem by following the fate of drug-sensitive and drug-
resistant clones in a 50:50 mixture through mice in the presence of two differing drug 
regimens, as well as in the absence of the drug. This experiment also allowed an 
evaluation of the Proportional Sequencing technique's ability to quantify the proportions 
of two different alleles of a gene throughout the course of an infection. The second 
experiment described in this chapter also addresses the differences in the growth of drug-
sensitive and drug resistant parasites in the presence and absence of drug treatment. In 
addition it includes an analysis of the effect of host genotype on the dynamics of such 
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infections. Some of the results from these experiments have been published (de Roode et 
al., 2004a; de Roode et al., 2004b). 
3.2 Drug Selection Experiment A 
The aim of this experiment was to determine whether it was possible to follow the 
disappearance of a strain under a selection pressure in a mixed infection of two strains, as 
well as to provide data on how the two strains respond to different levels of drug 
treatment in a mixed infection. 
Two cloned strains of P. chabaudi which differ in their sensitivity to pyrimethamine 
ASpyrl (resistant) and AJ (sensitive) were passaged through mice in 1:1 mixtures (5x10 5 
parasites of each clone) under two different drug regimens (20mg/kg, and 5mg/kg PYR 
for 4 days), and also through mice left untreated. Figure 3.1 shows a graphical summary 
of the experimental procedure. 
Drug Selection Experiment A. 
Control 	 High dose 	 Low dose 
	
1 x 106  parasites 	1 x 106  parasites 	1 x 106  parasites 
1:1 AS:AJ 1:1 AS:AJ 1:1 AS:AJ 
4 Y CBA mice 	 4 Y CBA mice 	 4 YCBA mice 
Untreated 	 20mg/kg PYR for 4 days 	5mg/kg PYR for 4 days 
Figure 3.1 The experimental groups used in drug selection experiment A. Infections were followed by thin 
blood smear on days 4,6,7,8 and 10 post-inoculation (PT), and blood samples were taken for proportional 














0 	1 	2 	3 	4 	5 	6 	7 	8 	9 	10 	11 
—control —low dose —s—high dose 
I 	I 	I 	AS single 	 AJ single 	—.—AS single high dose 
Day Post-Inoculation 	—4--AJ single high dose 
Figure 3.2 The mean parasitaemias of the three treatment groups through time, including single infection 
data for the two constituent clones. The arrows (1) indicate the days upon which PYR was administered to 
the drug-treated group. Each group consists of 4 mice, with the error bars representing 95% confidence 
intervals of the means. The untreated and low dose groups were terminated at day 8 due to high 
parasitaemias. Control = Untreated Mice. Low dose = 5mg/kg PYR for 4 days. High dose = 20mg/kg for 4 
days. 
Figure 3.2 shows the parasitaemias of the mice in all three treatment groups, as well as 
data for single clone infections in the presence and absence of pyrimethamine. The 
untreated control group shows the natural course of a 50:50 mixed infection of 
ASpyrl+AJ, with the mean parasitaemia reaching a peak of 59.3% (n = 4, 95% 
confidence interval (Cl) = 2.86) at day 7 post infection. The low dose group shows lower 
total numbers of parasites than the control group, with a mean peak parasitaemia of 
42.2% (n = 4, Cl = 9.89) also at day 7 post infection. The infections in the high drug dose 
group show considerable retardation of parasite growth, with a mean peak parasitaemia 
of 30.6% (n = 4, Cl = 6.43) attained at day 10 post infection. This is comparable with the 
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Using Proportional Sequencing based on the pcdhfr gene (see Chapter 2), it was possible 
to quantify the proportions of each strain in the infections. Figure 3.3 shows the 
percentage of the drug resistant strain (ASpyrl), in the above infections. 
• 	Untreated 1 
• 	Untreated 3 
• Untreated 4 
-*---- Low dose I 
-.- Low dose 2 
-4---- Low dose 3 
- Low dose 4 
---High Dose 1 
-'- High Dose 2 
-.-- High Dose 3 
Figure 3.3 The percentage of ASpyrl parasites in the three treatment groups through time. Each line 
represents one mouse. Data is available for 3 out of 4 mice in the untreated and high dose groups due to 
problems during DNA extraction. Control = Untreated Mice. Low dose = 5mg/kg PYR for 4 days. High 
dose = 20mg/kg for 4 days. 
The initial inoculum (i.e. the mixture of AS+AJ administered to all mice) was shown to 
contain 49.3% ASpyrl. In the control group, the percentage of ASpyrl dropped to a 
mean of 24.8% (n = 3, CI = 7.37) by day 4 post infection. By day 8, however, ASpyrl 
recovered to 5 1.6% and 27.7% in the two mice for which data is available. In three out of 
four mice in the low dose group, the percentage of ASpyrl in the mixtures rose to a mean 
of 91.63% (n = 3. CI = 7.92) by day 4 post infection. This remained constant at day 6, the 
last day of sampling for this group. One infection in this group showed a reduction in the 
proportion of ASpyrl present, dropping to 23.8% on day 4, and 18.6% on day 6. In the 
group receiving the high drug dose, ASpyrl increased from 49.3% to a mean of 55% (n = 
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3, CI = 0.96) by day 4. In two infections, ASpyrl reached a mean of 94.9% by day 6 (n 
2, CI = 5.49), and one infection reached 97.1% AS by day 8. 
These results show that AJ outgrows ASpyrl by day 4 in non drug-treated infections. 
This domination of AJ in a mixed infection is not total, however, as some ASpyrl 
parasites remain to recrudesce later in the infection. The high dose group sees the 
elimination of pyrimethamine-sensitive AJ parasites by day 6 in 3 mice, and by day 8 in 
the remaining mice. This high level of pyrimethamine also significantly inhibits the 
growth of ASpyrl parasites in the mixture, with little growth seen until day 6 pot-
infection (the last pyrimethamine dose was administered on day 3 P1). In the low 
pyrimethamine dose group, ASpyrl dominates the mixed infection by day 4 PT in 3 out of 
4 mice. This dose of pyrimethamine inhibits the growth of AJ in these mice, while 
allowing ASpyrl to grow normally. The fourth infection in this group sees AJ dominating 
the mixture on days 4 and 6 P1. It is possible that in this individual, enough AJ parasites 
survived the drug treatment to out-compete ASpyrl due to their faster growth rate. 
3.2.2 Discussion 
The following discussion of the results of drug selection experiment A is divided into 3 
paragraphs, each discussing one of the treatment groups 
3.2.2.1 Untreated control group 
In this group, the only selection pressure on the strains is direct competition with the 
other strain in the mixture. The proportion of AJ is seen to increase significantly by day 4 
of the infection, due to its faster growth rate compared to ASpyrl (Figure 3.3). It does 
not, however, completely dominate the infection, as ASpyrl is seen to recover slightly by 
day 8 in two mice. This result can be explained in the context of strain specific immunity, 
in which the host's immune response -to an infection of malaria parasites is specific to the 
strain that induces the response (Eisen et al., 2002). As AJ is the dominant parasite in the 
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mixture in the early stage of the infection, it is possible that it elicits an immune response 
from the host that is specific in targeting only AJ parasites. This could allow ASpyrl 
parasites that are not targeted by such a strain-specific immune response to out-compete 
AJ in the infection by day 8. 
3.2.2.2 High drug-dose group 
In this group, the proportions of the two strains appear to remain constant up to day 4 Pt. 
This could be due to the high drug dose arresting the growth of both the drug sensitive 
and drug resistant parasites. When the total parasitaemias of the group are analysed, it can 
be seen that very little growth occurs in the first 4 days post infection (Figure 3.1). As the 
growth of both strains has been inhibited during this early period, no change in 
proportions is seen by day 4. By day 6, however, ASpyrl has increased to almost 100% 
in two mice. This shows that some resistant parasites have survived the high drug 
pressure, and remain viable to start growing when the drug pressure is removed 
(pyrimethamine is administered up until day 3). Indeed, single clone infections composed 
of only AS(pyrl) are equally retarded in the presence of pyrimethamine. However, it also 
indicates the presence of a small proportion of the sensitive AJ parasites. It has been 
shown that DNA from dead parasites remains detectable by PCR up to 48 hours after 
parasite death (Jarra and Snounou, 1998). As drug treatment is given over 4 days with the 
last dose on day 3 P1, any AJ DNA amplified by PCR at day 4 of the infection could be 
due to residual "non-viable" parasites that have yet to be removed from the circulation. 
3.2.2.3 Low drug-dose group 
The application of a lower drug dose to this group allows ASpyrl to outgrow AJ by day 4 
Pt. This dose of drug inhibits the growth of AJ while allowing the resistant ASpyrl to 
grow. Three infections in this group all show the domination of ASpyrl parasites in the 
mixture by day 4 Pt, and this remains constant at day 6. In one mouse, however, the 
proportion of ASpyrl drops by days 4 and 6 Pt in much the same way as in the untreated 
control group. This cannot, however, be due to failure of drug treatment, as the 
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parasitaemia of this mouse is comparable with the other mice in the group, which show a 
marked effect of drug treatment inhibiting the growth of the infection. It is possible that 
in this infection, enough AJ parasites survived the drug pressure to allow the growth rate 
factor to influence the infection. This drug regimen, then, acts as an "imperfect selection 
pressure" in which it is possible for growth rate differences to overcome an applied 
selection pressure. Even though there is a selection pressure (pyrimethamine treatment) 
against the faster growing parasite, if it is not strong enough to completely arrest the 
growth of the faster growing strain, then growth rate factors can still determine the 
outcome of an infection. 
The overall results of this experiment show that it is possible to follow the disappearance 
of a single cloned strain of parasites under an applied selection pressure in infections 
containing a mixture of two genetically distinct clones. This experiment is the first to 
follow the growth of two strains in the same host throughout an infection using the 
Proportional Sequencing technique. It shows that the growth rate differences between 
ASpyrl and AJ are extremely important in determining the proportions of parasites in a 
mixture, especially in the early stages of infection 
The results from this experiment led to the design of the following drug selection 
experiment (Drug Selection Experiment B) involving mixtures of ASpyrl and AJ. It was 
seen from the previous experiment (Drug Selection Experiment A) that domination of the 
mixture by one or other of the strains was usually achieved by day 4 post infection. Drug 
Selection Experiment B was, therefore, designed to include daily blood sampling from 
day 1 post infection, in order to understand what is happening to ASpyrl and AJ in a 
mixture during the early stages of infection. 
3.3 Drug Selection Experiment B 
This experiment was carried in order to understand the interactions between ASpyrl and 
AJ in mixtures in the early stages of infection. Nine experimental groups were used, with 
50:50 mixtures of ASpyrl and AJ grown in both C57 and CBA mice, along with the 
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appropriate single infection controls (see Figure 3.4). The drug regimen used was 10 
mg/kg for 4 days. Both CBA and C57 mice were used in order to investigate whether 
there was any difference in parasite growth between these 2 mouse strains. Single strain 
infections were used to assess any differences in drug response between strains growing 
in mixed and single clone infections. 
Drug Selection Experiment B 
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I______ 	 ___________ 	I 
Pyrimethamine 	 Pyrimethamine 	 Pyrimethamine 
10 mg/kg days 0-3 10 mg/kg days 0-3 10 mg/kg days 0-3 
Figure 3.4 The experimental groups used in drug selection experiment B. Infections were followed by thin 
blood smear daily from day 1 until day 21 P1, and blood samples were taken daily on days 1-7 P1. 
3.3.1 Results 
The parasitaemias throughout the course of the infections for all treatment groups are 
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Figure 3.5 The mean parasitaemias of all treatment groups (n=5) up to day 21 P1. The arrows (1) indicate the days UOfl which PYR (10mg/kg) was 
administered to the drug-treated groups. The 9 groups have been split into 3 graphs for clarity; the scales of all graphs are equal. Panel A shows AJ single 
infections, B shows ASpyrl single infections and C shows mixed ASpyrl+AJ infections. Panel D shows the total areas under the parasitaenhia curves for 
each treatment group. Error bars indicate 95% confidence intervals for the means. 
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3.3.1.1 Statistical analysis of parasitaemia differences 
Data were analysed using a General Linear Model ANOVA in Minitab (v. 13.1, Minitab 
Inc.). The explanatory variables used were mouse strain, parasite strain and drug 
treatment. Mouse strain and drug treatment had two factors each (CBA and C57, and 
PYR-treated and non-treated respectively) and parasite strain had three factors (AS, AJ 
and AS+AJ). Analysis was performed on the total areas under the parasitaemia graphs for 
each treatment group, and these data were log transformed to meet the necessary 
normality and homogeneity-of-variance assumptions. Significant differences between 
individual treatment groups were identified by t-test analyses. 
There was a significant effect of parasite strain (F2,31 = 11.4, p < 0.00 1), mouse strain 
(F1,31 = 20.6,p < 0.001) and drug treatment 
( F1,31 = 17.4,p < 0.001) on the parasitaemias 
of mice in each of the 9 groups. Differences between individual treatment groups were 
analysed by Student's t-tests, the results of which are summarized in Table 3.1. 
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AS+AJ AS+AJ AS+AJ AS AS AS AJ AJ AJ 
C5 7 CBA CBA C5 7 CBA CBA C5 7 CBA CBA 
pyr pyr  Pyr 
AS+AJ 
C57 -- 0.002" n/a <0.001 n/a n/a 0.892 n/a n/a 
AS+AJ' 
CBA --- <0.001 n/a 0.002" n/a n/a 0.043 k n/a 
AS+AJ 
CBA -- n/a 0.011* 0.563 n/a n/a <0.001" 
pyr  
AS 
C57 - <0.001" 0.020 <0.001 n/a n/a 
AS 
CBA 0.031* n/a 0.001" n/a 
AS 
CBA --- n/a n/a <0.001" 
pyr  
AJ 
C57 0.011 n/a 
AJ I 




Table 3.1 The results of t-tests between individual treatment groups. • < 0.05, 	< 0.01, n/a = 
comparison not applicable 
It can be seen that there was a significant growth rate difference between the two, parasite 
strains, with AJ growing faster and reaching a higher parasitaemia than ASpyrl in single 
clone infections. This result was independent of mouse strain, with AJ outgrowing 
ASpyrl in both C57 and CBA mice. Mouse strain had a significant effect on parasite 
growth regardless of the strain of parasite and whether the infection was single clone or 
mixed, with parasite growth in C57 mice being lower than in CBA mice. Mixed 
infections produced significantly more parasites than single clone infections in CBA 
mice, but in C57 mice, there was no difference between the total parasitaemias of single 
clone AJ (the faster growing parasite) infections and mixed infections. Drug treatment 
completely arrests the development of AJ, with no parasites being visible up to day 21 PT. 
The growth of ASpyrl under pyrimethamine treatment was also significantly reduced, 
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but, interestingly, mouse strain had a more significant effect on the growth of ASpyrl 
than drug treatment, with ASpyrl growing significantly faster in CBA mice than in C57 
mice. Drug treatment had a significant effect on the growth of the parasites in the 
mixtures, comparable with that seen in drug selection experiment A. There was no 
difference between the growth of parasites in the drug treated mixture and the drug 
treated ASpyrl single infection. 
3.3.1.2 Effect of parasite strain on host body weight 
Previous work with P. chabaudi has shown that genetically distinct clones differ in their 
virulence (measured as anaemia, weight loss and mortality) (Mackinnon and Read, 
1999a). In order to investigate differences in virulence between the parasite strains used 
in this experiment (and to assess if mixed infections were more virulent than single clone 
infections), the effect of parasite strain on host body weight was measured. A comparison 
of parasitaemias between parasite strains elucidates the differences in growth rates 
between parasites, but is not a direct measure of virulence (where virulence is defined as 
"the ability of the pathogen to produce disease"). As a measure of the virulence of a 
parasite must include its effect on the host, changes in mouse body weight were recorded 
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Figure 3.6 The mean weights of mice in all treatment groups (n5) up to day 21 P1. The 9 groups have 
been split into 3 graphs for clarity; the scales of all graphs are equal, with the y-axis showing weight in 
grammes and the x-axis day post-inoculation. Panel A shows ASpyrl single infections; B shows AJ single 
infections and C shows mixed AS±AJ infections. Error bars indicate 95% confidence intervals for the 
means. 
ASpyrl parasites in single clone infections elicit no apparent weight loss in C57 mice, 
consistent with the low parasitaemia in this group (Figure 3.5). There is some weight loss 
peaking at day II P1 in the CBA mice, but this effect is removed with the addition of 
drug treatment. Infections with AJ parasites cause a marked weight loss in both CBA and 
C57 mice, with the latter effect being less pronounced. There is no apparent weight loss 
in the drug treated AJ infections. Mixed clone infections produce similar weight loss 
effects to single AJ inections, with the effect more pronounced in CBA mice compared to 
C57 mice. Again, the drug treated group shows no weight-loss effect of infection. 
3.3.1.3 Analysis of strain composition of mixed infections 
In order to quantify the proportions of each clone in the mixed infections, Proportional 
Sequencing was carried out as for drug selection experiment A. The data shown in Figure 
3.7 represents the Proportional Sequencing results for the mixed infections in CBA mice 
in drug treated and untreated infections. There are 8 single nucleotide polymorphisms 
between ASpyrl and AJ in the dhfr gene, and the proportions given in Figure 3.5 
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Figure 3.7 The proportion of ASpyrl in mixed infections of ASpyrl±AJ for the drug treated (PYR, 
10mg/kg for 4 days). The arrows () indicate the days upon which PYR was administered to the drug-
treated group. The dotted lines between day 0 and day 1 P1, indicated by an arrow (4w), represent an 
extrapolation from the hypothetical proportions of the alleles at day 0 (50%), which were not measured 
directly. Error bars indicate 95% confidence intervals for the means. There were five mice in each group, 
but each data point represents the mean for those mice for which proportional sequencing data was 
available (between 2 and 5). The open data point at day 7 in the drug-treated group indicates the 
Proportional Sequencing data for one mouse in the group. 
Both groups were infected on day 0 P1 with the same initial inoculum comprising of 
50:50 ASpyrl: AJ parasites. No molecular data is available on the actual proportions of 
the parasite clones in this inoculum, but previous experiments have shown that the 
techniques used to produce the mixed inoculum are accurate, and a variation of greater 
than 10% in favour of one particular clone is unlikely. It can be seen that by day 1 P1, 
there was already a significant difference between the two groups, with the untreated 
infection composed of more than 80% AJ, a reflection of the higher growth rate of this 
parasite. By day 4 P1, the proportion of the AJ clone had increased to above 95%, at 
which level it remained constant until day 7, the last day of sampling. There was not, 
however, complete exclusion of the ASpyrl parasite from the infection, and some 
residual ASpyrl parasites remained. Indeed, further analysis of this group at days 35 - 45 
EEO 
P1 showed relapse parasitaemias consisting of mainly ASpyrl parasites (de Roode et al., 
2004b). In the drug treated group, the AJ parasites are removed by day 6 P1, leaving only 
the resistant ASpyrl parasites present in the infection. Subsequent sampling of this 
infection after day 7 showed no re-emergence of AJ parasites (data not shown). 
3.3.2 Discussion 
In the pyrimethamine treated mixture, the proportion of ASpyrl initially drops to 32% at 
day I (from an initial inoculum containing 50% of each strain), before recovering to 88 % 
by day 5, and 97% by day 7 post infection. This represents an increase of AJ from 50% to 
68% by day I and can be explained in the context of the drug regimen administered. 
Pyrimethamine is given over the course of 4 days, and it is likely that the first drug dose 
is not enough to kill off all AJ parasites. This allows the faster growing AJ parasites to 
outgrow ASpyrl after this initial pyrimethamine treatment. Drug treatment on subsequent 
days, however, further inhibits the growth of AJ parasites, allowing the resistant ASpyrl 
strain to dominate the infection. A further explanation is that DNA from "dead" AJ 
parasites was amplified on days 1, as it has been shown that DNA from dead parasites 
remains detectable by PCR up to 48 hours after parasite death (Jarra and Snounou, 1998). 
In the untreated mixture, AJ is seen to outgrow ASpyrl, reaching a proportion of 96% by 
day 3 post infection. This shows that growth rate is a very strong selection pressure 
between these two parasite strains. The possibility that the growth rate differences 
between these parasites are related to a fitness cost associated with the S106N 
pyrimethamine-resistance mutation is discussed further in Chapter V. No recrudescence 
of ASpyrl was seen up to day 7 post .infection, although it was subsequently shown that 
ASpyrl was not completely eliminated from the infection, as it re-appeared after the 
chronic phase (days 35-45) (de Roode et al., 2004c). The rate by which AJ outgrows 
ASpyrl in a mixed infection had not been previously determined, and this result has 
important implications for understanding growth rate effects as a confounding factor in 
the LGS approach to gene identification. 
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The results from this experiment confirm the findings of drug selection experiment A, 
that AJ out-competes ASpyrl in mixed infections, and that it is possible to follow the 
proportions of genetically distinct parasites through mixed infections using proportional 
sequencing. This experiment gives an indication of the time scale over which the drug-
resistant strain outgrows the sensitive strain under drug pressure, and the rate at which the 
sensitive parasites dominate the infection in the absencë of such pressure. This is 
important to know for the optimal design of LGS experiments, in which parasites should 
be harvested from infections at the point in time at which there is the largest difference in 
proportions between the "sensitive" and "resistant" parasites for the selection pressure 
under investigation. 
3.3.2.1 Host heterogeneity and the dynamics of co-infections with parasites of 
differing growth rates and susceptibilities to pyrimethamine 
The results from both Drug Selection Experiment A and B show that ASpyrl is at a 
competitive disadvantage when grown in mixed infections with AJ. This can be 
explained by the fact that ASpyrl has a slower growth rate than AJ (observed by 
comparisons between single strain infections), and so the proportion of AJ in a mixed 
infection of the two strains would be expected to increase as the infection proceeds. What 
controls this difference in growth rate between the two strains is currently unknown, 
although suggestions for factors influencing growth rate differences between malaria 
parasites include erythrocyte selectivity, antigenic differences, intra-erythrocytic 
replication rates and cytoadherence factors (reviewed in Chapter I). The two strains used 
in these experiments also differ in their response to pyrimethamine, with the ASpyrl 
strain possessing a mutation in the dhfr gene that confers resistance to the drug. It is 
possible that this resistance mutation also confers a cost to the parasite that lowers its 
fitness compared to sensitive parasites in the absence of drug pressure. This possibility is 
explored in more detail in Chapter V. 
One of the more striking results of these experiments was the differences in the growth of 
parasites observed between mouse strains. Different strains of mice are known to have 
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varying levels of susceptibility to infection with P. chabaudi, and the genetic 
determinants regulating this effect are complex (Fortin et al., 2002; Stevenson et al., 
1982). In the current experiments, both strains of parasite achieved significantly higher 
levels of parasitaemia in CBA mice than in C57 mice, (this was also true for mixed 
infections). Most interestingly, the differences in growth rates of parasites observed 
between mouse strains was more pronounced for ASpyrl parasites (p <0.001) than for AJ 
parasites (p =0.0 1). 
One possible explanation for this effect is that ASpyrl parasites may provoke a stronger 
immune response from the host than AJ parasites (differences in immunogen i city), or 
they may be more susceptible to the immune response than AJ parasites. Such differences 
would not be detectable in single strain infections through one host genotype, as they 
would manifest simply as growth rate differences between strains. However, the fact that 
the growth of ASpyrl is suppressed to a greater degree in C57 mice (which have greater 
intrinsic immunity against the parasite than CBA mice (Stevenson et al, 1982)), than AJ 
suggests that host immune status is a greater restraint on the growth rate of ASpyrl than 
it is for AJ. In experiments conducted as part of an investigation into strain specific 
immunity in P. chabaudi, it was found that immunity induced against ASpyrl conferred a 
greater level of protection against challenge with other, genetically diverse strains, than 
did immunity induced against the other strains tested (R. Carter, pers. corn.). This 
supports the hypothesis that the relatively slow growth rate associated with ASpyrl 
infections is a function of the strong immunity which this strain induces against itself. Of 
course, such host-immunity mediated strain-specific growth rate differences are unlikely 
to be manifest in the early phase of an infection (i.e days 0-5), as strain-specific host 
immunity will not have developed during this period. 
3.3.2.2 Implications of these results for the design of an LGS investigation into 
pyrimethamine resistance 
The results from these two drug selection experiments provide important information on 
the interactions between ASpyrl and AJ parasites in a mixture. They provide information 
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on the time scale over which growth rate factors influence the proportions of parasites in 
mixed infection, and how the parasites respond to drug treatment. One of the main 
purposes of the experiments was to assess different levels of pyrimethamine dose, in 
order to carry out the LGS "proof of principle" experiment on the progeny of a cross 
between ASpyrl and AJ under pyrimethamine pressure (Chapter IV). Three levels of 
pyrimethamine dose were been investigated in these experiments. The lowest dose (5 
mg/kg) appears to provide the closest approximation of an imperfect selection pressure 
with some sensitive AJ parasites surviving the drug treatment. The highest dose used 
(20mg/kg) not only arrests the growth of drug sensitive parasites but also significantly 
affects the growth of the resistant strain. The intermediate drug dose (10mg/kg) was 
therefore chosen as the most suitable to use in the LGS experiment with the progeny of a 
cross between ASpyrl and AJ. 
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CHAPTER IV 
EXPERIMENTS TO PROVE THE PRINCIPLE OF LINKAGE GROUP 
SELECTION USING PYRIMETHAMINE SELECTION. 
- This chapter describes the application of LGS to a study of pyrimethamine resistance in P. 
c. chabaudi. The results of experiments aimed at testing the principle of LGS using a 
selectable phenotype for which the controlling genetic locus has been previously 
identified are presented. 
4.1 Introduction 
The main aim of these experiments was to test the principle of LGS by using a system in 
which the gene controlling the selectable phenotype is already known. A complete LGS 
experiment was carried out usin the uncloned recombinant progeny of a cross between P. 
chabaudi clones AJ and ASpyrl. These are genetically distinct cloned isolates of P. 
chabaudi that differ in their response to pyrimethamine, with ASpyrl being resistant to 
the drug, while AJ is sensitive. As discussed in Chapter I, resistance to pyrimethamine in 
P. chabaudi is conferred by a single base mutation in codon 106 (Si 06N) of pcdhfr (the 
P. chabaudi dihydrofolate reductase gene locus) which is homologous to the pfdhfr 
SI 08N mutation associated with pyrimethamine resistance in Plasmodium falciparum 
(Cheng and Saul, 1994). By applying pyrimethamine drug pressure to the uncloned 
recombinant progeny of a cross between these two parasites, it was hoped to identify 
AFLP markers of the sensitive (AJ) parent that were selected against by the drug 
treatment, while all other unlinked markers remained unselected by the drug pressure. By 
showing that markers linked to the AJ allele of dhfr were removed or reduced in 
proportion to their physical proximity to the allele by the selection pressure, the 
principles underlying LGS would be validated. 
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4.2 LGS experiment on previously generated crosses 
The first of these experiments involved applying pyrimethamine pressure (following the 
drug regimen optimised by the experiments described in Chapter III) to the uncloned 
recombinant progeny of 3 previously generated crosses which were available as deep 
frozen stabilates in this laboratory (described in Table 4.1). 
Cross Name Year 
Published 
Number of Recombinant 
Clones analysed  
Reference 
Walliker eta! 1975 10 (Walliker et al., 
1975b) 
Rosario 1976 38 (Rosario, 1976) 
Carlton eta! 1998 20 (Carlton et al., 1998) 
Table 4.1 Information relating to the history of the three crosses used in this experiment 
The decision to use these crosses was taken in order ta avoid the potentially time-
onsuming task of generating a new cross between these parasites. One of the conditions 
of LGS is that large numbers of recombinant progeny clones are present in the selected 
population. As these crosses had previously yielded reasonable numbers of cloned 
recombinants (68 independent recombinant clones in total) it was hoped that the uncloned 
progeny would contain adequate numbers of recombinants for an LGS analysis. Concerns 
were raised, however, about the viability of these recombinants after long term storage in 
liquid nitrogen, and the possible selection of faster-growing parasites through previous 
serial passage, so it was decided to pool all three 'brosses in order to maximise the 
numbers of recombinants present. The three crosses were removed from the deep freeze, 
pooled and inoculated into 4 experimental CBA mice, and the resulting infections 
monitored as described in Chapter II. When these infections reached their peak 
parasitaemias, blood was collected from all mice by incision of the distal portion of the 
tail, pooled and sub-inoculated into two further groups of 3 mice each according to the 
protocols previously described. One group was left untreated, so that a normal course of 
parasitaemia was observed, while the other group was treated with pyrimethamine 
according to the regimen previously determined. Parasites from all three experimental 
groups were collected at peak parasitaemia, and prepared for AFLP as previously 
described (Chapter II). See Figure 4.1 for a schematic representation of this experiment. 
The relative intensities of AFLP markers of each of the 3 experimental groups were 








4 	Pooled crosses subinoculated 
into 4 CBA mice 






















--- Drug Treated 
0.1 
0 	 2 	 4 	 6 	 8 	 10 	 12 	 14 
t DayPi 
Figure 4.2 Parasitaemia curves for the Untreated and Pyrimethamine Treated uncloned cross progeny of 3 
independent crosses of AJ and ASpyrl. The arrows (1) indicate the days upon which PYR (10mg/kg) was 
administered to the drug-treated group. Mice were killed and bled when parasitaemias exceeded 20%. 
Each group contains 3 mice, with the error bars indicating the standard deviation of the means. 
Figure 4.2 shows the mean parasitaemias of the mice in the two experimental groups. It 
can be seen that PYR treatment suppresses the growth of the parasites until day 7, when 
the resistant parasites recover and follow a normal growth curve. Mice were killed and 
bled when parasitaemias exceeded 20%, and parasite DNA was extracted as described in 
Chapter 11. This DNA was then prepared for AFLP analysis, and AJ marker intensities 
were compared between the untreated and PYR-treated groups. A total of 4 AFLP gels 
were run, comprising of 20 EcoRl/Msel combinations, from which it was possible to 
analyse 63 AJ markers. An example of two of the EcoRl/MseI combinations for this 
experiment is shown in Figure 4.3. 
ASAJI23 	ASAJI23 
Figure 4.3 Example of an AFLP gel showing 
markers generated from the experiment described 
above. This gel shows the results of bands 
generated with MseI (CA selective bases) + EcoRl 
(AG selective bases) in the left hand set of lanes, 
and Mse] (GG selective bases) + EcoRl (AG 
selective bases) in the right hand set of lanes. 
' 	 I The lanes are labelled as follows; 
AS: DNA from single ASpyrl clone infection 
AJ: DNA from single AJ clone infection 
I : DNA from NON-PASSAGED pooled crosses 
lopeasufte 	2 : DNA from UNTREATED group 
3 : DNA from PYR TREATED group 
Each lane represents the pooled DNA of all mice 
in the groups. 
ASpyrl specific markers are marked with a broken 
arrow (-, and AJ specific markers with an open 
arrow() 
-.9 	 - 
It can be seen from this gel that all AJ markers are present only in the non-passaged and 
untreated groups (lanes I and 2), and are completely absent from the PYR selected group 
(lane 3). This was true for all 63 AJ markers analysed, suggesting that there were very 
few recombinants in the cross material used. If the cross population contained only 
parental type parasites, then it would be expected that all the markers associated with the 
sensitive parent (AJ) would be removed under PYR selection, leaving only the resistant 
(ASpyrl) parental markers. Moreover, it was also observed that AS markers were absent 
from the pre-passaged and untreated groups, which is consistent with the theory that there 
were very few recombinant parasites in the cross material, and that the AJ parent 
competitively excludes ASpyrl when grown in competition (de Roode et al., 2004c). 
4.2.2 Discussion 
These results show that there were very few, if any, recombinant parasites in the cross 
material used in this experiment. Although recombinant parasites were undoubtedly 
generated from these crosses (as demonstrated by the successful cloning of recombinants 
from the crosses shown in previous studies) it seems likely that multiple freezing and 
thawing, and subsequent selection of fast-growing parasites through serial passage before 
they were used in this experiment greatly depleted the numbers of recombinants in this 
material. Consequently, it was decided to generate a new cross between ASpyrl and AJ 
with which to perform an LGS analysis, utilising the cross-generating techniques outlined 
in Chapter II. This fresh cross material would be subjected to LGS analysis without being 
frozen down and with the minimum number of passages in order to maximise the survival 
of recombinant parasites. 
4.3 LGS analysis of a new cross between ASpyrl and AJ 
A cross was generated between ASPyr1 and AJ following the protocols described in 
Chapter II. Briefly, single clone infections of ASpyrl and AJ were grown individually in 
donor mice. Blood from these mice was then extracted and mixed together to produce an 
inoculum containing equal proportions of the two clones. This inoculum was 
administered intra-peritoneally to 3 mice, so that each mouse received a total of 2 x 10 6 
parasites (1 x 106  of each clone). Six days post-inoculation, the presence of gametocytes 
was confirmed in the mice by thin blood-smear microscopy. The mice were then 
anaesthetised and each was placed on top of a mosquito cage containing -200 female 
mosquitoes 5-7 days post emergence from pupae. The mosquitoes were allowed to feed 
on the mice for 30 minutes. Ten mosquitoes from each cage were dissected 7 days post-
feed, and the mid-guts were checked for the presence of oocysts. Oocyst numbers are 
presented in Table 4.2. 
100 
Mosquito Gametocytaemia Numbers of Mean Number of Estimated 
Cage on day of feed Oocysts per number of mosquitoes number of 
Number' mosquito Oocysts Dissected for recombinants3 
dissected2 per sporozoites 
Mosquito  
Parental AJ 0.025 2,0,0,0,0 0.9 - - 
1,0,1,5,0  
Parental 0.100 4,29,11,3,6 9.5 - - 
ASpyrl 8,0,21,9,4 
Cross 1 0.030 8,20,28,0,37 15.7 143 4490 
28,0,16,9,11  
Cross2 0.075 2,5,20,17,15 11.8 120 2832 
0,15,8,27,9  
Cross 3 0.030 0,0,0,3,0 0.5 98 98 
_______________ 0,0,1,0,1 
Table 4.2 Numbers ot oocysts present in mosquitoes a aays post-Inrecuon. 
mosquitoes per cage. Numbers in brackets indicate the individual 
mouse upon which the cage was fed 
2 10 mosquitoes were dissected from each cage, on day 8 post infective blood-
meal 
3 Assumes 50% of oocysts are hybrid, with each producing 4 recombinants (see Figure 1.6) 
Mosquito salivary glands were dissected at day 14 post-infective blood meal, pooled 
from all three cages and sporozoites liberated by gentle crushing in a pestle and mortar 
containing 50:50 Ringer's solution : foetal calf serum. This inoculum was injected into 2 
mice and the resulting infections followed by thin blood film microscopy. 
When the sporozoite-induced infections reached peak parasitaemia (10-15%), the 
parasites were harvested, pooled, and inoculated into a group of 3 mice. Each mouse in 
the group received 1 x 106  parasites. This initial experimental group was left untreated, 
and the parasites were harvested at peak parasitaemia for AFLP analysis, to provide a 
reference point for markers analysed in the subsequent treatment groups. Parasites were 
pooled and sub-inoculated from this group into two further groups of 3 mice one of 
which was treated with pyrimethamine and the other left untreated. 
Pyrimethamine was administered orally at a dose of 10 mg per kg of mouse body weight 
daily at 24-hour intervals for four days, starting three hours after parasite challenge. 
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Both the pyrimethamine treated and the untreated blood-stage cross progeny were 
allowed to grow to peak parasitaemia (30-40 % for untreated and 15-20% for treated), at 
which point the blood was harvested. Two samples of parasite DNA were prepared for 
AFLP and other molecular analyses, by pooling separately the blood from the treated and 
untreated mice. A summary of this experimental procedure is depicted in Figure 4.4. 
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PYR Treated* 	U ntreated* 
Figure 4.4 A schematic representation of the procedure for the experiment to test LGS with a newly 
generated cross Experimental groups are referred to in the text by these names. 
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Parasitaemias Of Treated and Untreated Unctoned Cross Progeny 
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Figure 4.5 Parasitaemia curves for the Untreated and Pyrimethamine Treated uncloned cross progeny of a 
new AJ and ASpyrl cross. The arrows (1) indicate the days upon which PYR (10mg/kg) was administered 
to the drug-treated group. Mice were killed and bled when parasitaemias exceeded 10%. Each group 
consists of 3 mice, with the error bars representing the standard deviation of the means. 
Parasitaemia curves for both drug treated and untreated groups are shown in Figure 4.5. 
In contrast to the previous experiment, the drug treated group does not show such a 
marked inhibition of parasite growth when compared to the untreated group. This is an 
indication that there are many parasites in the cross material carrying the resistant dhfr 
allele. A comparison of the areas under these parasitaemia curves shows that there is no 
significant difference between the two groups (Student's t-test, p = 0.22). 
The relative intensities of 325 AFLP markers distinguishing the parental clones were 
compared between the untreated, passaged and drug-treated groups. 206 of these were 
markers unique to the sensitive parent (AJ) and 119 of the resistant parent (ASpyrl). A 
Table showing marker relative intensity index comparisons between all treatment groups 
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is included in Appendix 2 and a statistical analysis of the effects of treatment on the 
Comparative Intensities of markers in each treatment group is presented in Appendix 3. 
It was possible to assign 203 of the AJ parental AFLP markers to a genetic linkage map 
of P. c. chabaudi generated from previous crosses between AS and AJ (see Chapter II for 
a description of how markers were assigned to this map). 
When the PYR treated group was compared to the untreated group, 10 of the 206 AJ 
markers showed Comparative Intensities of less than 0.5 (i.e. reductions of greater than 
50 %). These are shown in Table 4.3, along with their derived positions as located on the 
linkage map. It can be seen that the markers that show the greatest reductions in intensity 
are located on chromosome 7. There is also some reduction in 3 linked markers on 
chromosome B. and in one marker that was not assigned to a chromosomal location on 
the linkage map. 
Marker Name Comparative 
Intensity 
Chromosomal 
Location in genetic 
linkage map 
AJAA05CA 0.01 7 
AJAG02CA 0.13 7 
AJTGOIAG 0.08 7 
AJTGOIGA 0.06 7 
AJACO2TT 0.42 7 
AJAT02AT 0.44 13 
AJGTOIAG 0.41 13 
AJAAOIAG 0.48 13 
AJTT03CT 0.17 Group E"' 
AJAT03AT 0.38 Unallocated 
Table 4.3 Comparative Intensities of AJ AFLP markers under selection in the PYR treated group, 
compared to the untreated group, and their chromosomal locations according to the AS/AJ Image map. 
Group E is a linkage group that could not be assigned to a particular chromosome. 
Figure 4.6 shows an example of an AFLP gel for the Msel (CA selective bases) and 
EcoRl (AG selective bases) combinations. Marker AJAG02CA is highlighted, one of the 
markers that displays almost complete removal in the selected material, while all other 
markers on the gel remain present. 
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ASAJ 12 3 Figure 4.6 AFLP gel showing bands generated 
from the experiment described above. This gel 
shows the results of bands generated with Me1 
(CA selective bases) + EcoRl (AG selective 
bases). The five lanes are labelled as follows; 
AS: DNA from single ASpyrl clone infection 
AJ: DNA from single AJ clone infection 
DNA from Non-Passaged pooled crosses 
2 : DNA from PYR TREATED group 
3 : DNA from UNTREATED group 
Each lane represents the pooled DNA of all 
AJAGO2CA 
	
mice in the groups. 
V 
ASpyrl specific markers are marked with a 
broken arrow (, and AJ specific markers with 
an open arrow () 
One marker (AJAG02CA) is almost completely 
removed (Comparative Intensity = 0.13) in the 
PYR treated group. 
By assigning AFLP markers to the AS/AJ linkage map, it is possible to generate graphs 
showing the change in marker intensities between treatment groups as they appear across 
the P.c.chabaudi genome. Figure 4.7 shows the Comparative Intensities of AJ (sensitive 
parent) markers between the PYR treated and the Untreated groups. It was found that all 
of the AJ markers which were most reduced under pyrimethamine pressure lie on 
chromosome 7 of P. c. chabaudi. Moreover, when these markers are put into order 
according to the genetic map, they form a 'selection valley" around the position of the 
marker (AJAA05CA) which had been eliminated by pyrimethamine treatment. Figure 4.8 
shows the same graphs for the AS (resistant) parental markers. No markers show 
significant reductions in Relative Intensity Indices between the PYR treated and 
Untreated groups. Figure 4.9 was created by superimposing Figure 4.7(A) on to Figure 
4.7(B). This allows a direct comparison between the Comparative Intensities of both sets 
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Figure 4.7 Comparative Intensities of AJ (sensitive parent) markers in the PYR treated group compared to 
the untreated group. for markers assigned to P.c.chabaudi chromosomes (A) and non-chromosomally 
allocated linkage groups (B). Markers are positioned on the X axis according to their positions in cM along 
the chromosomes/linkage groups, and the size of the chromosomes/linkage groups in cM according to the 




Figure 4.8 Comparative Intensities of ASpyrl (resistant parent) markers in the PYR treated group 
compared to the untreated group, for markers assigned to P. c .chabaudi chromosomes (A) and non-
chromosomally allocated linkage groups (B). Markers are positioned on the X axis according to their 
positions in cM along the chromosomes/linkage groups, and the size of the chromosomes/linkage groups in 





-A I tt 4 
Scale: 	50cM 
Figure 4.9 The Comparative Intensities of AJ markers (red line), and ASpyrl markers (blue line) in the 
PYR treated group compared to the untreated group (data combined from Figures 4.7 and 4.8). 
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4.3.1.1 Analysis of individual linkage groups and data summaries 
In this section, the relative intensities of AJ markers are compared between each 
treatment group for each chromosome/unassigned linkage group individually, in order to 
highlight the differences in marker relative intensity between treatment groups in detail. 
General Linear Model (GLM) analyses of variance were carried out on each chromosome 
/ linkage group in order to determine if there were statistically significant differences in 
marker intensities between treatment groups. The groups are referred to throughout by 
the names designated in Figure 4.4 (i.e. "non-passaged", untreated" and "PYR"). The 
analysis of each chromosome / linkage group consists of a graph showing the 
comparative intensities of markers between the three groups (A), in order to demonstrate 
the changes in relative intensities between treatment groups for individual markers, and a 
bar chart showing the mean relative intensities of markers in each treatment group with 
error bars indicating the standard error of the means (B). Each figure also contains a 
Table showing the results of individual GLMs (C). The section ends with a summary for 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results Number of Markers F-Value P-value Significant 
Overall effect 5 0.31 0.73 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.99 No 
PYR / Untreated 0.76 No 
Non-Passage / Untreated 0.78 No 
Figure 4.10 AJ Markers on Chromosome 1. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
Relative Intensities with "treatment" as an explanatory variable. 
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GLM Results Number of Markers F-Value P-value Significant 
Overall effect 9 0.09 0.91 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.90 No 
PYR I Untreated 0.96 No 
Non-Passage I Untreated 0.98 No 
Figure 4.1IAJ Markers on ChromosomeS. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
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PYR/NON-PASSAGED • PYR/UNSELECT -*-- UNSELECT/NON-PASSAGED 
NON-PASSAGED 	 UNTREATED 	 PYR 
CLM Results Number of Markers F-Value P-value Significant 
Overall effect 11 2.45 0.10 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.08 No 
PYR / Untreated 0.58 No 
Non-Passage / Untreated 0.45 No 
Figure 4.12 AJ Markers on Chromosome 6. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results 	==Number of Markers F-Value P-value Significant 
Overall effect 19 3.54 0.03 Yes 
Pairwise Comparisons 
PYR / Non-Passaged 0.06 No 
PYR I Untreated 0.06 No 
Non-Passage I Untreated 0.99 No 
Figure 4.13 AJ Markers on Chromosome 7. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
Relative Intensities with treatment" as an explanatory variable. 
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PYRINON-PASSAGED -- PYR/UNSELECT -e-- UNSELECT/NON-PASSAGED 
GLM Results Number of Markers F-Value P-value Significant 
Overall effect 10 1.87 0.18 No 
Pairwise Comparisons 
PYR I Non-Passaged 0.08 No 
PYR / Untreated 0.58 No 
Non-Passage / Untreated 0.45 No 
Figure 4.14 AJ Markers on Chromosome 8. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results Number of Markers F-Value P-value Significant 
Overall effect 8 0.13 0.87 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.86 No 
PYR / Untreated 0.97 No 
Non-Passage / Untreated 0.95 No 
Figure 4.15 AJ Markers on Chromosome 9. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means). C; the results of a General Linear Model analysis of variance performed on the 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results 	 7 Number of Markers F-Value P-value Significant 
Overall effect 16 3.88 0.03 Yes 
Pairwise Comparisons 
PYR / Non-Passaged 0.02 Yes 
PYR / Untreated 0.54 No 
Non-Passage / Untreated 0.21 No 
Figure 4.16 AJ Markers on Chromosome 11. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
Relative Intensities with "treatment" as an explanatory variable. 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results Number of Markers F-Value P-value 	Significant 
Overall effect 8 0.21 0.81 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.85 No 
PYR I Untreated 0.83 No 
Non-Passage / Untreated 0.99 No 
Figure 4.17 AJ Markers on Chromosome 12. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means). C; the results of a General Linear Model analysis of variance performed on the 
Relative Intensities with "treatment" as an explanatory variable. 
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GLM Results Number of Markers F-Value P-value Significant 
Overall effect 32 0.89 0.41 No 
Pairwise Comparisons 
PYR I Non-Passaged 0.99 No 
PYR / Untreated 0.48 No 
Non-Passage I Untreated 0.47 No 
Figure 4.18 AJ Markers on Chromosome 13. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
Relative Intensities with "treatment" as an explanatory variable. 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results Number of Markers F-Value P-value Significant 
Overall effect 18 0.84 0.44 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.58 No 
PYR / Untreated 0.97 No 
Non-Passage / Untreated 0.44 No 
Figure 4.19 AJ Markers in Linkage group A. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results Number of Markers 	F-Value P-value Significant 
Overall effect 6 	 0.33 0.71 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.99 No 
PYR / Untreated 0.78 No 
Non-Passage / Untreated 0.71 No 
Figure 4.20 AJ Markers in Linkage group B. A; the Relative intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
Relative Intensities with treatment" as an explanatory variable. 
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NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results 	TNumber of Markers 	F-Value P-value Significant 
Overall effect 3 	 0.3 0.75 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.83 No 
PYR / Untreated 0.99 No 
Non-Passage / Untreated 0.77 No 
Figure 4.21 AJ Markers in Linkage group C. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
Relative intensities with treatment" as an explanatory variable. 
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UNTREATED 	 PYR 
CLM Results 	 TNurnber of Markers F-Value P-value Significant 
Overall effect 14 0.24 0.78 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.77 No 
PYR / Untreated 0.97 No 
i Non-Passage / Untreated 0.88 No 
Figure 4.22 AJ Markers in Linkage group D. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 
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GLM Results Number of Markers F-Value P-value Significant 
Overall effect 9 1.03 0.37 No 
Pairwise Comparisons 
PYR . Non-Passaged 0.83 No 
PYR / Untreated 0.34 No 
Non-Passage / Untreated 0.67 No 
Figure 4.23 AJ Markers in Linkage group E. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means), C; the results of a General Linear Model analysis of variance performed on the 



















NON-PASSAGED 	 UNTREATED 	 PYR 
GLM Results Number of Markers F-Value P-value Significant 
Overall effect 7 0.17 0.84 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.85 No 
PYR i'Untreated 0.99 No 
Non-Passage / Untreated 0.88 No 
Figure 4.24 AJ Markers in Linkage group F. A; the Relative Intensities of markers positioned along the 
chromosome according to the genetic linkage map are compared between all three treatment groups. B; 
the average Relative Intensities of markers in the three treatment groups (error bars indicate the standard 
error of the means). C; the results of a General Linear Model analysis of variance performed on the 



















NA,L UNTREATED 	 PYR 
CLM Results Number of Markers F-Value P-value Significant 
Overall effect 204 2.99 0.05 No 
Pairwise Comparisons 
PYR / Non-Passaged 0.53 No 
PYR / Untreated 0.35 No 
Non-Passage I Untreated 0.03 Yes 
Figure 4.25 AJ Markers in All chromosomes I linkage groups. A; the average Relative Intensities of 
markers in the three treatment groups (error bars indicate the standard error of the means). B; the results 
of a General Linear Model analysis of variance performed on the Relative Intensities with treatment" as an 
explanatory variable. 
Taken overall, the AJ markers in the three treatment groups show no significant effects of 
treatment. There is, however, a significant difference between the non-passaged and the 
untreated group, possibly reflecting the AJ parasite's faster growth rate. This effect is 
most pronounced with markers on chromosome ii, and Linkage Group C (see above). 
This effect is unlikely to be caused by the parental form of AJ overgrowing parental 
ASpyrl and recombinants, however, as the same trend (although not statistically 
significant) can be seen in the comparison of the non-passaged and PYR treated groups. 
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Figure 4.26 Mean Relative Intensity values of AJ markers for all chromosomes / linkage groups. Error bars represent the standard error of the means. 
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4.3.1.2 Data Summary 
The following results (Figures 4.27 - 4.29) describe the distribution of markers on the 
genome according to their positions on the genetic linkage map, and the results of 
repeated measurements on the same markers to assess the degree of reproducibility of 
marker relative intensities. 
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Figure 4.27 The distribution of numbers of AJ markers to chromosomes and linkage groups on the genetic linkage map between ASpyrl and AJ. The group 
"unassigned / unlinked" contains markers that could not be assigned to linkage groups on the map. 
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Figure 4.28 shows the numbers of markers present on each chromosome / linkage group as 
they were assigned to the linkage map. The uneven distribution of markers reflects the sizes of 
the chromosomes / linkage groups, with more markers present on the largest chromosomes. 27 
markers could not be assigned to either a chromosome or a linkage group and were designated 
'unassigned / unlinked". Chromosomes 2, 3, 4 and 14 are missing from the linkage map, and 
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Figure 4.28 The relative intensity indices of repeated intensity measurements of selected specific markers. Each pair of columns represents the results for the 
same marker in the PYR treatment group. The measurments were repeated from the DNA stage (i.e. each marker of a pair was independently subjected to the 
AFLP process from the digested and ligated DNA stage, and run on different polyacrylamide gels at different times) 
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Figure 4.28 shows the results of repeated measurements of relative intensity of selected 
markers. Each individual reading of a pair of measurements on the same marker comes from a 
separate AFLP PCR and was run on a different gel. The largest discrepancy between marker 
relative intensities was 0.3 (AJTT03AA), while the smallest variation was 0.03 
(AJTTOIAA).The mean difference was 0.11 (standard error of the mean = 0.02) Figure 4.29 
shows the differences between these same pairs of repeated measurements of markers for the 
comparative intensity between the PYR treated and the unselected groups. Differences 
between measurements is crucial, as a high variation between repeats could result in an 
inaccurate estimation of the number of markers under selection in an LGS analysis. The mean 
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Figure 4.29 The comparative intensities of repeated intensity measurements of selected specific markers between the PYR and unselected groups. Each pair of columns 
represents the results for the same marker. The measurements of intensity were repeated from the DNA stage (i.e. each marker of a pair was independently subjected to 
the AFLP process from the digested and ligated DNA stage, and run on different polyacrylamide gels at different times). 
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4.3.2 Further investigation of markers under selection on chromosome 7 
The genetic linkage map allows the positioning of markers upon the P. chabaudi genome 
according to genetic linkage data based on the characterization of 28 clones of a cross 
between AS and AJ (Martinelli, A., Hunt, P., Fawcett, R., Cravo P., Walliker, D. & 
Carter, R., submitted). It is impossible to be confident, however, that the genetic linkage 
observed reflects actual physical linkage on the genome. Markers that appeared to be 
greatly reduced in the PYR treated group compared to the non-selected group, were 
assumed to be physically linked to genes that control the PYR response of sensitive 
parasites. In order to confirm this physical linkage, it was necessary to obtain the genetic 
sequences of such markers, and map their physical location on the genome. Ideally, 
markers would be located on the P. chabaudi genome, but unfortunately, the genome 
sequence of this species remains incomplete. It was possible, however, to utilize the 
strong synteny between P falciparum and the rodent malarias (Carlton et al., 1998; Hunt 
et al., 2004), in order to physically locate the markers in relation to closely linked genes. 
The markers that are strongly selected against on P chabaudi chromosome 7 according to 
the linkage map, are genetically linked to dhfr in this species. Indeed, the marker that 
shows the greatest reduction in intensity under PYR treatment (AJAA05CA) lies only 5.3 
cM from dhfr according to the P. chabaudi linkage map (see Table 4.4), while the 
comparative intensities of the other markers under strong selection decrease with 
increasing proximity to this locus. 
In order to determine the physical linkage with dhfr of the 6 AFLP markers which 
showed the greatest comparative intensity reductions in the selected population (Table 
4.4), they were sequenced and their homologues located in the P.falciparurn genome 
wherever possible. It was possible to identify P. faiciparum homologues for 3 of these 
markers, all of which lay within 120 Kb of the P. falciparum dhfr locus (pJdhfr) (Figure 
4.30). The homologue of AJAA05CA which was virtually eliminated following 
pyrimethamine selection lay 10 Kb from the location of pfdhfr. 
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(cM) from dhJr 
(P. chabaudi) 
AJAA05CA 0.00 5.3 
AJAG02CA 0.13 9.5 
AJTGOIAG 0.06 13.4 
AJTGOIGA 0.08 13.4 
AJACO2TT 0.42 3 3. 0 
AJAA03AT 0.60 44.5 
AJAAOIGAa 1.02 53.5 
Table 4.4. The Comparative Intensities of markers under pyrimethamine selection, and their positions on 
the P. chabaudi linkage map. The Comparative Intensities of the markers are seen to decrease with 
increasing proximity to the gene under selection. Markers were assigned to a linkage map between AS and 
AJ as described in the methods. 
8This marker is not under pyrimethamine selection, and is included as an example of a flanking marker to 
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Figure 4.30 The Comparative Intensities of AJ AFLP markers after selection of the cross progeny, and 
their positions on P. chabaudi chromosome 7. Homologues of markers that were reduced in intensity 
under pyrimethamine pressure were located on P. falciparum chromosome 4. Marker intensity decreased 
with increasing proximity to pfdhfr. AJAA05CA, whose intensity was most reduced, was located only 10 
Kb from pfdhfr. Numbers in brackets below marker names give the distances in kilobases of the markers 
along the P. falciparum chromosome 4. Two discrepancies were observed between the P. chc,baudi 
linkage map and the P. falciparum genome database: Marker AJACO2717 was located on opposite sides of 
dhfr by the two resources, and the homologue of the marker indicated with an asterisk (*) was found to lie 
on P. falciparum chromosome 6, and was not linked to pfdhfr. It is thought that these differences are due to 
errors in the production of the P. chabaudi linkage map. 
4.3.3 Proportional Sequencing of the d/ifr locus 
The presence of a selection valley around dhfr is strong evidence that this gene was 
involved in the response to PYR treatment of the cross-progeny population. It is possible, 
however, that PYR selection may be acting on a locus closely linked to dhfr, and not on 
the gene itself. Therefore, in order to confirm that dhfr was, indeed, the target of drug 
selection, the proportion of the sensitive to the resistant allele was directly measured 
using Proportional Sequencing in all three treatment groups. Additionally, three other 
polymorphic genes (dihdropteroate synthase (dhps), dihydrofolate synthetase (dhfs), and 
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6-pyruvoyl tetrahydropterin synthase (6-pthps)) were measured in the same way, as 
controls. These additional loci were chosen because they are unlinked to pcdhfr, yet all 
encode enzymes that are associated with the folate biosynthesis pathway, but are not 
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Figure 4.31 The proportions of AJ alleles of 4 genes associated with the Plasmodi urn folate biosynthesis pathway, as determined by Proportional Sequencing. 
Bars show the percentage of the AJ allele of four genes in 3 different treatment groups. Each individual measurement was repeated S times from the P('R stage, 
and error bars give the standard errors of the means. 
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Figure 4.31 shows the proportions of AJ alleles of 4 genes, dhfr (the gene responsible for 
PYR resistance) and three other genes involved in the folate biosynthesis pathway. 
Individual GLM analyses were performed on the proportion of each allele's 
representation in the three treatment progeny populations to test for significant 
differences between treatment groups. 
For each of the four genes analysed, there was a significant difference in allele 
proportions between all groups (Non-passaged versus Untreated. Non-passaged versus 
PYR Treated, and PYR Treated versus Untreated) (p<O.00I), except for the Non-
passaged versus Untreated for dhfs (p=0.9558). The AJ allele of dhfr was reduced to 0% 
in the PYR treated population, whereas the AJ alleles of the three other genes were 
significantly increased in the PYR group compared to the untreated group. This result 
shows that the AJ allele of dhfr is completely removed in the drug treated population, 
confirming the indication from the LGS analysis that it lies at the bottom of the selection 
valley observed on chromosome 7 of P. chabaudi (Figure 4.10). 
4.3.4 Evidence of a selection valley on chromosome 13 
In addition to the selection valley observed around dhfr, a less prominent valley was 
identified on chromosome 13 (see Table 4.3). Markers that appeared under selection at 
this locus were also sequenced, and their homologues located in the P. falciparum 
genome database wherever possible (Figure 4.32) 
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Figure 4.32 The Comparative Intensities of AJ AFLP markers after selection of the cross progeny, and 
their positions on P. c. chabaudi chromosome 13. Homologues of markers that were reduced in intensity 
under pyrimethamine pressure were located on the P. falciparum genome database. Dotted lines link the 
markers on P. c. chabaudi chromosome 13 to their homologues on P. fa/ciparum chromosomes 13 and 14. 
Numbers above the P. falciparurn chromosomes indicate distances in kilobases. Marker names are given 
below the chromosomes. 
4.3.5 Estimate of size of a centiMorgan in the dhfr selection valley 
For practical purposes a selection valley will comprise the genomic region on either side 
of a locus under selection, in which markers linked to the selected locus can be expected 
to show measurable reductions (or increases) in frequency (Comparative Intensity) 
among recombinant progeny following selection. In reality, this is going to lie within a 
region of about 50 centiMorgans (cM) on either side of the target locus. The physical size 
of a cM is likely to vary within a genome. It is necessary, therefore, to calculate the size 
of a cM in the region of the genome under investigation, in order to determine the 
physical size of a selection valley in this region. 
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An estimate of the physical width (in Kb) of selection valleys is important for several 
reasons. It allows the estimation of the number of markers across the genome required in 
order to be certain of locating a selection valley. The size of a selection valley (in Kb) 
will also determine how close the results of an LGS analysis will locate markers under 
selection to the selected locus itself. The narrower" a selection valley is, the closer its 
apex will be to the locus under selection. 
One centiMorgan (cM), the unit of measurement for recombination frequency between 
two loci, is equal to a 1% chance that a marker at one genetic locus will have recombined 
away from a marker at the second locus as the result of a crossing over event in a single 
generation. The number of kilobases per centiMorgan varies between genomes. In 
humans, for example, one cM is equivalent to around 1000 Kb (Human genome Project, 
2004). For P. fàlciparum, one cM has been estimated to be 17 Kb in size (Su etal., 1999). 
The data generated in the experiments described above allow an estimation of the size of 
one cM in P. chabaudi, or, more accurately, the size of 1cM in the locality of the 
selection valley associated with dhfr (cM distances are likely to vary across the genome, 
there may, for example, be 'recombination hotspots"- areas of the genome where 
recombination is particularly frequent (Lichten and Goldman, 1995)). A 1% difference in 
representation of a marker in a population translates to a change in Comparative Intensity 
of 0.01. By plotting a graph of the Comparative Intensities of AFLP markers in the 
selection valley against their known physical distances (Kb) from dhfr in the P. 
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Figure 4.33 The Comparative Intensities of AJ AFLP markers in the PYR versus the Unselected treatment 
groups. The x axis shows Kb distances from dhfr as determined from marker homologue location on the P. 
falciparum genome. Dotted lines link Comparative Intensities of 0.1, 0.2 and 0.3 (10, 20, and 30 cM 
respectively) to their extrapolated distances from dhfr. 
From this graph it is possible to estimate the distances in Kb of markers that show 
Comparative Intensities of any given value. By extrapolating the distance in Kb of 
markers showing a given Comparative Intensity, it is possible to calculate the size of a 
centiMorgan in the region of the genome on which these markers lie. In this case, a 
Comparative Intensity of 0.1 (10cM) translates to approximately 30 Kb, giving one cM a 
size of 3 Kb at this locus. This is much smaller than that estimated for P.falciparum. This 
value can only be taken as a rough estimate, however, as it relies on the results of only 
three markers, and assumes that the comparative intensities are accurate. If 1cM = 3kb, 
then the width of the selection valley around dhfr is about 150 Kb (from the target locus 
to the edges of the valley). 
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4.3.5 Summary of results 
These results show that there was significant reduction in the intensities of 10 out of 206 
AJ (drug-sensitive) AFLP markers in a population of recombinant progeny of a cross 
between a drug-resistant (ASpyrl) and a drug-sensitive (AJ) P. chabaudi parasite under 
PYR pressure, compared to a non-drug treated population of the same recombinant 
progeny. Five of these AJ markers were genetically linked to dhfr in P. chabaudi, the 
gene that controls the drug sensitivity of the parental parasites from which the cross 
progeny were generated. This linkage to dhfr was confirmed by physically mapping the 
individual AFLP markers that appeared under selection to the genome of a related 
malaria parasite, P. falciparum. It was observed that the degree of reduction in intensity 
of the markers was directly correlated to their physical distance from dhfr in P. 
falciparum, so that the closer the markers were linked to the gene, the greater their 
reduction in intensity under drug treatment, forming a "selection valley" around the dhfr 
locus. In order to confirm that the AJ allele of dhfr was the target of the drug treatment, 
the proportions of the sensitive and resistant alleles were measured directly, using 
Proportional Sequencing at this locus. It was found that the sensitive allele of the gene 
was not detectable after PYR treatment, and was therefore likely to be the target locus of 
PYR selection. 
In addition to the selection valley observed on P. chabaudi chromosome 7, a lesser effect 
of PYR pressure on AJ AFLP markers was seen on chromosome 13, where three 
genetically linked markers were reduced in intensity under PYR pressure by more than 
50% compared to the untreated population. Physical location of these markers placed 
them on chromosome 13 of P. falciparum. 
4.4 Discussion 
These results have demonstrated the validity of LGS as a method to locate the genes 
controlling a selectable phenotype such as drug resistance in malaria parasites. Using 
PYR selection on the progeny of a cross generated between a sensitive and resistant line 
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of P. chabaudi, and by measuring the intensity of numerous, genome-wide AFLP 
markers in populations of progeny after growth in the presence or absence of the drug, it 
was possible to visualize a selection valley around dhfr, the gene known to control PYR 
sensitivity in the parental parasites. These results have exciting consequences for the 
future investigations of the genetic determinants of drug resistance, and, indeed, of other 
selectable phenotypes such as transmissibility, parasite growth rate and strain-specific 
immunity. LGS offers a relatively quick and cost-effective laboratory-controlled 
experimental procedure for gene identification in comparison to previous methods of 
genetic investigation. 
The selection valley produced around dhfr on P. chabaudi chromosome 7 consists of 5 
consecutive linked markers that have a Comparative Intensity of less than 0.5 (and one 
closely linked marker with a Comparative Intensity of 0.67). Nowhere else on the 
genome was such a pronounced reduction in marker Comparative Intensity observed in a 
group of linked markers. Furthermore, the Comparative Intensities of these markers 
decreased with increasing genetic distance from dhfr. This effect, when visualized on a 
graph showing all AJ markers distributed along the entire genome, produces a dramatic 
selection valley that points to dhfr (Figure 4.7). 
By sequencing the markers in this selection valley and locating their homologues in the P. 
falciparum database, their physical linkage to dhfr was confirmed, as was the fact that the 
Comparative Intensity of the markers was proportional to their proximity to pfdhfr in P. 
falciparum (Figure 4.30). As well as strengthening the evidence for the selection valley 
around dhfr, these results also reflect the high degree of synteny between P. falciparum 
and P. chabaudi. 
Discrepancies were, however, discovered between the P. chabaudi linkage map and the P. 
falciparum genome database. One marker (AJACO2TT) was physically located on the 
opposite side of pfdhfr in the P. falciparum genome from that predicted by the P; 
chabaudi linkage map. This disparity can best be explained by errors in the linkage map 
resulting from the relatively low number of progeny clones, 28, analysed for the 
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generation of the map. Nevertherless, this marker was linked topfdhfr and at a distance in 
accordance with that shown on the linkage map. 
Another marker (AJTT03TG) presented a problem when it was first located on the 
linkage map. The map indicates that this marker was genetically linked to pcdhfr at a 
distance of 9.6 cM. A marker so closely linked to pcdhfr would be expected to be 
significantly reduced under PYR pressure, yet it did not appear to be under any selection. 
When the homologue of this marker was located on the P. falciparum genome, however, 
it was found to lie on chromosome 6, and was, therefore, completely unlinked to pfdhfr. 
It seems likely, therefore, that this marker has been incorrectly assigned to the genetic 
linkage map, and is not closely linked to pcdhfr. 
The occasional inaccuracy of the P. chabaudi genetic linkage map in locating markers on 
the P. chabaudi genome is not a limitation for LGS itself. A successful LGS analysis 
could have been carried out without the use of a linkage map at all, simply by sequencing 
markers that appeared under selection and finding their homologues in the published 
parasite genomes. For the present work, it was necessary to rely on the high degree of 
synteny between P. falciparum and the rodent malarias, but as the sequencing project for 
P. chabaudi continues, it will eventually be possible to locate markers directly onto the 
species specific genome, and so by-pass any difficulties encountered due to breakdowns 
in synteny. 
Figure 4.9 shows the Comparative Intensities of AJ markers in the PYR selected cross 
progeny on the same graph as those of ASpyr I. Small movements in Comparative 
Intensity seen in AJ makers across the genome are, for the most part, mirrored by 
movements in the opposite direction of closely linked ASpyrl markers. This suggests that 
such small differences in marker intensities represent real effects in the regions of these 
markers and are not the result of general inaccuracies in the measurement of marker 
intensity. 
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4.4.1 Evidence for PYR selection of ASpyrl markers on P. chabaudi Chromosome 
13 
In addition to the selection valley around dhfr on chromosome 7, another group of linked 
markers was shown to be under selection on chromosome 13 (Figures 4.7 and 4.32). The 
markers in this valley were not under as strong a selection as those linked to dhfr (the 
lowest comparative index of the three markers under strong selection was 0.41, compared 
with 0.01 in the dhfr selection valley). This was the only other area on the genome that 
appeared under significant selection and which had more than one marker showing a 
significant reduction at the same locus. When these markers were sequenced and their 
homologues located on the P. falciparum genome, they were found to lie on chromosome 
13 (known to contain loci syntenic with parts of chromosome 13 in P. chabaudi) and 
formed a linkage group that spanned a 430 Kb stretch of the chromosome (Figure 4.32). 
The presence of selection for ASpyrl markers other than those linked to dhfr was 
unexpected, as control of pyrimethamine resistance in ASpyrl is known to be caused by a 
single point mutation in dhfr, and no other genes are thought to be involved. However, 
the possibility of mutations in other genes caused by selection with PYR after the dhfr 
mutation has occurred cannot be ruled out. Sequential mutations of resistance genes are 
well documented, in which a first mutation leads to a level of drug resistance, and further 
sequential mutations in the same gene increase the level of resistance to the drug 
(Sirawaraporn et al., 1997a). This is known to occur in PYR resistance in P. falciparum, 
where an initial mutation from a serine to an asparagine at amino acid position 108 in 
DHFR appears to be essential to confer PYR resistance, and further mutations at 
positions 51 (asparagine to isoleucine), and 59 (cysteine to arginine) increase this 
resistance (Sirawaraporn et al., 1997a) (see also chapter I). It is conceivable, then, that 
amino acid sequence differences on a gene on chromosome 13 in P. chabaudi ASpyrl 
compared to AJ confers an additional level of resistance when combined with the 
mutation at dhfr. Such a difference could be the result of a mutation in that gene selected 
by drug pressure during the generation of ASpyrl from AS(sens), or could be the result 
of intrinsic differences between AS and AJ. 
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The fact that complete selection of ASpyrl AFLP markers is not seen at this locus, in 
contrast to the dhfr selection valley, suggests that the ASpyrl allele to which the markers 
are linked is not essential to confer PYR resistance. It does seem, however, to convey a 
significant advantage to those parasites possessing the ASpyrl rather than the AJ allele, 
but not enough to out-compete the AJ parasites in the 7 days for which they were grown. 
It is possible, however, that further passage of this population under PYR pressure would 
have produced a population monomorphic for the ASpyrl allele at this locus. By 
physically locating the homologues of markers in this selection valley, it was discovered 
that the marker under the greatest selection (AJAT02AT) was 39 kb away from a gene 
(cytidine and deoxycytidylate deaminase family, putative) whose product is involved in 
the deoxypyrimidine nucleotide/side metabolism pathway, which also involves the 
product of dhfr (Yeh et al., 2004) (Figure 4.34). 
P. falciparum Chromosome 13 
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Figure 4.34 Positions of homologues of AJ markers within the chromosome 13 selection valley. The 
marker displaying the lowest comparative intensity (AJAT02AT) is 39 Kb from the cytidine and 
deoxycytidylate deaminase family" gene which is involved, along with DHFR / Thymidylate synthase in 
the deoxypyrimidine nucleotide/side metabolism pathway. Numbers in brackets below the marker names 
show comparative intensities on the PYR treated population versus the untreated population. 
Deoxycytidylate deaminase and thymidylate synthase (a product of the dhfr gene) are 
functionally associated with one another, since they catalyze sequential reactions 
(McGaughey et al., 1996). This association can be seen in Figure 4.35. 
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Figure 4.35 The deoxypyrimidine nucleotide/side metabolism pathway of P fa/ciparum showing the 
actions of cytidine and deoxycytidylate deaminase and DHFR / thymidylate synthase. Box A shows the 
interaction between DHFR and thymidylate synthase. Adapted from the PlasmoCyc website; 
http://biocyc.orgIPFA  
From the deoxypyrimidine nucleotide/side metabolism pathway it is possible to develop a 
hypothesis to explain why a mutation at the cytidine and deoxycytidylate deaminase gene 
may lead to increased parasite growth under PYR pressure. PYR is known to interfere 
with the binding of DHFR to its substrate, dihydrofolate. This leads to the rate of the 
reaction catalysed by DHFR being reduced in the presence of PYR (even in the resistant 
parasites, it is likely that inhibition of DHFR by PYR still occurs, only to a much lesser 
extent than in sensitive parasites). 
One way of increasing the rate of an enzyme-catalysed reaction is to increase the amount 
of substrate available to the enzyme. From Figure 4.35, it can be seen that an increase in, 
the activity of cytidine and deoxycytidylate deaminase, upstream of the DHFR / 
thymidilate synthase catalysed reaction, will increase the amount of substrate in the 
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DHFR / thymidilate synthase catalysed part of the pathway. Therefore, in a resistant 
parasite under PYR pressure, any mutation in cytidine and deoxycytidylate deaminase 
that leads to an increased efficiency of the enzyme is likely to be positively selected. 
Such an up-regulation of the activity of cytidine and deoxycytidylate deaminase could 
also be beneficial to resistant parasites in the absence of PYR pressure. 
ASpyrl parasites have a slower growth rate than the AS clone from which they are 
derived. As these parasites are thought only to differ genetically at the single point 
mutation in dhfr, then one the explanation for their differing growth rates is that the 
mutated resistant form of dhfr is "less fit" than the wild-type allele. If this is the case, 
then resistant parasites growing in the absence of PYR pressure would benefit from an 
increase in the efficiency of another enzyme in the same pathway as DHFR, such as 
cytidine and deoxycytidylate deaminase. Such a mutation, arising from the inhibition of a 
metabolic pathway due to a change in a constituent enzyme caused by selection for a 
drug resistant mutation, can be thought of as a "compensatory mutation" which increases 
the overall efficiency of the pathway involved. A further discussion of possible "fitness 
costs" associated with drug resistance mutations is given in Chapter V. 
4.4.2 Selection for an AJ locus on Chromosome 11 
There appears to be some selection for AJ markers on chromosome 11 under 
pyrimethamine pressure. These markers show a "selection peak" on this chromosome 
(Figure 4.9), which is mirrored by a slight selection valley of ASpyrl markers. Markers 
on the peak, either side of the marker showing the greatest increase, map to the end of 
chromosome 6 in P. falciparum, indicating that the target locus is between 998 and 1334 
Kb along the chromosome. The marker in the corresponding ASpyrl selection valley that 
is most greatly reduced in intensity maps to a position 1310 Kb along the same 
chromosome. Intriguingly, a gene called IvL4L6PJ.121 which codes for "FolD 
bifunctional protein" is found at. 1329kb along chromosome 6 (see Figure 4.36), closely 
linked to those markers that appear under selection. 
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Figure 4.36 The comparative intensities of AJ (blue line) and ASpyrl (red line) AFLP markers after 
selection of the cross progeny, and their positions on P. c. chabaudi chromosome 11. Homologues of 
markers that appear to be selected for under pyrimethamine pressure were located on the P. falciparum 
genome database. Dotted lines link the markers on P. c. chabaudi chromosome II to their homologues on 
P. falciparum chromosome 6. Numbers above the P. /alciparurn chromosomes indicate distances in 
Kilobases. Marker names are given below the chromosomes. 
The two components of this protein are methylenetetrahydrofolate dehydrogenase and 
methylenetetrahydrofolate cyclohydrolase, two enzymes that are closely associated with 
DHFR / thymidilate synthase in both the folic acid biosynthesis and formyl THF 
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Figure 4.37 The formyl TI-IF biosynthesis pathway of P. falciparum showing the actions of 
methylenetetrahydrofolate dehydrogenase / methylenetetrahydrofolate cyclohydrolase and DHFR / 
thymidylate synthase. Adapted from the PlasmoCyc website; http://biocyc.orgIPFA  
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Figure 4.38 The folic acid biosynthesis pathway of P. falciparum showing the actions of 
methylenetetrahydrofolate dehydrogenase / methylenetetrahydrofolate cyclohydrolase and DHFR / 
thymidylate synthase. Adapted from the PlasmoCyc website; http://biocyc.org/PFA  
Following the arguments presented for the selection of more efficient alleles of genes 
encoding enzymes in the same pathway(s) as the target enzyme of a drug under drug-
pressure (Section 4.4.1), it is conceivable that selection may occur for the AJ allele of 
MAL6PJ. 121 if its enzyme product is more efficient than that of the ASpyrl allele and 
leads to greater productivity in the pathway(s) overall. This effect must be due, however, 
to intrinsic differences between ASpyrl and AJ parasites, and cannot be the result of a 
compensatory mutation, as it involves the selection of an allele from the AJ parent which 
has not been subject to selection for PYR resistance. 
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4.4.3 Growth rate advantage of AJ alleles 
Analysis of the change in AJ marker intensities between treatment groups (Non-passaged, 
Untreated and PYR treated) shows that there is a significant increase in the average AJ 
marker intensity between the Non-passaged and the Untreated progeny. This effect is 
seen in 14 out of the 16 chromosome / linkage groups with the only exceptions being 
chromosome 12 and linkage group D. This effect could be explained by parental type AJ 
parasites out-competing ASpyrl parasites due to their faster growth rate (as seen in 
Chapter III), leading to an increase in AJ marker intensity overall. This explanation 
cannot, however, account for the observation that there is also an increase in AJ marker 
intensity from the Non-passaged to the PYR treated group overall (although not 
significant), and in 11 out of the 16 chromosome / linkage groups, as the parental AJ in 
this population was completely removed by the drug treatment (Figure 4.31 - dhfr). 
This effect is supported by the proportional sequencing data (Figure 4.3 1), which shows a 
significant increase in the proportion of the AJ allele in all genes except dhfr. One 
possible explanation for this effect is that AJ is"fitter" than ASpyrl at many different 
loci across the genome, which would mean that AJ type alleles would out-compete their 
ASpyrl equivalents at all these loci. This would explain the growth rate differences 
between the two parental parasites in terms of genome-wide differences in fitness, rather 
than there being a small number of "growth-rate genes". 
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CHAPTER V 
EXPERIMENTS INVESTIGATING THE FITNESS COST OF 
PYRIMETHAMINE RESISTANCE 
This chapter contains further analysis of the results of the experiments described in 
chapter [V. The analysis in this chapter concerns growth rate differences and the apparent 
fitness cost of the mutation at dhfr which results in PYR resistance. In addition, further 
experiments are described which attempt to establish whether parasites carrying the PYR 
resistance mutation are at a selection disadvantage when in competition with parasites 
carrying PYR sensitive alleles of dhfr. 
5.1 Introduction 
Evidence for fitness costs associated with drug resistance in malaria parasites is relatively 
scarce. There is circumstantial evidence to suggest that chloroquine resistance may carry 
a selective disadvantage to parasites in competition with sensitive strains when there is no 
chloroquine pressure applied (Kublin et al., 2003a; Liu et al., 1995; Mita et al., 2003; 
Mita et al., 2004; Thanh et al., 2001), and experimental evidence has shown that there is a 
cost associated with atovaqoune resistance (Peters et al., 2002). For pyrimethamine 
resistance the evidence for a related fitness cost is inconclusive, with some studies 
apparently revealing a cost for some mutations (Fohi and Roos, 2003; Sirawaraporn et al., 
1997a; 1997b), while others find no resistance-associated fitness disadvantage (Rosario Ct 
al., 1978). These studies were discussed in more detail in Chapter 1. 
The results described in Chapter 111 show that ASpyrl parasites are out-competed by AJ 
parasites when grown in mixed infections. As the two parasite clones are genetically 
divergent (there is, on average one single nucleotide polymorphism per 150 base pairs, 
(Hunt, pers. corn.)), it is impossible to attribute this growth rate difference to any 
particular genetic determinant, such as the mutation that confers PYR resistance. In order 
to ascertain whether the SI 06N mutant allele of pcdhfr confers a reduction in growth rate, 
it is necessary to investigate the results of competition between parasites that differ only 
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at this mutation in mixed infections. This was, in effect, the approach taken by Rosario et 
al. (1978) when ASpyrl was grown in mixed infections with AS(sens), the parasite line 
from which ASpyrl was derived. It is supposed that these parasites differ genetically only 
at the SNP in pcdhfr responsible for the SI06N mutation. but confirmation of this is 
impossible without extensive sequencing at other loci. The results of these experiments 
were inconclusive, with both sensitive and resistant parasites present in 3 independent 
infections at day 10 post-inoculation, and sensitive parasites appearing to competitively 
exclude the resistant strain by between days 26 and 36 in two out of the 3 infections. 
The production of large numbers of recombinant progeny of a cross between a 
pyrimethamine sensitive and a resistant parasite effectively introduces the resistant allele 
into a wide range of diverse genetic backgrounds. The growth of this recombinant 
progeny population in mice without the presence of pyrimethamine, and the direct 
measurement of the proportions of parasites carrying the resistant and sensitive alleles of 
dhfr allows a direct measurement of the relative fitness of both alleles which is 
independent of genetic differences at other loci. This approach solves the inherent 
problems associated with using the isogenic lines described above, namely the inability to 
be completely confident that the lines differ only at the dhfr locus, and the fact that the 
different number of passages each line was subjected to may have selected for differences 
in growth-rates between them. The results of such experiments involving the progeny of 
crosses between ASpyrl (resistant) and AJ (sensitive), and ASpyrl and CB (sensitive) 
are described here. 
A further experiment was conducted on the progeny of a cross between AS(sens) and AJ 
in order to control for the possibility that single nucleotide polymorphisms in the dhfr 
gene between AS(sens) and AJ are responsible for the apparent difference in fitness 
between ASpyrl and AJ 
5.2 Further analysis of the progeny of a cross between ASpyrl and AJ described in 
Chapter IV (section 4.3) 
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The uncloned progeny of the cross between ASpyrl and AJ described in Chapter IV 
(Section 4.3) were grown in a group of 3 mice for 6 days until a parasitaemia of 3 0-40% 
was reached. At this point all mice were bled, the blood was mixed and 0.3 ml was used 
to inoculate a further 3 mice, the remainder being used for the extraction of parasite DNA 
for AFLP analysis. The resulting infection in the second group of mice was allowed to 
proceed, without the administration of pyrimethamine, until peak parasitaemia was 
achieved (6 days post-inoculation) at which point blood was collected, pooled and 
parasite DNA extracted. AFLP analysis was then performed on samples from both groups 
as previously described, and the relative intensities of markers of both parental parasites 
were compared between the two groups (First Passage and Second Passage, respectively, 
see Figure 5.1). This allowed the comparison of the intensities of AFLP markers before 
and after six days of erythrocytic growth in the absence of pyrimethamine treatment. 
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Figure 5.1 A schematic representation of the procedure for the generation of a cross between ASpyrl and 
AJ. Numbers in the boxes refer to the cage numbers of the mice used in the experiment. Experimental 
groups are referred to in the text by these names 
5.2.1 Results 
Figure 5.2 shows the Comparative Intensities of ASpyrl makers in the Second Passage 
progeny of the cross compared to the First Passage progeny. This graph therefore shows 
the effect on marker representation of 6 days of erythrocytic cycle growth in a population 
of genetically diverse parasites without the influence of drug selection. The same 
156 
comparison of marker intensities is shown for AJ markers in Figure 5.3, superimposed 
upon the data from Figure 5.2 in order to facilitate comparisons between the markers 
from the two parents. 
Chromosome Number 
Scale: 	50cM 
Figure 5.2 Comparative Intensities ofASpyrl (resistant parent) markers in the Second Passage group 
compared to the First Passage group, for markers assigned to P. chabaudi chromosomes. Markers are 
positioned on the X axis according to their positions in cM along the chromosomes, and the sizes of the 






Figure 5.3 Comparative Intensities of AJ (sensitive parent) (red line) and ASpyrl (resistant parent) (blue 
line) markers in the Second Passage group compared to the First Passage group, for markers assigned to P. 
chabaudi chromosomes. Markers are positioned on the X axis according to their positions in cM along the 
chromosomes, and the sizes of the chromosomes in cM according to the map are indicated by the width of 
the columns. The arrow points to the position of pcdhfr. 
From these results there appears to be little selection against linked groups of ASpyrl 
markers. There is, however, a slight selection valley present on chromosome 7 around the 
position of dhfr (marked with an arrow), which is associated with a large 'selection peak' 
of an AJ marker in the same region. In order to investigate this effect in more detail, the 
proportions of ASpyrl and AJ alleles of dhfr in both the First Passage and Second 
Passage groups were measured by Proportional Sequencing. The proportions of ASpyrl 
and AJ at 3 other loci (dhps, dhfs, and 6-pthps) were likewise measured as controls. The 




















































First Passage Second Passage 	 First Passage 
Figure 5.4 Proportions of ASpyrl alleles of dhfr, dhps, dhft and 6-p1hp in the First Passage and Second Passage progeny of the cross between ASpyrl and AJ, 
measured by Proportional Sequencing. Each individual proportional sequencing measurement was repeated 5 times on the same DNA (so that each measurement 
represents an independent nested PCR and measurement of sequencing peaks from the same DNA sample - each DNA sample represents about 6x I O' parasites). 
Error bars give the standard errors of the means. 
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The proportion of the ASpyrl allele of dhfr is 29.2% in the First Passage progeny, compared to 
55.5%, 74.3% and 38.8% for dhps, dhfs, and 6-pthps respectively. This suggests that there has 
been some selection against parasites carrying the ASpyrl allele of dhfr during the growth of the 
progeny of the cross in the 4 mice in which the progeny were initially grown from sporozoites 
prior to inoculation into the First Passage group (assuming a 50% representation of alleles from 
both parents in the sporozoites produced during the cross). Furthermore, the proportion of the 
ASpyrl allele of dhfr decreases by an average of 9.72% between the First Passage group and the 
Second Passage group, a much greater decrease than those observed for the other 3 alleles 
investigated (dhps = 2.73, dhfs = 0.26, and 6-pthps = 4.66). This suggests that, in the absence of 
drug pressure, the ASpyrl allele of dhfr confers a growth rate disadvantage upon the parasites 
carrying it compared with those carrying the AJ allele. This difference is measurable over the 
course of 6 days growth in mice (the difference between the First Passage and Second Passage 
groups of mice). It is possible that further passage without drug treatment may produce a larger 
effect of selection against the ASpyrl allele dhfr. 
5.2.2 Estimate of the relative fitness of parasites carrying the ASpyrl allele of dhfr 
From this data it is possible to calculate the relative fitness "s" of those parasites carrying the 
pyrimethamine resistance mutation at the dhfr allele, using the formula: 
Srt 	L 1 1a12 - 	1a11 n 	J -In  
where a = the relative proportion of those parasites carrying the ASpyrl allele of dhfr (resistant) 
b = the relative proportion of those parasites carrying the AJ allele of dhfr (wild-type) 
r = the replication rate 
t = time (or number of generations - in this case "6" (for 6 days of growth in the Second 
Passage group) 
Using the values a1 1 = 29.20, a12 = 19.48, b1 1 = 70.08, and b12 = 80.52, obtained from the 
Proportional Sequencing data described above, and r = 5 (given by the slope of the parasitaemia 
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curve from day 0 to day 6 in the Second Passage group), the selection co-efficient (5) of 
parasites carrying the ASpyrl allele of dhfr is -0.018, and hence their relative fitness 
(1+S),compared to those carrying the AJ allele in the absence of pyrimethamine pressure is 0.98. 
5.3 Analysis of a cross between ASpyrl and CB (pyrimethamine sensitive) 
It is possible that the growth rate disadvantage conveyed by the ASpyrl allele of dhfr measured 
in the experiment above is only apparent when parasites carrying this allele are in competition 
with parasites carrying the AJ dhfr allele. It is conceivable, therefore, that the growth rate 
differences observed above are due simply to inherent differences in the relative fitness of the 
ASpyrl dhfr allele compared to the AJ allele (independent of the specific mutation that confers 
PYR resistance to ASpyrl), and so it is impossible to conclude that the ASpyrl allele carries a 
fitness cost due to the PYR-resistance mutation itself. 
In order to address the question of whether the fitness disadvantage conveyed by the ASpyrl 
allele of dhfr is only apparent when in competition with the AJ dhfr allele, a further genetic cross 
was generated between ASpyrl and another sensitive parasite clone, CB. The cross (Figure 5.5) 
was generated as previously described for ASpyrl x AJ, and in an analogous fashion, First 
Passage and Second Passage progeny were analysed. 
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vv V First Passage* 
643 ASxCB 
vv,v  Second Passage* 
Figure 5.5 A schematic representation of the procedure for the generation of a cross between ASpyrl and CB. 
Numbers in the boxes refer to the cage numbers of the mice used in the experiment. *Expermenta1  groups are 
referred to in the text by these names. 
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Mosquito % Number of Mean Number of Estimated 
Cage Gametocytaemia oocysts per number of mosquitoes number of 
Number on day of feed mosquito oocysts per Dissected for recombinants 3 
dissected2 Mosquito sporozoites  
Parental CB 0.13 0,0,5,1,1, 4.5 - - 
11,9,1,16,1  
Parental 0.07 3,5,6,6,4, 12.36 - - 
ASpyrl 2,9,1,63,37 
Cross 1 0.11 0,5,14,0,68 1 	17.4 1 	122 4245 
Cross2 0.04 36,0,18,27,0 1 16.2 1 153 1 	4957 
Fable 5.2 Numbers of oocysts preseit in mosquitoes 8 days post-infection. 
1200 Y mosquitoes per cage. Numbers in brackets indicate the individual mouse upon which the cage was 
fed. 
210 mosquitoes were dissected from each parental cage, and 5 from each cross cage, on day 8 post 
infective blood-meal 
3 Assumes 50% of oocysts are hybrid, and each produces 4 recombinants (see Figure 1.6). 
5.3.1 Results 
Figure 5.6 shows the proportions of ASpyrl alleles of dhfr, dhps and 6-pthps in the First Passage 



































First Passage 	 Second Passage 
6-pthps 
First Passage 	 Second Passage 
Figure 5.6 Proportions of ASpyrl alleles of dhfr, dhps, and 6-pthps in the First Passage and Second Passage progeny of the cross between ASpyrl and CB, 
measured by Proportional Sequencing. Each individual proportional sequencing measurement was repeated 5 times on the same DNA, and error bars give the 
standard errors of the means. 
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These results show that, in the cross between ASpyrl and CB, the proportion of the ASpyrl 
allele of dhfr is greatly reduced in the First Passage cross progeny compared to the proportions 
of the ASpyrl alleles of dhps and 6-pthps. This suggests that selection against the ASpyrl 
allele of dhfr had already occurred in the sporozoite-induced infections of the cross progeny 
population prior to inoculation into the First Passage experimental group. In contrast to the 
results from the ASpyrl x AJ cross, however, there was little further decrease in proportion of 
ASpyrl dhfr the First Passage and Second Passage progeny (indeed, there appears to be a 
greater decrease between the representation of ASpyrl alleles for dhps and 6-pthps than for 
dhfr). 
5.4 Analysis of a cross between AS(sens) and AJ (both pyrimethamine sensitive) 
The results from the two experiments described above suggest that there is a growth rate cost 
conferred to parasites carrying the ASpyrl allele of dhfr when grown in competition with 
parasites carrying a pyrimethamine sensitive allele of the same gene. 
In the experiment involving the progeny of a cross between ASpyrl and AJ, the ASpyrl allele 
of dhfr appears to be selected against in the absence of drug pressure in a mixed infection 
containing the uncloned recombinant progeny of a cross between ASpyrl and AJ. It is 
conceivable that this is evidence of a fitness cost associated with the mutation in dhfr which 
confers resistance to pyrimethamine. It is known that the mutation responsible for 
pyrimethamine resistance in the dhfr gene is a single nucleotide polymorphism which results in 
a change in amino acid at position 106 from a serine to an asparagine (Cheng and Saul, 1994). 
However, ASpyrl and AJ differ not only at this SNP, but at 7 other bases within the gene (one 
of which is non-synonymous). It is possible, therefore, that the fitness cost observed for the 
ASpyrl dhfr allele when in competition with the AJ allele, may be due to these other 
polymorphisms, and may not be associated with pyrimethamine resistance. 
In order to investigate this possibility, an experiment was conducted in which the 
pyrimethamine sensitive progenitor of ASpyrl, AS(sens), was crossed with AJ and the 
resulting uncloned recombinant progeny were passaged through a series of groups of mice 
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(Figure 5.7) in the absence of any selection pressure other than growth competition between 
parasites. Blood samples were taken from all groups on day 4 post-inoculation and the 
proportions of AS(sens) and AJ alleles of dhfr were measured in order to determine if there 
was selection against AS(sens) dhfr. The relative proportions of alleles of another, unrelated, 
polymorphic gene, multi-drug resistance -1 (mdr-1) were also measured as a control. 
In the experiments conducted with the uncloned progeny of crosses between ASpyrl and AJ, 
and ASpyrl and CB (see above), there had appeared to be selection against the dhfr allele of 
ASpyrl already in the sporozoite induced infections in which the cross progeny population was 
grown before inoculation into the First Passage groups. In order to measure any possible 
selection at this stage, samples were taken daily from the sporozoite induced infections in 
which the progeny of the cross between AS(sens) and AJ were grown, and were analysed for 













Figure 5.7 A schematic representation of the procedure for the generation of a cross between AS(sens) and AJ, 
and the subsequent passage of the uncloned recombinant progeny through a series of groups of mice. Numbers in 
the boxes refer to the cage numbers of the mice used in the experiment. *Experimental  groups are referred to in 
the text by these names. 
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5.4.1 Results 
Parasitaemias of all mice infected with sporozoites from the cross between AS(sens) and AJ 
are shown in Figure 5.8. The course of an infection induced by sporozoites differs from that 
seen when blood stage parasites are directly inoculated into hosts. The fact that sporozoites 
must enter the liver where they undergo pre-erythrocitic development (which takes around 48 
hours before release of merozoites), means there is a period of time post-inoculation in which 
there are no blood-form parasites present in the circulation. In such sporozoite induced 
infections, peak parasitaemia is only approached by day 10 post-inoculation; whereas infected 
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Figure 5.8 The parasitaemias (on a log scale) of individual mice inoculated with sporozoites from a cross between 
AS(sens) and AJ. 
The key refers to each mouse by the cage numbers given in Figure 5.7 
All mice from the sporozoite induced infections were blood-sampled daily, and the infections 
monitored by Proportional Sequencing in order to determine the proportions of AS(sens) and 
AJ alleles of dhfr and of the control gene (mdr-1). Of the two groups of mice (243 IAS/AJ and 
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2432AS/AJ) inoculated with sporozoites from the cross, both mice in group 2432AS/AJ were 
found to contain both AS(sens) and AJ alleles of dhfr and mdr-1 genes as assayed by 
Proportional Sequencing. Although a patent parasitaemia was observed in the mice in 
233 1AS/AJ (Figure 5.8), only alleles from AJ were present in the infection, suggesting that 
only the AJ parent was present, with zero (or very few) recombinants represented in the 
population. As both these groups were inoculated with sporozoites from different cages of 
mosquitoes (Figure 5.7), differences in the compositions of the resulting infections are not 
unexpected. 
The proportions of the AS(sens) alleles of dhfr and ,ndr-I in the infections from the progeny in 
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Figure 5.9 The proportions of AS(sens) and AJ alleles of dhfr and mdr-I in two individual mice (from group 
2432AS/AJ) inoculated with sporozoites from a cross between the two parasites, as determined by Proportional 
Sequencing. 
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The Proportional Sequencing results for the sporozoite induced infections vary between the 
two mice analysed. In mouse 1, the proportions of both alleles are approximately the same, and 
continue at similar levels throughout the infection. In mouse 2, however, the proportion of the 
AS(sens) allele of dhfr was much greater than that of mdr-l. The discrepancies between the 
mice can be explained by the fact that each mouse received a separate inoculation of cross 
progeny sporozoites, resulting in each infection being composed of a different subset of the 
total progeny population. In neither infection, however, was selection against the AS(sens) dhfr 
allele observed over the course of the infection. 
Blood from all sporozoite inoculated mice, including those subsequently found to contain only 
AJ alleles of dhfr and mdr-J, was pooled and passaged in 4 serial experimental infections in 
mice as shown in Figure 5.7. The parasitaemias of these infections are given in Figure 5.10, 
and the proportions of the AS(sens) alleles of d/zfi- and mdr-1 from parasites present in these 
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Figure 5.10 Mean parasitaemias (n=5) of infections of uncloned AS(sens) x AJ cross progeny in 4 serial passage 
infections in mice. Error bars indicate the 95% Cl for the mean parasitaemia of the 5 mice in each group. The key 
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Figure 5.11 The proportions of AS(sens) alleles of dhfr  and mdr-1 in infections of uncloned progeny of a cross 
between AS(sens) and AJ in serial passage through 4 groups of 5 mice, as determined by Proportional Sequencing. 
Errors bars indicate the 95% Cl for the mean of the 5 mice in each group. Samples were taken on day 4 post-
inoculation. Groups are referred to as described in Figure 5.7. 
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It can be seen that the proportions of AS(sens) alleles of both dhfr and mdr-1 decrease within 4 
serial passages, starting from around 20% in the initial inoculum and decreasing to around 8% 
in the 4th  passaged group. There is, however, no significant difference in the rate of decrease 
between dhfr and mdr-1, suggesting that there is no preferential selection against the ASpyrl 
dhfr allele. The fact that there is a decrease in AS(sens) alleles of both genes throughout the 
passages is probably due to the AJ parental type parasites out-growing AS(sens) parental types, 
and most other recombinant types, as was seen in the experiments described in Chapter III. 
-5- 
5.5 Discussion 
The results from the experiments in which a clone of ASpyrl (pyrimethamine resistant) was 
crossed with a clone of either AJ, or CB (both pyrimethamine sensitive), and the resulting 
uncloned progeny of the crosses were grown in mice in the absence of drug treatment, 
indicated that parasites carrying the ASpyrl allele of dhfr were at a growth rate disadvantage 
compared to those carrying the sensitive allele (whether.AJ or CB) of the same gene. 
In the ASpyrl x AJ cross, this growth rate disadvantage manifested itself both as an overall 
reduction in the proportion of the ASpyrl dhfr allele compared to other ASpyrl alleles in the 
First Passage group (possibly explained by selection against ASpyrl dhfr in the sporozoite 
induced infection from which the First Passage progeny were obtained), and as a significant 
reduction in the proportion of the allele from progeny in the First Passage group to the Second 
Passage group, when compared to reductions of other alleles between progeny in the two 
groups. 
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In experiments involving the uncloned recombinant progeny of a cross between AS(sens) and 
AJ, the possibility that the growth rate disadvantage associate with the ASpyrl allele of dhfr 
was due to polymorphisms in the gene between ASpyrl and AJ other than that which confers 
pyrimethamine resistance, was investigated. It was shown that the AS(sens) allele of dhfr, 
conferred no significant growth rate disadvantage to parasites when compared to another, 
unlinked, gene. it can be concluded, therefore, that the growth rate differences attributed to the 
ASpyrl dhfr allele in the cross between ASpyrl and AJ,are due to the S106N mutation that 
confers pyrimethamine resistance, and not to any other polymorphisms within this gene 
between the two parasite clones. 
5.5.1 Summary 
The results from these experiments show that ASpyrl alleles of dhfr confer a selection 
disadvantage on parasites when grown in the presence of parasites containing AJ and CB 
alleles of the gene. This effect was subsequently shown to be due to the Si 06N mutation in the 
dhfr gene that confers resistance to pyrimethamine and is independent of other SNP 
polymorphisms between AS and AJ. 
This is the first time a direct fitness cost of pyrimethamine resistance directly attributable to the 
Si 06N mutation has been measured and demonstrated. Previous work involving measuring the 
kinetic parameters of pyrimethamine-resistant enzymes of DHFR (Sirawaraporn et al., I 997a) 
and studies in which pyrimethamine resistant alleles of dhfr were transfected into T gondii 
parasites (Fohl and Roos, 2003), fail to address the natural situation in which parasites 
possessing resistant alleles are competed against parasites with sensitive alleles of dhfr in 
genetically diverse backgrounds. 
In an investigation into the enzyme kinetics of pyrimethamine-resistant DHFR enzymes, 
Sirawaraporn et al (1 997a) found that the isoform of the enzyme encoded by the S 1 08N P. 
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falciparum allele of dhfr (homologous to P. chabaudi S106N) did not exhibit a significantly 
lower kcat/Km value than the wild-type allele (Figure 1.12). Such a result may be interpreted to 
suggest that there would be no fitness cost associated with this single amino acid mutation. The 
results presented here, however, imply that there is a fitness cost associated with this mutation. 
It would be interesting to perform these experiments using the other mutations in dhfr that are 
know to influence resistance to pyrimethamine (N5 11, C59R and Ii 64L in P. falciparum), but 
there are no homologous mutants of P. chabaudi as yet available. It would be also be useful to 
subject the progeny of the ASpyrl x AJ and ASpyrl x CB crosses to further passages without 
selection, as performed with the AS(sens) x AJ cross. 
As previously discussed (Chapter I) the repercussions of this result for drug policy in endemic 
areas are significant. If resistant parasites are selected against in the absence of drug pressure, 
then it is possible that resistance will disappear from a population when the drug pressure is 
removed. This opens the possibility that a carefully controlled drug programme in which two 
independently acting drugs were provided as first line treatments in alternate succession, could 





The main aim of the work presented within this thesis was the validation of the Linkage Group 
Selection approach to the identification of genes controlling selectable phenotypes in malaria 
parasites. The approach taken to achieve this aim involved the application of LGS to an 
investigation of the genetic determinants of pyrimethamine resistance in Plasmodium 
chabaudi. By showing that LGS was capable of identif'ing pcdhfr as the gene responsible for 
controlling pyrimethamine resistance in this parasite, the technique was shown to be reliable. 
During the course of this work, the dyiamics of the interactions between pyrimethamine 
resistant and sensitive parasites grown in mixed infections were investigated, and data were 
produced that indicated there was a fitness cost associated with pyrimethamine resistance in P. 
chabaudi. 
6.2 Experiments described in Chapter III 
In Chapter III, experiments were described in which ASpyrl (pyrimethamine resistant) and AJ 
(pyrimethamine sensitive) cloned strains of P. chabaudi were grown in mixed infections under 
varying conditions, including different mouse strains and varying levels of pyrimethamine 
treatment. Throughout these experiments, ASpyrl was shown to have a reduced growth rate (in 
terms of the total numbers of parasites produced during the acute phase of the infection) 
compared to AJ in the absence of drug pressure, irrespective of host genotype. This difference 
in growth rates between the two clones was reflected in differences in virulence between them 
(as measure by host weight loss during Drug Selection Experiment B), as the faster growing AJ 
clone caused a greater degree of weight loss in infected mice than did ASpyrl. Whether this 
difference in growth rate reflects a difference in fitness between the clones (where fitness is 
defined as "the reproductive success of individuals of a particular genotype relative to the most 
fit genotype"), is unknown, as the comparative ability of the clones to transmit through 
mosquitoes was not measured. 
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Fitness differences between the clones are likely to manifest themselves in mixed infections, 
however, especially as one clone was seen to dominate mixed infections both in the absence of 
pyrimethamine (clone AJ), and in its presence (clone ASpyrl). In order to quantify fitness 
differences between the clones, however, further experiments would need to be designed in 
which the gametocyte production of each clone in a mixed infection was measured, and the 
infectivity of these gametocytes to mosquitoes determined. This would be an interesting 
direction for further work on this subject. 
6.3 Linkage Group Selection (Chapter IV) 
Linkage Group Selection is "the application of a specific selection pressure (such as drug 
treatment) to the entire recombinant progeny of a genetic cross between two members of the 
same species that differ phenotypically in their response to the selection pressure, and 
evaluation of the effects of the selection upon the progeny at loci across the entire genome 
using quantitative genetic markers" (Culleton et al., 2005). This approach ultimately allows the 
identification of specific genes that control the phenotype under investigation. The LGS 
approach is ideally suited to organisms such as the malaria parasites whose genetics are 
conventionally Mendelian but which are in a haploid state for most of their life cycle when 
phenotype-specific selection pressures can be applied. These circumstances apply to all the 
protozoan parasites of the phylum Apicomplexa which include not only the malaria parasites 
but also their relatives Theileria, Babesia, Toxoplasma and Coccidia, all of which are 
important pathogens of humans andlor animals. 
Using the rodent malaria parasite P. chabaudi, and applying the LGS method, the work 
presented in this thesis has demonstrated that a group of linked AFLP markers were reduced in 
intensity when the uncloned progeny of a genetic cross between a pyrimethamine resistant 
(ASpyrl) and a pyrimethamine sensitive clone (AJ) were subjected to pyrimethamine 
treatment. These markers were linked on a P. chabaudi genetic linkage map to pcdhfr, the gene 
already known to determine pyrimethamine resistance in the resistant parental line used in the 
cross. The homologues of these markers were also found to be physically linked to pfdhfr, the 
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homologous gene in P. falciparum. The data demonstrate the existence, under pyrimethamine 
treatment, of a "selection valley" with the dhfr locus at its apex and have, therefore, validated 
LGS as a method for locating a gene controlling a selectable phenotype such as drug 
resistance. 
A full discussion of the potential uses of LGS as a method to identify genes controlling 
selectable phenotypes has recently been published (Culleton et al., 2005), and includes a 
discussion of the potential application of the technique to diploid organisms, and its ability to 
identify multiple genes controlling certain phenotypes. Additionaly, LGS has recently been 
applied to an investigation of the genes controlling strain-specific immunity in P. chabaudi 
(Martinelli, 2003). 
6.4 Growth-rate cost associated with Pyrimethamine Resistance 
The results presented in Chapter IV indicate that there is a growth-rate cost associated with the 
mutation at Si 06N in P. chabaudi that confers pyrimethamine resistance. This is the first time 
that such a cost has been shown for pyrimethamine resistance in malaria parasites in which 
growth-rate differences between sensitive and resistant parasites were measured directly in 
mixed infections. 
Whether the impaired growth rate of a parasite carrying the pyrimethamine resistant mutant 
allele of dhfr would translate to fitness cost that would manifest in a reduced ability to transmit 
through mosquitoes was not determined. This is because the experimental design was confined 
to analysis of the blood stages of the parasite life-cycle. Further experiments in which the 
proportion of the resistant allele of dhfr in the uncloned recombinant progeny of a cross 
between a pyrimethamine resistant and a sensitive clone was measured throughout the parasite 
life cycle (including transmission through mosquitoes) would show whether there is a fitness 
cost associated with the resistant allele. Such an experiment provides an exciting potential 
direction for future work on this subject. 
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As previously discussed (Chapter 1), some evidence form the field suggests that resistant 
mutants are at a selection disadvantage compared to sensitive parasites in the absence of drug 
pressure. Studies on the prevalence of chloroquine resistant mutants show a decline in the 
prevalence of resistant parasites after periods of cessation of chloroquine usage in several 
geographic locations (Kublin et al., 2003b; Liu et al., 1995; Mita et al., 2003; Mita et al., 2004; 
Thanh et al., 2001). This evidence is supported by a recent in vitro study in which chloroquine 
resistant mutants were competed in culture with sensitive parasites, in which the proportion of 
resistant parasites declined through time (Hayward et al., 2005). This finding, combined with 
the aforementioned field observations, prompted the authors to suggest that chloroquine may 
be effectively re-introduced to areas from which it was previously withdrawn due to parasite 
resistance after a suitable time period. 
This idea has been expanded to include the possibility of "cycling" two drugs with different 
modes of action for fixed time periods, allowing parasites resistant to the first drug to be 
removed by natural selection while the second drug was in use, so that it could be used 
effectively at the end of the second drug's usage period, and so on (Beck, HP pers. corn). 
Such suggestions should be treated with caution, however, as the declining rate at which 
resistant strains disappear from the population must be taken into account. For example, in a 
study reported from Tanzania in 1967, Clyde et al (1967) report the presence of pyrimethamine 
resistant parasites 10 years after the cessation of the use of the drug in this country. It should 
also be noted that in all the field reports described above which show a drop in the prevalence 
of chloroquine resistant parasites in the absence of chloroquine pressure, resistant parasites do 
still persist in the population. The re-introduction of drugs to parasite populations where even a 
small proportion of resistant mutants persist is likely to lead to the rapid selection of resistance 
once more. 
It is probable, however, that the most effective approach to anti-malaria chemotherapy is the 
use of combinations of drugs with different modes of action. This type of approach was first 
developed for antituberculous chemotherapy, and has also been adopted for the treatment of 
AIDS and early HIV-1 (Barnes and White, 2005; White et al., 1999). The chance of selecting a 
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mutant that is simultaneously resistant to two drugs in a combination is given by the product of 
the individual mutation rate per parasite for each drug, multiplied by the number of parasites 
exposed to the drugs (White et al., 1999), and their use will, therefore, greatly diminish the 
selection of resistant parasites compared with single drug regimens. It is for this reason that the 
future of malaria chemotherapy is likely to be based on this type of drug therapy, especially 
using drug combinations that include artemisinin and its derivatives, to which there is currently 
no known parasite resistance. 
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APPENDIX 1 
SOLUTIONS AND BUFFERS 
J 
1:1 FCS : Ringer's Solution 
50% (v/v) heat inactivated foetal calf serum 
50% (v/v) mammalian Ringer's solution 
20 units heparin/ml mouse blood 
Buffer A 
150 mMNaCI 
25 mM EDTA 
Citrate saline 
0.9% (w/v) NaCl 
1.5% (w/v) Sodium citrate 
pH 7.2 
Deep-freeze solution 
28% (vlv) glycerol 
3.0% (v/v) sorbitol 
0.65% (v/v) NaCI- sterilise by filtration. 




TBE buffer (sterilised by filtration) 
lOOnM Tris 
100 mM Boric Acid 
2 mM EDTA (Ethylenediaminetetraacetic Acid) 





THE RELATIVE INTENSITY INDICES AND COMPARATIVE INTENSITIES OF 
ALL AFLP MARKERS ANALYSED IN THE LGS EXPERIMENT DESCRIBED IN 
CHAPTER IV 
CM distance Relative Intensity Comparative Intensity 
along 
arker Name Chromosome I 
Linkage Group  
PYRI PYR! UNTREATED 
J Markers Non- PYR Untreated NON- UNTREATED /NON- 
_____________  Passaged treated PASSAGED PASSAGED 
16.20 0.63 0.63 0.67 1.00 0.94 1.06 
16.20 0.42 0.47 0.68 1.13 0.69 1.63 
301GT 16.20 0.80 0.79 0.82 0.99 0.96 1.03 
302TC 16.20 0.73 0.73 0.77 1.00 0.94 1.06 
43.40 1.00 0.88 0.90 1 	0.88 0.98 1 	0.90 
AJAr02AG 0.00 0.38 0.35 0.35 0.92 1.00 0.92 
AJTAO5AT 4.00 0.62 1.03 1.02 1.66 1.01 1.64 
AJGTO6AA 54.40 0.73 0.24 0.44 0.33 0.56 0.60 
AJA04AC 70.00 0.71 0.82 0.79 1.15 1.05 1.10 
AJATO7AT 70.00 0.80 0.83 0.83 1.05 1.00 1.05 
AJAT07AT 70.00 0.74 0.79 0.72 1.07 1.11 0.97 
AJAT01AT 73.90 0.67 0.40 0.56 0.60 0.72 0.84 
AJTAO1AC 77.50 0.66 0.79 0.62 1.20 1.27 0.94 
AJAG01TT 82.70 0.42 0.31 0.46 0.74 0.67 1.11 
AJAAO3TA 82.90 0.70 0.88  1.26  0.00 
Chromosome 6 
AJAG02AG 11.30 0.33 0.54 0.39 1.61 1.39 1.16 
AJAT02TA 11.30 0.51 0.49 0.56 0.95 0.87 1.10 
AJG;TO1TA 11.30 0.44 0.59 0.50 1.33 1.18 1.13 
AJTG02AA 11.30 0.66 1.03 0.79 1.56 1.31 . 	 1.19 
AJTT05AT 11.30 0.73 0.75 0.75 1.02 1.00 1.02 
AJAGO1CT 16.10 0.32 0.39 0.35 1.24 1.13 1.10 
AJAT03TG 29.30 0.46 0.81 0.92 1.76 0.88 2.00 
AJT1AO2GA 37.10 0.61 0.58 0.59 0.96 1.00 0.97 
AJT;TO1CA 44.30 0.69 0.95 0.87 1.37 1.10 1.25 
AJC;TO3AT 62.60 0.40 0.74 0.49 1.88 1.52 1.24 
.1iA02AC 62.70 0.53 0.67 0.49 1.28 1.38 0.93 
Chromosome 7 
A02TG 24.10 0.50 	- 0.58 0.43 1.16 1.35 0.86 
001AG 37.20 0.54 0.66 0.57 1.22 1.15 1.06 
A01GA 37.30 0.68 0.54 0.54 0.80 1.02 0.79 
T01GT 37.30 0.92 0.51 0.54 0.55 0.93 0.59 
AJ.T01GT 37.30 0.40 0.33 0.37 0.83 0.91 0.92 












JT01CA 62.30 0.45 0.61 0.55 1.38 1.11 1.24 
JAT02TC 77.70 0.36 0.41 0.36 1.14 1.14 1.00 
JTG02AT 77.70 0.76 0.79 0.74 1.04 1.07 0.97 
JAT02AC 77.70 0.71 1.06 1.04 1.50 1.02 1.47 
JAT02TC 77.70 0.79 0.63 0.62 0.80 1.01 0.79 
JTA02TA 77.70 0.44 0.52 0.41 1.17 1.27 0.92 
JTT03TG 81.40 0.65 0.68 0.67 1.05 1.02 1.04 
JA405CA 96.30 0.33 0.00 0.41 0.01 0.01 1.26 
JAG02CA 100.30 0.86 0.13 0.97 0.15 0.13 1.14 
JTG01AG 104.40 0.58 0.06 0.65 0.10 0.08 1.13 
kJTGOIGA 104.40 0.71 0.12 1.91 0.17 0.06 2.69 
kJACO2TT 123.80 0.64 0.40 0.94 0.63 0.42 1.48 
JAI03AT 135.30 0.70 0.50 0.83 0.71 0.60 1.19 
;nromosome S 
\JA303AG 0.00 0.46 0.73 0.56 1.58 1.30 1.21 
JTiO3TA 17.30 0.31 0.53 0.38 1.70 1.42 1.20 
JTt02AT 17.30 0.61 0.93 0.79 1.52 1.18 1.28 
JAr01TA 21.30 0.46 0.51 0.51 1.09 1.00 1.09 
JT 07AT 25.90 0.45 0.89 0.55 1.99 1.60 1.24 
JG 02TA 34.30 0.38 0.44 0.35 1.15 1.27 0.91 
JT 04AT 34.30 0.53 0.60 0.80 1.13 0.75 1.50 
JA 02AT 46.20 0.21 0.31 0.29 1.50 1.07 1.40 
JT 03AA 55.00 1 	0.38 0.43 0.35 1 	1.12 1.22 0.92 
JA 03AT 73.20 0.58 0.85 0.81 1.47 1.05 1.40 
Thromosome9 
JAT01TC 40.20 0.57 0.81 0.65 1.42 1.25 1.14 
JAT01TC .40.20 0.44 0.58 0.44 1.34 1.33 1.01 
JAT05TG 40.20 0.31 0.26 0.23 0.84 1.11 0.76 
JTA01GT 40.20 0.66 0.62 0.58 0.95 1.07 0.88 
JAC01AA 51.70 0.22 0.43 0.41 1.95 1.05 1.86 
J14CO3AA 51.70 1.18 1.10 1.21 0.93 0.91 1.03 
UAG01TC 63.50 0.39 0.43 0.43 1.11 1.00 1.11 
UAT04TA 67.20 0.70 0.84 0.86 1.20 0.98 1.23 
10 
JACO2AA 	I 	18.40 	I 	0.23 	I 	0.49 	I 0.36 	I 2.13 	1 1.36 	I 1.57 	I 
UAT03CT 5.30 0.63 1.53 1.05 2.42 1.45 1.67 
J1iT02GA 9.70 0.60 0.89 0.89 1.49 1.00 1.49 
.J AO1TT 9.70 1.00 0.79 0.78 0.79 1.01 0.78 
J TO3AT 9.70 0.68 1.10 0.84 1.61 1.30 1.24 
'.J TO3CA 9.70 0.64 0.81 0.71 1.26 1.14 1.11 
'.J 703AA 13.60 0.73 0.79 0.68 1.08 1.15 0.93 
'.J TO3AA 	- 13.60 0.41 0.51 0.42 1.25 1.22 1.02 
J T03AA 17.60 0.55 0.74 0.66 1.34 1.12 1.20 
J TO1AA 21.60 029 0.86 0.48 2.96 1.79 1.65 
J TO4TA 31.20 0.32 0.76 0.53 2.34 1.45 1.62 
J G05AT 39.30 1.44 2.81 2.13 1.96 1.32 1.48 
J AO1TA 39.30 0.50 0.72 0.59 1.45 1.21 1.20 
183 
J9 O1TA 39.30 0.45 0.65 0.74 1.44 0.88 1.64 
AJA '06CT 44.60 0.52 0.74 0.66 1.42 1.12 1.26 
AJA 4O1TA 48.70 0.50 0.54 0.60 1.06 0.89 1.19 
AJA 01TA 53.00 0.85 0.91 1.09 1.06 0.83 1.28 
Chr mosomel2 
AJT 04AT 13.30 0.92 1.02 0.77 1.11 1.32 0.84 
AJP 02TC 35.90 0.45 0.40 0.42 0.88 0.96 0.92 
AJA 'OlAG 50.90 0.66 0.62 0.74 0.94 0.84 1.12 
AJG 02AA 66.40 0.40 0.59 0.40 1.50 1.50 1.00 
AJA 'O4CT 79.90 0.49 0.59 0.41 1.19 1.42 0.84 
AJA 4O1TG 106.80 0.50 0.81 0.74 1.60 1.09 1.47 
AJT 02eA 123.50 0.47 0.30 0.36 0.64 0.82 0.77 
AJT O2AA 123.50 0.42 0.41 0.45 0.97 0.90 1.08 
Chr imosomel3 
AJT OIAG 15.20 0.74 0.49 0.75 0.66 0.66 1.01 
AJG F02AG 15.20 0.94 0.65 0.96 0.68 0.67 1.02 
AJ.A 06AA 19.30 0.69 0.59 0.76 0.85 0.77 1.10 
AJ.A 03TG 28.50 0.42 0.34 0.51 0.81 0.67 1.20 
AJA 04AT 28.50 0.34 0.31 0.40 0.90 0.78 1.16 
AJT 01GA 28.50 0.61 0.61 0.69 1.00 0.89 1.12 
AJT, 04AA 32.40 0.45 0.34 0.52 0.77 0.67 1.15 
AJI T04AA 32.40 0.32 0.26 0.37 0.80 0.69 1.16 
AJI 02AC 36.70 0.63 0.65 0.73 1.03 0.89 1.15 
AJ/ 01AT 44.50 0.65 0.82 0.80 1.26 1.02 1.23 
AJT T02TA 44.50 0.50 0.51 0.67 1.01 0.76 134 
AJT 02TA 44.50 0.55 0.45 0.39 0.83 1.16 0.71 
AJ( TOITG 60.40 0.32 0.31 0.33 0.99 0.94 1.05 
AJ/ u02TG 64.00 0.30 0.52 0.46 1.72 1.14 1.51 
AJT01AG 72.90 0.66 1.07 0.78 1.62 1.37 1.18 
AJ.' 03AC 136.10 0.50 0.56 0.46 1.13 1.23 0.92 
AJI 01CT 154.80 0.56 0.74 0.67 1.32 1.10 1.20 
AJ/ G04AG 177.90 0.39 0.93 0.51 2.40 1.84 1.30 
AJ1 G02AG 183.40 0.66 0.81 0.68 1.23 1.20 1.02 
AJ GO2GA 183.40 0.51 0.86 0.97 1.70 0.89 1.91 
AS TO2CA 183.40 0.54 0.71 0.60 1.32 1.19 1.11 
AS TO2TG 183.40 0.44 0.54 0.61 1.21 0.88 1.37 
AJ TO2TT 183.40 0.23 0.32 0.32 1.40 1.00 1.40 
A TO1AT 183.50 0.30 0.33 0.38 1.11 0.87 1.28 
AJ4 AO3CA 200.00 0.36 0.23 0.34 0.64 0.67 0.95 
AJ CO3TT 200.00 0.53 0.35 0.49 0.67 0.71 0.94 
AJ4 TO2AT 200.00 0.45 0.27 0.44 0.60 0.61 0.98 
AJ4 TO2AT 200.00 0.46 0.18 0.41 0.40 0.44 0.90 
A T05AA 200.10 0.41 0.23 0.32 0.56 0.71 0.78 
AJOT01A G 200.10 0.35 0.14 0.34 0.39 0.41 0.97 
AiA01AG 208.20 0.36 0.20 0.42 0.56 0.48 1.16 
AJ,A01AA 212.40 0.37 0.26 	1 0.33 0.71 0.79 0.89 
184 
ILinkqe Group A 
JAT03TA 4.60 0.70 0.75 1.10 1.07 0.68 1.59 
AJAjkOlGT 8.70 0.42 0.64 0.64 1.50 1.00 1.50 
JA 02AA 8.70 0.39 0.34 0.43 0.88 0.81 1.08 
AJA O1AC 8.70 0.72 0.67 0.94 0.94 0.72 1.31 
AJAj .05AC 16.80 0.64 0.81 0.68 1 	1.26 1.19 1.06 
AJA 02GT 16.80 0.69 0.73 0.83 1.06 0.88 1.20 
AJA 02GT 16.80 0.65 0.76 1.02 1.16 0.75 1.56 
AJI O3TA 16.80 1.01 0.91 0.90 0.91 1.01 0.90 
AJA 04TG 25.50 0.39 0.34 0.27 0.87 1.22 0.71 
AJA 02T1 29.90 0.42 0.53 0.57 1 	1.25 0.92 1.36 
AJA O1TG 43.90 0.57 0.92 0.97 1.63 0.95 1.71 
AJA 04AA 47.50 0.43 0.75 0.63 1.74 1.18 1.48 
AJA O1CT 84.20 0.98 1.12 0.94 1.15 1.18 0.97 
AJT 01CT 84.20 0.60 0.89 1 	0.81 1.48 1.11 1.34 
AJG T03AG 84.20 0.75 0.61 0.62 0.82 0.98 0.83 
AJT O6AA 84.40 0.61 0.79 0.76 1.30 1.03 1.26 
AJG T02AT 92.70 1 	1.08 0.75 0.66 0.69 1.13 1 	0.61 
AJA303AT 92.70 1.01 1.02 0.86 1.00 1.19 0.84 
Lini age Group B 
AJT 01AT 10.90 0.67 0.70 0.62 1.05 1.13 0.93 
AJT 02AT 25.60 0.49 0.51 0.51 1.04 1.00 1.04 
AJ. 01AT 40.70 0.48 0.58 0.62 1.21 0.94 1.29 
AJT E07AA 40.70 0.66 0.71 0.88 1.07 0.80 1.33 
AJI EO1AC 49.50 1 	0.92 1 	0.75 1 	1.06 0.82 1 	0.71 1.15 
AJ. 02AA 76.00 0.89 0.91 0.89 1.01 1.01 1.00 
Lini age Group C 
AJ 01TG 0.00 0.76 1.12 1.12 1.47 1.00 1.47 
AJAIA02AT 8.50 0.37 0.61 0.80 1.65 0.76 2.18 
AJG01AT. - 	 19.40 0.34 0.63 0.45 1.85 1.41 1.31 
inage iroup U 
AJPG02TT 19.80 0.86 0.57 0.59 0.66 0.96 0.69 
JNC05AT 24.40 0.70 0.86 0.67 1.24 1.28 0.96 
AJ1IT01TC 44.60 0.79 0.79 0.78 0.99 1.01 0.98 
AJ17T01GT 71.90 0.34 0.35 0.53 1.03 0.67 1.54 
AJT03TA 71.90 0.43 0.35 0.40 0.82 0.88 0.94 
AJ1A03AC 79.60 0.43 0.33 0.35 0.76 0.94 0.81 
AJA C01TT 88.40 0.31 0.28 0.27 0.91 1.05 0.87 
AJGT01AA 88.40 0.84 0.83 0.77 0.98 1.08 0.91 
AJIG02AT 88.40 0.44 0.44 0.37 1.02 1.22 0.84 
AJT04AA 99.20 0.45 0.38 0.29 0.86 1.33 0.64 
AJTG04AA 103.60 0.61 0.50 0.52 0.82 0.96 0.85 
AJiT05AT 120.60 0.28 0.30 0.36 1.10 0.85 1.29 
AJT05AT 1 	120.60 0.48' 0.30 0.35 0.62 1 	0.84 1 	0.74 
AJTA04TA 	1 120.60 0.26 0.30 0.37 1.16 1 0.81 1 1.44 
Linkage uroup 
AJAG02TA 	1 	0.00 	0.60 	0.88 	0.62 	1.47 	1.42 	 1.03 
AJAC04TA 1 4.00 0.36 1 	0.45 1 0.38 1.25 1.18 1.06 
185 
AJAT02GA 4.00 0.63 0.68 0.88 1.08 0.77 1.39 
JTG03AT 12.80 0.56 0.64 0.52 1.14 1.23 0.92 
JAC04AA 20.30 0.42 0.29 0.32 0.69 0.91 0.76 
JAT04AT 20.30 0.63 0.54 0.63 0.85 0.85 1.00 
AJAT04AT 20.30 0.51 0.41 0.55 0.80 0.75 1.07 
AJAT03TT 20.30 0.59 0.75 0.84 1.26 0.89 1.42 
AJTT03CT 28.30 0.61 0.14 0.81 0.23 0.17 1.32 
ILink Group F 
AJA 03AC 0.00 1.04 0.80 0.78 0.77 1.02 0.75 
AJT 01TT 0.00 0.54 0.68 0.69 1.25 0.98 1.28 
AJI O1TA 4.40 0.56 0.51 0.45 0.91 1.14 0.79 
AJT O1TA 4.40 0.58 0.64 0.65 1.10 0.98 1.12 
AJT 04AT 24.50 0.81 1.39 1.39 1.72 1.00 1.72 
AJI O1AA 48.40 0.56 0.58 0.58 1.04 1.00 1.04 
AJI O1AA 48.40 0.49 0.54 0.56 1.11 0.98 1.14 
Unhi iked Markers 
AJA TO1CA  0.55 0.50 0.59 10.17 0.84 -6.78 
AJG 101TC  0.62 0.81 0.54 -30.91 1.50 12.73 
JA roirr  0.92 0.78 1.03 14.81 0.75 -12.96 
AJTF01TT  0.22 0.28 0.29 -23.08 0.94 -30.77 
AJI 02CT 1 0.60 0.59 0.62 2.27 0.96 -2.27 
AJI O1AT  0.81 0.90 0.92 -11.25 0.98 -13.75 
AJI k02AG  0.75 0.87 0.85 -16.49 1.03 -13.40 
AJP 01AC  0.63 0.55  12.20  
AJP A02AC  0.45 0.45 045 0.00 1.00 0.00 
AJI AO1CA  0.51 0.67 0.85 -30.00 0.78 -66.67 
AJA T06AT  0.66 0.81 0.85 -22.13 0.94 -29.51 
AJI 03GT  1.01 1.28 1.22 -26.39 1.05 -20.14 
AJTG01AT  0.69 0.84 0.50 -20.62 1.67 27.84 
AJ) TO6AT  0.73 0.71 0.69 2.70 1.03 5.41 
AJI TO2CA  0.57 0.53 0.55 5.88 0.97 2.94 
AJ AO1CT  0.66 0.77 0.89 -17.54 0.87 -35.09 
AY AO2GT  2.00 2.75 1.67 -37.50 1.65 16.67 
AY TO3GA  0.87 0.96 1.52 -10.00 0.63 -75.00 
AJI GO1AA  0.56 0.75 0.65 -33.70 1.15 -16.30 
AJ) 01TC  0.69 0.71 0.71 -4.17 1.00 -4.17 
AJ TO3AT  0.59 0.21 0.54 65.22 0.38 8.70 
AJ TO1GA  0.46 0.32 0.41 30.00 0.78 10.00 
AJPT03GT  0.80 1.17 0.97 -46.24 1.21 -20.97 
AJIT03AC  0.50 0.66 0.69 -32.26 0.95 -38.71 
AJTT02AG  0.62 0.65 0.63 -4.58 1.04 -0.76 
AJTT01GA  0.60 0.64 0.57 -7.25 1.12 4.35 
AJTT02GT  0.62 0.73 0.73 -17.95 1.00 -17.95 
186 
j ARKERS 
mosome I Chr 
ST k02GT 16.20 0.75 0.85 0.53 1.13 1.62 0.70 
AST kO1TT 16.20 0.75 0.80 0.92 1.08 0.87 1.24 
AS. 02CA 16.20 0.45 0.43 0.41 0.96 1.04 0.92 
ASA O1TC 16.20 0.32 0.28 0.32 0.88 0.88 1.00 
AST 301A 43.40 0.51 0.48 0.39 0.94 1.23 0.76 
Chr mosome5 
ASAEO3TC 23.00 1.02 1.00 0.86 0.98 1.16 0.85 
ASA 02AG 34.50 0.29 0.29 0.33 0.98 086 1.14 
ASAA02GA 54.40 0.92 1.07 0.64 1.16 1.67 0.70 
ASA 03AT 69.90 0.62 0.65 0.64 1.06 1.02 1.04 
AST 05TA 69.90 1.13 0.90 0.80 0.79 1.13 0.70 
AS 04AC 69.90 0.83 0.94 0.81 1.13 1.17 0.97 
AST 01AC 74.60 0.80 0.84 0.67 1.04 1.25 0.83 
AST 01AC 74.60 0.99 0.83 1.00 0.84 0.83 1.01 
Chr mosome 6 
AS) CO2AT 11.30 0.48 0.40 0.63 0.84 0.64 1.32 
ASlTOlCA 44.20 1.45 1.70 1.61 1.17 1.06 1.11 
AS) GO1TG 62.60 0.78 0.53 0.88 0.68 0.60 1.13 
Chr mosome 7 
AS) TO4AG 27.90 1.64 1.45 1.52 0.89 0.96 0.93 
AS) 01CA 48.40 0.68 0.56 0.68 0.82 0.82 1.00 
AS 03CA 62.20 0.94 1.01 0.88 1.07 1.15 0.94 
AS) CO2TT 62.20 0.86 0.70 1.01 0.82 0.70 1.18 
AS T02AT 69.70 0.66 0.38 0.54 0.57 0.70 0.81 
AS)T02TC 77.50 0.75 0.55 0.61 0.74 0.90 0.82 
AS4G02CA 100.30 0.63 0.78 0.50 1.24 1.56 0.79 
ASAA06AT 104.10 0.81 1.10 0.69 1.35 1.59 0.85 
AS1701AG 123.60 0.75 1.14 0.84 1.52 1.36 1.12 
AS/C01TA 127.60 0.56 0.61 0.54 1.09 1.13 0.96 
AT05AT 127.60 	1 0.81 0.73 	1 0.69 0.90 	1 1.06 0.86 
Chrlomosome 8 
AS4G01AG 0.00 0.46 0.27 0.43 0.59 0.63 0.94 
AS4A07AC 0.00 0.38 0.22 0.36 0.57 0.59 0.96 
AS4T03TA 21.30 0.51 0.19 0.42 0.38 0.47 0.81 
_ 25.90 0.67 0.53 0.73 0.80 0.73 1.10 
ASTA01AT 34.30 0.36 0.21 0.36 0.60 0.60 1.00 
AS~GWCA 38.20 0.80 0.80 0.72 1.00 1.11 0.90 
ASC01AT 73.20 0.68 0.68 0.68 1.00 1.00 1.00 
AT03AC 73.20 1.19 1.03 0.89 0.86 1.16 0.75 
Chromosome 9 
AST04TC 40.20 0.86 0.62 0.62 0.72 1.00 0.72 
ASTA01GT 40.20 0.62 1.14 0.49 1.83 2.33 0.78 
ASM04CA 40.20. 0.56 0.48 0.48 0.87 1.02 0.85 
]FT05CA 51.70 0.63 0.40 0.47 0.63 0.86 0.74 
ASAT04AA 59.20 0.68 0.68 1 	0.73 1 	1.00 1 	0.93 1 	1.08 
187 
IO2TT 71.10 	0.47 	I 0.54 	0.57 	1.15 	J 0.95 	 1.20 	7 
Chrémosome 10 
ASTT01TT 10.90 0.58 0.49 0.73 0.84 0.67 1.25 
ASTA02AG 18.40 0.41 0.42 0.53 1.04 0.81 1.29 
ASAT05AA 18.40 0.55 0.50 0.54 0.90 0.92 0.98 
ASAT05AG 18.40 0.30 0.25 0.32 0.83 0.77 1.08 
nromosome ii 
ASA303CA 5.30 0.43 0.45 0.44 1.04 1.02 1.02 
ASAT03AA 5.30 0.95 0.41 0.71 0.43 0.57 0.75 
ASAT03GA 21.50 0.71 0.37 0.74 0.51 0.50 1.03 
ASAT02TA 39.20 0.90 0.46 0.56 0.51 0.82 0.62 
ASTA01TA 39.20 0.59 0.56 0.62 0.96 0.91 1.05 
ASAGOITA 48.70 0.93 0.70 0.82 0.76 0.86 0.88 
ASACO2TA 52.90 0.70 0.57 0.65 0.81 0.88 0.92 
Chrmosome 12 
ASPC03TT 5.60 0.65 0.32 0.38 0.50 0.86 0.58 
ASiA01AT 54.60 0.63 0.34 0.45 0.54 0.76 0.71 
ASAT03AG 70.20 0.57 0.37 0.47 0.66 0.79 0.83 
AS.AT01CT 70.20 1.04 1.22 1.03 1.17 1.19 0.99 
Chrmosome 13 
ASi 01AA 1,5.20 0.78 0.65 0.52 0.83 1.27 0.66 
AS1 IO1GA 28.50 0.72 1.01 0.84 1.41 1.21 1.17 
AS1A02CA 36.10 0.98 0.61 0.75 0.62 0.81 0.77 
AS4 TO3TG 64.10 1.22 1.11 0.95 0.91 1.17 0.78 
AS AOIAG 73.00 0.90 0.87 0.98 0.97 0.88 1.09 
ASTIT02TC 132.50 0.32 0.25 0.29 0.80 0.89 0.90 
AS G03AA 183.50 0.63 0.58 0.59 0.92 0.97 0.95 
A5 AO3TA 183.50 0.69 0.68 0.65 0.99 1.06 0.93 
ASltT02CA 183.50 0.79 0.64 0.64 0.80 1.00 0.80 
ASi TO1AG 183.50 1.07 0.93 1.23 0.86 0.75 1.15 
AS. TO1GA 183.50 0.71 0.44 0.72 0.62 0.61 1.02 
AS AO1CT 200.10 1.14 1.15 1.15 1.01 1.00 1.01 
AS TO3AT 200.10 0.81 0.90 0.76 1.10 1.18 0.93 
AS TO1AT 209.20 	1 0.97 1.02 0.86 1.06 1.19 0.89 
AS GO3AT 217.80 1 0.45 0.50 0.54 1.11 0.92 1.20 
ageGroupA  Lin 
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ASAA03CA  0.67 0.60 0.68 0.89 0.87 1.01 
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AS A01AC  0.51 0.56 0.51 1.09 1.10 0.99 
AS J02CA  0.57 0.72 0.73 1.26 0.99 1.28 
AS J02AC  0.97 1.18 0.92 1.22 1.28 0.95 
AS J04GA  0.61 0.53 0.76 0.87 0.70 1.25 
AS T01TT  0.90 0.53 0.77 0.59 0.69 0.85 
AS A02AA  0.71 0.50 0.59 0.71 0.85 0.83 
AS AO3AA  0.92 0.79 0.69 0.86 1.14 0.75 
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